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Abstract 
The use of antibiotics in food-producing animals may result in unwanted residues in 
food products. The main objective of the present research was to study the 
development and application of fast and automated multiplex surface plasmon 
resonance (SPR)-based biosensor immunoassays (BIAs), based on multi-component 
antibodies and/or combined immunoassays in serially connected flow channels, for the 
detection of selected antibiotics in the food chain. The scientific challenges to deal 
with were: the development of multi-sulfonamide monoclonal antibodies (Mabs) 
against the generic structure of sulfonamides and the evaluation of mutated 
recombinant antibodies (Rabs) derived thereof, finding of the best BIA format with 
aminoglycosides as model compounds and solving foreseen matrix and combined 
immunoassay interferences, and to study the use of antibiotic concentrations in blood 
serum as predictors for concentrations in edible tissue.  
Broiler’s blood serum, easy to collect in slaughterhouses, was chosen for the detection 
of sulfonamides and quinolones which are frequently used in poultry. With a Mab 
raised against sulfamethazine (21C7), the BIA could detect at least eight sulfonamides 
in ten times diluted broiler serum with limits of detection (LODs) far below the 
desired detection limit. Other less performing Mabs were developed against the 
generic part of sulfonamides. The best Mab-producing hybridoma cell-line (27G3) 
was used by the University of Turku to develop better performing mutated Rabs and 
the mutant-based BIA in broiler serum was found to be the most sensitive towards 
most of the sulfonamides. The assay was fast (5 min per sample), robust (>1000 runs 
per chip) and the sample preparation was easy (dilution in buffer only). The Rab-based 
multi-sulfonamide immunoassay was applied to analyze serum samples from broilers 
treated with sulfamethoxazole and sulfadiazine and the concentrations found were 
higher than the concentrations found in tissue by LC-MS/MS. This, and the good 
correlation with tissue concentrations, made this assay suitable to predict levels in 
edible tissue. A similar result was obtained with the specific BIA for flumequine.  
Unique direct BIAs for the detection of aminoglycosides in milk were developed with 
Mab-coated chips. However, the inhibition assays with aminoglycosides on the chips 
were found to be more robust. For the simultaneous detection of five aminoglycosides 
in milk, the sensor chip surfaces in the four serially connected flow channels were 
covered with four aminoglycosides. In combination with a mixture of four specific 
antibodies, gentamicin, neomycin, kanamycin and (dihydro) streptomycin could be 
detected in milk far below the maximum residue limits (MRLs) and within 7 min.  
In conclusion, serum and milk are suitable sample materials for the biosensor 
detection of antibiotics in the food chain. Such assays are fast, robust, automated, easy 
to handle, and require simple sample preparations (dilutions in antibody-containing 
buffer). In principle, such assays can be combined with assays for the detection of 
anti-pathogens, which broadens the application area in a food safety control system. 
However, the four-channel biosensor systems are too limited and the antibodies too 
specific for the simultaneous detection of more antibiotics. More extended multiplex 
systems (e.g. imaging SPR sensors or multiplex flow cytometry-based systems) need 
to be explored in which the knowledge obtained in the present research will likely be 
of great value. 
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1.1 ANTIBIOTICS IN THE FOOD CHAIN 
 
Antibiotic means “against life” and antibiotics are medicines that kill or cause growth 
retardation of micro-organisms. In the original definition, an antibiotic was described 
as any substance produced by a micro-organism that is antagonistic to the growth of 
other micro-organisms. This excluded synthetic compounds such as the sulfonamides 
and quinolones. In modern usage, an antibiotic is any chemotherapeutic agent with 
activity against micro-organisms such as bacteria, fungi or protozoa (Davey, 2000).  
Penicillin was the first antibiotic originating from a micro-organism and was 
discovered by Alexander Fleming in 1929, when he observed by chance that bacterial 
growth was inhibited by the contaminating mold Penicillium (Stryer, 1996). Fleming 
was encouraged to find that an extract from the mould was not toxic when injected 
into animals. The search for other antibiotics was stimulated because penicillum was 
only effective against some infections caused by Gram-positive bacteria (Biotol, 
1993). A second success was obtained through the discovery of streptomycin which 
showed a broad action spectrum and was found to be also effective against Gram-
negative bacteria. Nowadays, the variety of antibiotics is enormous and there are 
hardly any processes in the living cell that are not sensitive to one of these antibiotics. 
Some antibiotics are still produced and isolated from living organisms, such as the 
aminoglycosides. Many others are produced via purely synthetic means, such as the 
quinolones and sulfonamides. Antibiotics can be classified as either bactericidal or 
bacteriostatic. Bactericidals (such as the quinolones and sulfonamides) kill bacteria 
directly where bacteriostatics (such as aminoglycosides) target protein synthesis and 
prevent cell division.  
Veterinary drugs are used to treat disease and improve health in animals, analogous to 
pharmaceuticals in human beings. The use of antibiotics as feed additives is one of the 
most effective management tools available to meat cattle producers (Gillespie, 2004). 
Added in low doses to the feed of farm animals, they improve growth performance. 
Broad-spectrum antibiotics were preferred for use as feed additives. They generally 
give better results in terms of rate of gain, feed efficiency, and improved animal 
health. Therefore, antibiotics have extensively been used in animal production 
worldwide for decades. The International Federation for Animal Health (IFAH) 
reported in 2007 about a global market value of 17.9 billion US dollars for the animal 
health industry (http://www.ifahsec.org/media_room/IFAH_annual_report_2007_ 
final.pdf).   
However, the potential for widespread use of agricultural antibiotics to provoke 
development of antibiotic-resistant bacteria has stimulated intense debate. This 
antibiotic resistance may spread to other microbial populations and infectious diseases 
that have become resistant to standard anti-microbial treatments present a threat to 
human and animal health (Sapkota et al., 2007). Staphylococcus aureus is one of the 
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major resistant pathogens. It was the first bacterium in which penicillin resistance was 
found in 1947, just four years after the drug started being mass-produced. Methicillin 
was then the antibiotic of choice, but has since been replaced by oxacillin due to 
significant kidney toxicity. MRSA (methicillin-resistant Staphylococcus aureus) was 
first detected in Britain in 1961 and is now frequently discovered in hospitals. MRSA 
causes an infection that is resistant to an entire class of penicillin-like antibiotics 
called beta-lactams, which includes penicillin, amoxicillin, oxacillin, methicillin, and 
others. MRSA is acknowledged to be a human commensal and pathogen, but it has 
also been found in cats, dogs and horses, where it can cause the same problems. 
Owners can transfer the organism to their pets and vice versa, and MRSA in animals 
is generally believed to be derived from humans. Farm animals are able to infect 
people with MRSA and the transmit of MRSA from pigs to humans was reported 
previously (Huijsdens, et al., 2006). Other antibiotic-resistant strains of bacteria 
known to be foodborne pathogens - including Salmonella spp., E. coli, and 
Campylobacter spp - have been isolated from farm animals (Doyle, 2006). These 
resistant bacteria could cause human diseases that are difficult to treat. Dechet et al., 
(2006) found that a multi-state outbreak of a multi-drug resistant strain of Salmonella 
enterica serotype Typhimurium DT104 was associated with ground beef. Even if the 
antibiotic-resistant bacteria in meat animals are not human pathogens, they may pass 
their resistance genes to other pathogenic bacteria. 
The serious problems caused by the emergence and spread of antimicrobial resistance 
was the reason for an EU-wide ban on the use of antibiotics as growth promoters in 
animal feed which has been effective since 2006 (EC, 2003). According to this 
regulation, only additives that have passed an authorization procedure may be placed 
on the market. Authorizations are granted for specific animal species, for specific 
conditions of use, and for ten-year periods only. This ban was the final step in the 
phasing out of antibiotics used for non-medicinal purposes. Antibiotics are now only 
allowed to be added to animal feed for veterinary medicine. However, in many 
countries outside the EU they are still used widely as feed additives for growth 
promotion. This EU regulation did not result in a decrease in the use of veterinary 
medicines. The Dutch Organization of Manufacturers and Importers of Veterinary 
Medicines reported a total use of 543 tons of antibiotics in 2006, which implies a 7% 
increase compared with 2005 with a comparable number of farm animals (FIDIN, 
2007). In 2007, the total use of veterinary drugs increased again with 9% to 590 tons 
with the same number of farm animals (FIDIN, 2008). Due to this massive and 
increasing use of antibiotics in food-producing animals, residues may be found in 
food (e.g. milk, eggs or meat). This is especially the case when products from animals 
have been sent for processing within the withdrawal periods - ranging from a few 
days to a few weeks - of approved therapeutic antibiotics, or when animals have had 
access to excreted residues in their environment (Kümmerer, 2003). 
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To guarantee a high level of consumer protection, Community legislation (EC, 1990) 
requires that the toxicity of potential residues is evaluated before the use of a 
medicinal substance in food-producing animals is authorized. If considered necessary, 
maximum residue limits (MRLs) are established and in some cases the use of the 
relevant substance is prohibited. All pharmacologically active substances are divided 
into two groups: (i) Group A compounds, which comprise prohibited substances 
(listed in the Directive 96/22/EC (EC, 1996a) and in Annex IV of the Council 
Regulation (EC, 1990)); (ii) Group B compounds, which comprise substances with 
final and provisional MRLs (listed in Annex I and III of the regulation). Veterinary 
medicinal products can only be authorized or used in food-producing animals if 
pharmacologically active substances contained therein have been assessed as safe 
according to this MRL regulation and rules concerning the documentation of use, 
prescription and distribution have been established (EC, 2001). 
Within the EU, residue monitoring plans for antibiotics and other groups of 
compounds are established from 1996 (EC, 1996b). They include the frequencies and 
level of sampling, investigation procedures and requirements on the documentation of 
use. The plans give indications for sanctions in case of non-compliance, requirements 
for targeted investigations and for the establishment, reporting and the groups of 
substances to be controlled for each food commodity. Another Commission Decision 
(EC, 1997) lays down additional rules for milk, eggs, honey, rabbits and game. A 
summary report for 2006 on the results of the national residue monitoring plans in 
food of animal origin in all EU member states (SANCO, 2008) described that the 
percentage of non-compliant results for antibacterials (exceeding the MRL levels) 
increased from 0.20% in 2005 to 0.30% in 2006 and that antibacterials remain the 
main problem for meat (bovine, pigs, sheep, goats, poultry, and rabbits), milk and 
honey.  
For the research described in this thesis, antibiotics belonging to three different groups 
were used as models. Sulfonamides and quinolones (with flumequine as the model 
compound) were chosen because of their frequent use in poultry. Biosensor 
immunoassays were developed for their detection in blood serum of broilers, to 
indicate the level of these compounds in edible tissue. As third category, 
aminoglycosides and their detection in milk were selected, because they are often 
used in dairy cattle for the treatment of mastitis.  
1.1.1 Sulfonamides 
 
Figure 1. Molecular structure of sulfanilamide. 
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Sulfonamide drugs were the first synthetic antimicrobial drugs and they contain the 
sulfonamide group. German bacteriologist and pathologist Gerhard Domagk was 
awarded the 1939 Nobel Prize for Physiology or Medicine for discovering the 
antibacterial effects of prontosil red, a dye which contained the active component, 
sulfanilamide (Figure 1). Once sulfanilamide was recognized as an active 
antimicrobial agent, scientists synthesized many sulfonamides to test for bactericidal 
activity.
 
Figure 2. Molecular structures of the different sulfonamides used in this study. 
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It was later realized that sulfonamides do not actually kill bacteria, they interfere with 
bacterial growth and replication. Such bacteriostatic sulfa drugs inhibit the enzyme 
dihydropteroate synthetase (DHPS). DHPS catalyses the conversion of para-
aminobenzoate (PABA) to dihydropteroate, a key step in folate synthesis. Folic acid is 
necessary for the biosynthesis of thymine and the purine bases, the building blocks of 
DNA and in its absence cells will be unable to divide. Sulfonamides have broad 
spectrum activity against both Gram-positive and Gram-negative bacteria. In the 
Netherlands at least nine different sulfonamides have been approved for veterinary 
applications. For instance, for the medication of poultry, five sulfonamides 
(sulfamethoxazole, sulfadiazine, sulfamethazine (sulfadimidine), sulfachloro-
pyridazine and sulfaquinoxaline) are approved (CBG, 2009) of which the first two are 
most frequently applied. For the medication of dairy cattle, sulfamethoxazole, 
sulfadiazine and sulfadoxine are approved (KNMVD, 2007; CBG, 2009). Intensive 
use of these drugs in animal breeding can lead to unwanted residues in food. To 
establish safe limits for human consumption, the European Union therefore 
established an MRL of 100 μg kg-1 for the total amount of the parent sulfonamides in 
muscle, fat, liver and kidney of all food-producing species and bovine, ovine and 
caprine milk (EC, 1999). In this research, sulfonamides were chosen as model 
compounds to study the development and performance of group-specific monoclonal 
antibodies (described in Part I) raised against the generic part of sulfonamides (Figure 
1). The development of fast and automated multi-sulfonamide biosensor 
immunoassays, based on monoclonal and mutated recombinant multi-sulfonamide 
antibodies, their performance with a range of sulfonamides (Figure 2) and their 
application in broiler serum as predictor for the levels in tissue are described in Part 
II. 
1.1.2 Aminoglycosides 
Aminoglycosides are broad-spectrum antibiotics most commonly used in veterinary 
drug medicine in the treatment of infections caused by Gram-negative bacteria, such 
as mastitis (Brander, 1986). The bactericidal ability of aminoglycosides is not fully 
clear yet, although the main lines of action have been delineated (Shakil et al., 2008). 
The drug attaches to a bacterial cell wall and is drawn into the cell via channels made 
up of porin proteins. Once inside the cell, the aminoglycoside attaches to the 
ribosomes. Ribosomes are the intracellular structures responsible for manufacturing 
proteins. This attachment either shuts down protein production or causes the cell to 
produce abnormal, ineffective proteins. The bacterial cell cannot survive with this 
impediment.  
Neomycin  is an aminoglycoside antibiotic consisting of 3 components (A, B 
and C). Neomycin B (see Figure 3I) is the largest component of commercial 
preparations of neomycin (over 90%). Neomycin is used to treat bacterial infections 
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of cattle, sheep, pigs, goats and poultry. MRL’s for neomycin B were elaborated for 
cattle, sheep, goats, pigs, chickens, turkeys and ducks of 500 μg kg-1 in muscle, liver, 
fat and eggs. For milk and kidney, the MRL’s are 1500 and 5000 μg kg-1, 
respectively.  
 
Figure 3. Molecular structures of the aminoglycosides I is neomycin B, II is gentamicin C (in 
C1 R1 = R2 = CH3; in C2 R1 = CH and R2 = H and in C1a, R1 = R2 = H), III is streptomycin 
and IV is kanamycin. 
Gentamicin (Figure 3II) is a complex mixture, the main components being 
gentamicin C1, C1a, C2 and C2a. Gentamicin is an aminoglycoside antibiotic indicated 
for the treatment of a variety of bacterial infections in pigs and cattle and is normally 
used as the sulfate salt. Gentamicin is included in Annex III of the Council Regulation 
(EC, 1990) in which MRL’s have been established for bovine milk (100 μg kg-1) and 
bovine or porcine muscle, fat, liver and kidney of 50, 50, 200 and 750 μg kg-1, 
respectively.  
Streptomycin (Figure 3III) and dihydrostreptomycin are aminoglycoside 
antibiotics that are closely related in structure. Streptomycin, was the first 
aminoglycoside isolated from Streptomyces griseus in the mid-1940s. This antibiotic 
was very effective against tuberculosis. The use in lactating cows may lead to the 
presence of residues of these antibiotics in milk. Streptomycin is also used as a 
pesticide, to combat the growth of bacteria, fungi, and algae. Streptomycin controls 
bacterial and fungal diseases of certain fruit, vegetables, seed, and ornamental crops, 
and controls algae in ornamental ponds and aquaria. A major use is in the control of 
fireblight on apple and pear trees.  
In 2002, the Food Safety Authority of Ireland (FSAI, 2002) requested retailers to 
remove honey from China and blended honey that contains or may contain honey 
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from China from the shelves because of the presence of residues of streptomycin. 
Reybroeck (2003) found streptomycins in a small fraction of honey samples from 
Belgium beekeepers (4 out of 248 samples (1.6%)) but in imported honey samples 
available on the Belgium market, streptomycins were frequently found (51 out of 108 
(47.2%)). One of the main drawbacks to streptomycin is its toxicity, especially to cells 
in the inner and middle ear and to the kidney. Furthermore, some strains of 
tuberculosis have become resistant to treatment with streptomycin. Therefore, medical 
researchers have put considerable effort into identifying other antibiotics with 
streptomycin's efficacy, but without its toxicity. The MRL’s for streptomycin and 
dihydrostreptomycin (EC, 1999) are comparable, and for bovine, ovine and porcine 
muscle, liver and kidney they are 500, 500 and 1000 μg kg-1, respectively. For bovine 
and ovine fat and milk, the MRL’s are 500 and 200 μg kg-1, respectively, and for 
porcine skin and fat 500 μg kg-1. 
Kanamycin (Figure 3IV) is an aminoglycoside antibiotic produced by the 
growth of Streptomyces kanamyciticus and it comprised three components, kanamycin 
A - the major component usually designated as kanamycin - and kanamycins B and C, 
the minor congeners. The MRL’s for kanamycin A in bovine, ovine, porcine, chicken 
and rabbit muscle, fat, liver and kidney are 100, 100, 600 and 2500 μg kg-1, 
respectively and for bovine milk 150 μg kg-1 (EC, 1999). 
Other aminoglycosides not included in this study are apramycin and 
paronomycin – as they are not for use in animals from which milk is produced for 
human consumption - and spectinomycin, for which an MRL in milk of 200 μg kg-1 is 
established. MRL’s for spectinomycin in muscle, fat, liver and kidney of all food 
producing species are 300, 500, 2000 and 5000 μg kg-1, respectively. The MRL’s for 
apramycin in bovine muscle, fat, liver and kidney are 1000, 1000, 10.000 and 20.000 
μg kg-1 and the MRL’s for paronomycin in muscle, liver and kidney of all food 
producing animals are 500, 1500 and 1500 μg kg-1, respectively. 
In this study, the aminoglycosides gentamicin, neomycin, (dihydro)streptomycin and 
kanamycin were used as model compounds to study different biosensor immunoassay 
formats (direct, inhibition and combined) for the analysis of milk samples, as 
described in Part III. 
1.1.3 Fluoroquinolones  
The quinolones are a family of synthetic broad-spectrum antibiotics, and they are 
divided into generations based on their antibacterial spectrum (Ball, 2000). The earlier 
generation agents are, in general, more narrow-spectrum antibiotics than the later 
ones. Flumequine is a first-generation broad-spectrum antibiotic often used in 
veterinary medicine for the treatment of enteric infections. The majority of quinolones 
in clinical use belongs to the subset of fluoroquinolones, which have a fluoro group 
attached the central ring system (Figure 4). Quinolones and fluoroquinolones are 
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bactericidal drugs, actively killing bacteria. They inhibit the bacterial DNA gyrase or 
the topoisomerase IV enzyme, thereby inhibiting DNA replication and transcription. 
Quinolones can enter cells easily via porins, and therefore are often used to treat 
intracellular pathogens such as Legionella pneumophila and Mycoplasma 
pneumoniae. 
 
Figure 4. Molecular structures of the (fluoro)quinolones. 
For many Gram-negative bacteria DNA gyrase is the target, whereas topoisomerase 
IV is the target for many Gram-positive bacteria. Eukaryotic cells do not contain 
DNA gyrase or topoisomerase IV. Fluoroquinolones are well distributed into bone 
tissue, and so well absorbed that in general they are as effective by the oral route as by 
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intravenous infusion. They are widely used to treat infections in farmed fish, turkeys, 
pigs, calves and poultry and monitoring of their residues in food is therefore regulated 
by law. The illegal and/or overuse of fluoroquinolones in animal production is of 
particular concern to humans because of their important applications in human 
medicine, and repeated exposure via food will limit the future effectiveness of these 
drugs due to the build up of antimicrobial resistance. As shown in Figure 4, 
flumequine has a deviating structure compared to most of the other quinolones and 
that is the reason why it was included in this study to develop antibodies and a 
biosensor immunoassay for this compound (Chapter 9). Outside the scope of this 
thesis, this assay was combined with another multi-fluoroquinolone immunoassay, to 
obtain a dual biosensor immunoassay for the simultaneous detection of six 
fluoroquinolones in chicken muscle (Marchesini, 2007). 
1.2 DETECTION OF ANTIBIOTICS IN FOOD 
For the detection of antibiotics in food and related products (e.g. blood, urine, renal 
pelvis fluid, etc.), three techniques are mainly applied: (i) microbial inhibition 
screening tests; (ii) chromatography-based screening and confirmation methods; and 
(iii) immuno- or receptor screening assays. 
Because of their high cost-effectiveness and broad spectrum characteristics, 
microbial inhibition methods are preferred for large scale surveillance programs on 
veterinary drug residues. The methods usually use a medium inoculated with a 
susceptible bacterium and rely on diffusion of the antimicrobial residue. Inhibition of 
growth indicates the presence of antimicrobial compounds. Many test systems have 
been developed based on this principle, and methods using one to seven agar plates 
have been reported. The fast antimicrobial screening test (FAST) is a one-plate 
microbial method with Bacillus megaterium that requires a minimum of 6 h for 
development (USDA, 2006). The Premi® test uses a vial containing spores of the 
thermophile B. stearothermophilis in agar, and acts similarly to a single-plate method 
(Cantwell and O’Keeffe, 2006). This test is more rapid, with development times 
typically from 3 to 4 h. Recently, a similar test, the kidney inhibition swab (KIS™) 
test, has been developed. It uses a differently configured vial of B. stearothermophilis 
spores in agar, and also allows results within 3-4 h (Charm Sciences, 2008). These 
three fast tests were compared for screening antibiotic residues in beef kidney juice 
and serum (Schneider, 2008) and one of the conclusions was that there is not one 
rapid screening microbial inhibition assay for antibiotics that is ideal for all analytes. 
To cover all possibilities, one would have to run a number of different assays or 
separate plates. Such a five-plates test has been described (Pikkemaat et al., 2008), 
and comprises various microbes for the group-specific identification of antimicrobial 
residues in slaughter animals, the so-called Nouws antibiotic test (NAT screening). 
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The NAT screening combines a simple and efficient sampling and sample processing 
strategy with a high detection capability because it detects the great majority of 
antibiotics used in veterinary medicine at or below their maximum residue levels in 
kidney. However, it requires a rather lengthy incubation time of 16-18 h.  
A faster alternative for the microbial inhibition assay is a whole-cell-based 
bioassay, also named whole-cell biosensor, which has been described for the detection 
of tetracyclines by Korpela et al. (1998). They constructed a genetically engineered 
luminescent bacterial strain that contained the regulation unit of tetracycline 
resistance factor (tetracycline-responsive element) to control the expression of the 
luciferase operon. This resulted in a tetracycline-dependent light production. The time 
needed for optimal induction of light emission was 90 min. They found that this kind 
of sensor cell can be freeze-dried without any loss of sensitivity or overall 
performance which simplifies the applicability of the assay system. This tetracycline 
group-specific bioassay was sensitized to meet the EU MRL for tetracycline residues 
in poultry tissue (100 ng g-1) by adding membrane-permeabilizing and chelating 
agents and sensitivities of 5 ng g-1 for doxycycline, 7.5 ng g-1 for chlortetracycline and 
25 ng g-1 of tetracycline were reached (Virolainen et al., 2008). The assay was 
performed in 96-well flat bottom microtiter plates within 4 h with little preparation, as 
lyophilized cells are always ready, and a multitude of samples can be assayed easily in 
this format. Being at least as sensitive and better suited for high-throughput analysis, 
whole-cell biosensors have the potential to displace growth inhibition assays as the 
favored method for tetracycline residue screening. However, such bioassays are not 
yet described for other antibiotics although the use of the multidrug-binding repressor 
protein (QacR) from Staphylococcus aureus  (Schumacher et al., 2001) might offer an 
interesting approach for the future development of a multi-drug biosensor. Currently, 
cellular biosensors - based on various microbial species containing reporters that are 
specifically induced via selected promotors - are  widely used in pharmaceutical drug 
discovery and in environmental biology (Urban, et al., 2007) and for monitoring 
environmental chemical contaminants (Patel, 2006). This will also further influence 
the development of new bioassays for the detection of antibiotics in food. 
Of the chromatographic techniques, high-performance thin-layer chromato-
graphy (HPTLC) has been applied successfully for the qualitative and quantitative 
detection of multi-residues in food samples even though its use has rapidly decreased 
during the last decade (Toldrá and Rieg, 2006). The use of high-performance liquid 
chromatography (HPLC) expanded during the 1990s and the availability of 
automation facilitated its use as a screening technique. The choice of the detection 
system is very important to obtain both sufficient selectivity and sensitivity. UV-diode 
array detection in combination with reversed-phase HPLC has been applied for the 
detection of many antibiotics in a lot of different food matrices. Nowadays, more than 
80% of the analytical techniques for the determination of veterinary drugs use HPLC 
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in combination with mass spectrometry (MS) (Gentili, 2008). Chromatographic 
methods are mainly used for the simultaneous detection and quantification of closely 
related compounds belonging to a single drug class. In combination with an MS/MS 
technique they fulfill the established criteria (EC, 2002a) for confirmation of identity 
of drugs (Danaher et al., 2007; Yuan, et al., 2008; Nielen et al., 2008). Recently, ultra-
performance liquid chromatography combined with time-of-flight mass spectrometry 
(UPLC-Tof-MS) was used for the screening and quantification of more than 100 
veterinary drugs in milk (Stolker et al., 2008) and in muscle, kidney and liver 
(Kaufmann et al., 2008). This technique combines high resolution for both LC and 
MS with high mass accuracy, and as such is very powerful for the multi-compound 
analysis of veterinary drugs. However, in general, chromatography-based methods are 
laborious and require trained personnel with high expertise and expensive equipment 
which make them only suitable for specialized laboratories and less suitable for 
measurements in the food chain.  
According to the General Food Law (EC, 2002b), the food and feed industries 
are responsible for the safety of their products and their demand for simplified and 
rapid test methods at critical control points in the entire chain has never been greater. 
These methods must be able to detect an analyte or class of analytes at the level of 
interest. Some false positives (false non-compliants) are acceptable, as they will be 
further submitted for confirmatory analysis. However, the test must avoid or reduce to 
a minimum the number of false negative results (false compliants), because they will 
not be further analyzed.  
There are different techniques available for the fast screening of veterinary 
drugs in animal foods. Of the immunochemical methods, the 96-wells microtiter plate 
enzyme-linked immunosorbent assay (ELISA) is most frequently used and many test 
kits to detect specific compounds or groups of compounds are commercially 
available. In general, they are sensitive and easy to use, have a high specificity, 
require minimal sample preparations, and are therefore suitable for the screening of a 
large number of samples in a short time (about 2-3 h). These tests can be used within 
food-producing facilities. For instance, antibiotic-ELISAs are described for the 
detection of sulfamethazine in swine urine and plasma (Haasnoot et al., 1996), 
aminoglycosides in milk and kidney (Haasnoot et al., 1999), chloramphenicol in 
urine, tissue, milk and eggs (Cazemier et al., 1996; Gaudin et al., 2003), 
nitroimidazoles in eggs and chicken muscle (Huet et al., 2005) and gentamicin in milk 
(Jen et al., 2005). In Part I of this thesis, the ELISA technology is used during the 
evaluation of antibodies against different sulfonamides and sulfonamide derivatives 
aiming for the development of multi-sulfonamide antibodies.   
Immunochromatographic or lateral flow tests or dip sticks are much faster antibody-
based assays, which can be performed in minutes. In these tests, all ingredients are 
already present in the test device, and the sample (extract) is needed only to perform 
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an assay. Therefore, this format is ideal for some food-producing facilities and field 
applications. Such fast tests are described for the detection of sulfadimidine in calf 
serum (Verheijen et al., 1998) and (dihydro) streptomycine in raw milk (Verheijen et 
al., 2000). Based on this technology, Unisensor (Angleur, Belgium) developed a 
receptor-based assay dipstick format (Twin sensorBT) for the rapid detection of β-
lactams and tetracyclines molecules in raw milk. Other examples of commercially 
available products are the Rapid One Step Assay (ROSA®) tests for β-lactams, 
tetracyclines, enrofloxacin and sulfadimethoxine/sulfamethazine of Charm Sciences 
Inc. (Lawrence, MA, USA). The commercial availability of these rapid tests is still 
limited to a few antibiotics. This has been the reason to include the development of 
such fast multi-component dipsticks for tetracyclines, quinolones, sulfonamides, 
chloramphenicol and tylosin in the new EU-project entitled “Contaminants in Food 
and Feed: Inexpensive detection for control of exposure” (CONffIDENCE 
(http://www.conffidence.eu)).  
Another more recent approach to screen animal products for veterinary drugs consists 
of the application of biomolecule-based biosensors. While bioassays or cellular 
biosensors utilize the response of whole cells to detect biologically active agents, 
these biosensor instruments use a biological recognition element (e.g. antibodies, 
enzymes, lectins, receptors and nucleic acids) in close contact with a signal 
transduction element (e.g. optical, acoustic, and electrochemical) connected to data 
acquisition and processing systems (Patel, 2006). Thus, the signal from the biological 
element is converted to a quantifiable signal, e.g., electrical. Enzymatic biosensors 
utilize specific enzymes for the capture and catalytic generation of the product, which 
is then directly determined using a range of transducers (e.g. electrochemical, optical, 
photothermal, amperometric, and acoustic). In contaminant analysis, enzyme 
biosensors have largely been used for organophosphorus and carbamate pesticide and 
herbicide analysis, with fewer applications being reported for antibiotics, e.g. for the 
detection of penicillins using penicillinase (Kiran et al., 2002). 
Antibody-based immunosensors are frequently described with transduction elements 
based on piezoelectric, electrochemical, and optical components. A piezoelectric 
immunosensor is a device based on materials such as quartz crystals, which resonate 
on application of an external alternating electric field. The frequency of the resulting 
oscillation is a function of the mass of the crystal. This mass increases during 
interactions of e.g. antibodies to immobilized antigens, and thus yields a directly 
measurable decrease in the frequency. Such a fast (5 min) inhibition piezoelectric 
immunosensor is described for the detection of the mycotoxin ochratoxin A in liquid 
food samples (Hauck et al, 1998). 
For the detection of antibiotics, electrochemical and optical immunosensors are most 
frequently applied. Electrochemical biosensors include potentiometric and 
amperometric immunosensors. The potentiometric immunosensors are based on the 
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change in potential that occurs when an antigen in a sample reacts with the 
corresponding antibody previously immobilized to an electrode. The potential 
difference between an antibody-immobilized electrode and a reference electrode is a 
function of the analyte in the sample. Amperometric immunosensors rely on the 
measurement of current generated when an electroactive species is either oxidized or 
reduced at an antibody- (or antigen-) coated electrode to which an analyte (or 
antibody) binds specifically. Zacco et al. (2007) developed a novel electrochemical 
immunosensing strategy for the detection of sulfonamide antibiotics in milk based on 
magnetic beads coated with class-specific anti-sulfonamide antibodies and a 
sulfonamide-peroxidase as tracer. 
The interest in optical biosensors for food analysis, with fluorescent, bioluminescent 
or chemiluminescent labels for detection, as well as the direct (label-free) detection, is 
increasing. Label-free biosensors do not require the use of reporter elements to 
generate a signal, which is convenient during assay development and during 
application by saving washing steps and time (Morrow, 2007). One of the most 
popular label-free technologies for performing rapid analysis is based on 
commercially available automated multi-channel surface plasmon resonance (SPR)-
based biosensors. Such SPR sensors are used in the present research to investigate 
different assay formats for the detection of drug residues in food and the principle of 
the technology and coupling procedures to the biosensor surfaces are described below. 
 
1.3 SPR-BASED BIOSENSORS 
Biacore™ SPR-based biosensors (models 3000 and Q (nowadays from GE 
Healthcare)) were used in this study, and the SPR principle and the essential 
components (Figure 5) are described in more detail below.  
 
Figure 5. Essential components of the Biacore™  instruments used in this study. 
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The SPR phenomenon (Figure 6) occurs when monochromatic and p-polarized light 
(i.e. the electric vector component is parallel to the plane of incidence), under 
conditions of total internal reflection, strikes an electrically conducting metal (e.g. 
gold) layer at the interface between media of different refractive index: the glass of a 
sensor surface (high refractive index) and a buffer (low refractive index). An electric 
field intensity, known as an evanescent wave (EW), is generated when the light strikes 
the glass. This EW interacts with, and is absorbed by, free electron clouds in the gold 
layer, generating electron charge density waves called surface plasmons, and causes a 
reduction in the intensity of the reflected light at a specific angle of reflection (Figure 
6). The incident light angle at which this reduction occurs is called the SPR angle.   
 
 
Figure 6. Schematic view of the optical and flow channel setup of a Biacore™  system 
(reproduced from www.biacore.com) 
 
This angle varies with the refractive index close to the sensor chip surface on the side 
opposite from the reflected light (in the flow channel). This refractive index changes 
when molecules are immobilized on and/or bound to the surface. SPR response values 
are expressed in resonance units (RU) and one RU is 0.0001°. A close correlation 
between the SPR response and the amount of surface-bound protein has been 
demonstrated to be close to 1000 RU/ng protein/mm2 for different proteins using 
radioactively labeled proteins to enable measurement of absolute surface 
concentration (Stenberg et al., 1991). The SPR angle changes when immobilized 
molecules (ligands) interact with molecules (analyte) in a mobile phase running along 
a flow cell (Figure 6 left panel). If binding occurs to the immobilized ligands, the 
local refractive index changes and the change of the SPR angle over time results in a 
sensorgram (Figure 6 right panel). A typical “real life” sensorgram (Haasnoot et al., 
2005) of one cycle of analysis obtained with a blank sample (broiler serum) mixed 
with anti-sulfonamide antibodies is shown in Figure 7. After the increase of the bulk 
Chapter 1 
 
 
27 
response of the diluted sample (having a higher refractive index than the running 
buffer), the binding of the antibodies to a sulfonamide derivative immobilized on the 
biosensor chip is shown as the increasing response during the injection (association). 
This is followed by a fast bulk response decrease after the injection and a slow 
response decrease during the dissociation in which some of the bound antibodies are 
released. The response obtained just prior to the injection of the regeneration solution 
is caused by the bound antibodies (without bulk response) and is used for the 
calculations of sulfonamide concentrations. After the injection of the regeneration 
solution and stabilizing of the baseline with running buffer, a new cycle can be 
started. For the concentration analysis applied in this study, calibration curves were 
obtained by plotting the responses versus concentrations after injections of blank 
samples to which different concentrations of the analytes were added and comparing 
these responses with those obtained with the samples of interest. 
 
Figure 7. Sensorgram obtained in the Biacore 3000 after the injection of 50 µl of diluted 
broiler serum (20 µl serum diluted with 100 µl of diluted anti-sulfonamide antibodies) 
followed by a 20 µl injection of 0.1 M hydrochloric acid for the regeneration: (1) start sample 
injection (at this moment the relative response is set to 0); (2) bulk response; (3) binding of 
the mutant; (4) stop sample injection; (5) response used for calculation; (6) start injection 
regeneration solution; and (7) stop injection regeneration solution. 
 
Although not applied in the present study, an important application of SPR biosensors 
is the possibility to perform kinetic analysis on interaction plots. The association and 
the dissociation phases are often used to obtain kinetic information from monitoring 
interactions in real time, yielding values for association and dissociation rate constants 
and/or equilibrium constants.  
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The reaction between the immobilized ligand (L) and the analyte (A) can be described 
by: 
      ka 
 (1)    L + A   LA 
      kd 
where ka is the association rate constant [M-1s-1] describing the rate of 
complex formation, i.e. the number of LA formed per second (typical range 1 
× 10-3 – 1 × 107) and kd is the dissociation rate constant [s-1] describing the 
stability of the complex. 
 
The association rate is  
 
(2) 
 
The dissociation rate is 
 
(3) 
 
At equilibrium the rate of association equals the rate of dissociation, and provide KA. 
 
(4) 
 
(5)  
 
 
where KA is the equilibrium association constant [M-1] describing the 
association tendency and a high KA is a high affinity (typical range 1 × 105 – 1 
× 1012).  
 
Analogously, the equilibrium dissociation constant KD can be defined: 
 
(6) 
 
 
where KD is the equilibrium dissociation constant [M] describing the 
dissociation tendency and a high KD is a low affinity (typical range 1 × 10-5 – 
1 × 10-12).  
 
In the association phase of the interaction, the observed rate of formation is the sum of 
reaction equations 2 and 3 and the net rate of binding is: 
 
 (7)    
 
In the biosensor, the formation of complex (d[LA]) is observed as an increase in 
response R (measured in resonance units RU). The concentration of free analyte (A) is 
]A][L[k
dt
]LA[d
a=
]LA[k
dt
]LA[d
d−=
]LA[k]A][L[k da =
d
a
A k
k
]A][L[
]LA[K ==
a
d
D k
k
]LA[
]A][L[K ==
]LA[k]A][L[k
dt
]LA[d
da −=
Chapter 1 
 
 
29 
equal to the bulk analyte concentration, since analyte is constantly replenished during 
the sample injection. The available concentration of the ligand attached to the sensor 
surface (L) may be expressed in RU as the difference between the maximum analyte 
binding capacity Rmax and the amount of complex formed at equilibrium (Req). The 
observed rate of formation (dR/dt) is zero at equilibrium. 
Submitting these terms gives: 
(8)     
  
where C is the concentration of analyte in the sample. 
 
This equation can be rearranged to: 
(9)    
 
A plot of Req/C (y-axis) versus Req (x-axis) results in a straight line with a slope of –KA 
and an y-intercept of KARmax. Therefore, the association constant KA can be 
determined by linear regression from transformed data points at equilibrium. 
This represents the pseudo-first order kinetics observed for binding of analyte to 
surface-attached ligand with 1:1 stoichiometry. Similar model equations may be 
applied to more complex interaction models. 
 
The size of the change in SPR signal is directly proportional to the mass being 
immobilized and bound. For a given number of ligand sites, a higher molecular 
weight (MW) analyte will give a proportionally larger response. Conversely, for a 
given level of ligand immobilization in RU, a higher molecular weight ligand will 
provide fewer binding sites on the sensor surface. Therefore, a low molecular weight 
analyte will give a low response, particularly when the ligand response is low 
(equation 10).  
 
(10)    
 
 
where valence is the number of analyte molecules that can bind to one ligand 
molecule 
 
With current instrumentation (Biacore 3000), analytes as small as 200 daltons can be 
detected directly, although the response is low (see Chapter 7). As shown in Table 1, 
the theoretical maximum binding capacity (Rmax) of a direct immunoassay for 
streptomycin (MW 581), in which the chip surface is coated with Mab (corresponding 
to 15000 RU) with an MW of 150000, is 116 RU, which corresponds with the Rmax 
obtained in Chapter 7 of this thesis. Much higher responses can be obtained in the 
inhibition assay format, in which streptomycin is coated on the chip surface (direct 
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dt
dR
eqdeqmaxa =−−=
eqAmaxA
eq RKRK
C
R −=
valenceresponseligand
MWligand
MWanalyteRmax ××=
Introduction 
 
 
30 
or as an ovalbumin-streptomycin conjugate) and the bound antibodies are responsible 
for the response (Table 1). 
 
Table 1. Theoretical maximum RU’s for combinations of ligand and analyte molecular 
weights (MW). 
Ligand RU Ligand MW Analyte MW Valence Rmax 
15000 150000 581** 2 116 
1000 48000* 150000 5*** 15600 
100 581** 150000 1 25800 
*MW of ovalbumin-streptomycin; **MW of streptomycin ***Estimated number of 
streptomycin molecules per protein molecule available for antibody binding 
 
For a more detailed description of SPR as an analytical technique, see Markey (2000). 
The SPR detection system in the Biacore biosensors uses the light from a near-
infrared light-emitting diode (LED), with a peak intensity wavelength of 760 nm, 
which is focused through a prism on to the sensor chip surface in a wedge-shaped 
beam, giving a fixed range of incident light angles. Light reflected from the sensor 
chip is monitored by four separate linear arrays of light-sensitive diodes, one for each 
flow channel, covering the range of incident light angles. The spacing between diodes 
corresponds to a difference of 0.1° in incident light angle. Computer algorithms 
automatically calculate the angle at which minimum reflection occurs (the SPR angle) 
with a resolution of about 10-5°.  
The fluidic system consists of two liquid delivery pumps (one for maintaining a 
constant flow of liquid over the sensor chip surface and the other for handling samples 
in the autosampler), the autosampler, the microfluidic system (Integrated μ-Fluidic 
Cartridge (IFC), containing liquid delivery channels, sample loop and valves), 4 
detector flow cells formed by the IFC pressing against the sensor chip and 
microprocessors (for controlling pumps, autosampler and IFC valves). The IFC 
(Figure 8) consists of a series of channels and pneumatic valves encased on a plastic 
housing and serves to control delivery of liquid to the sensor chip surface. It is 
connected to the buffer supply through the connector block. This has an injection port 
for loading samples from the autosampler into the IFC, which connects directly with 
the detector flow cells. The two biosensor systems used within this study (Biacore Q 
and 3000) have four flow channels (Fcs) each and are fully automated with a capacity 
of 192 samples (two 96-wells microtiter plates). The Biacore Q is dedicated to the 
qualitative or quantitative determination of analytes in food related products and can 
be used in combination with specially developed Qflex® Kits of which two (for 
sulfamethazine and for sulfonamides) were used in this study (Chapter 5). A 
disadvantage of  the Biacore Q is that only one of the four Fcs can be used at the same 
time. In the Biacore 3000, the four Fcs can be serially connected and simultaneously 
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detected (Figure 8). 
 
Figure 8. Schematic illustration of the IFC and a pneumatic valve (right panel) and the 
serial flow cell configuration of the Biacore 3000 (left panel). Software-controlled valves at 
each outlet and at the entry to each flow cell enable the user to select a combination of 
active flow cells during the experiment.  
 
This gives the opportunity to run multi-assay or multiplex analysis, as was proven 
with the simultaneous detection of five aminoglycosides using a mixture of four 
specific antibodies and four different aminoglycosides immobilized into the four Fcs 
(Chapter 8). According to the manufacturer, the Biacore 3000 is the most sensitive 
instrument of their SPR biosensors and suitable for the direct detection of small 
molecules, as was shown in this study for the direct detection of aminoglycosides 
(Chapter 7). 
The sensor chip (Figure 9) is the signal transducer and is a glass slide with a thin layer 
of gold deposited on one side. Gold is chosen for its combination of chemical 
inertness and good SPR response. The gold film is covered with a covalently bound 
matrix (attached through a linker layer) onto which biomolecules can be immobilized. 
The removable sensor chip is inserted into the cassette port on the detector unit, and 
docks into the instrument to form one side of the detector flow cell. Different sensor 
chips are available for different purposes. All, however, use the same principle 
(Figure 9).  
 
Figure 9. The surface of a sensor chip consists of three layers: glass, a thin gold film and a 
dextran layer, to which (bio)molecules can be immobilized. 
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The most generally applicable chip is the CM5 chip with a surface matrix of non-
crosslinked carboxymethyl dextran covalently attached to the gold via a self-
assembled monolayer of ω-hydroxyalkanethiol. Dextran is a linear polymer of glucose 
units, which exhibits very low non-specific adsorption of biomolecules. The dextran 
on the sensor chip surface is swollen in aqueous media, providing an extensively 
solvated hydrogel of 100 nm thickness and it is carboxymethylated to a substitution 
degree of approximately one carboxyl group per glucose residue. This modification 
serves two primary purposes. It provides a chemical possibility for covalent 
immobilization of biomolecules and it places a net negative charge on the dextran at 
physiological pH values, so that positively charged biomolecules (e.g. proteins at pH 
values below their isoelectric point (IP)) are attracted electrostatically to the dextran 
layer under conditions of low ionic strength. This concentrates biomolecules in the 
matrix, and allows effective covalent immobilization even from solutions with low 
bulk concentration. The carboxymethyl groups also enhance the hydrophilicity of the 
dextran matrix. The matrix is chemically stable in most buffers used in biomolecular 
interaction studies and can be exposed to extremes of pH for short periods without 
deterioration. The matrix enhances the ligand immobilisation capacity of the surface 
from typically 1-5 ng/mm2 on untreated gold to up to 50 ng/mm2 in the matrix. The 
carboxymethylated matrix is amenable to a range of generally applicable 
immobilization chemistries via -NH2, -SH, -CHO, -OH or -COOH groups (see Figure 
10 and O’Shannessy et al., 1992).  
The amine coupling is the most common conjugation method in which the surface is 
activated with a 1:1 mixture of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and N-hydroxysuccinimide (NHS), to give reactive succinimide esters. The 
ligand (in a buffer giving a positive charge to the ligand) is passed over the surface 
and the esters react rapidly with amino groups or other nucleophilic groups. Any 
sterically unrestricted amine groups can react with the surface. Most proteins contain 
several of such amine groups via lysine residues, so that an efficient and random 
attachment can be achieved, which usually yields many bioconjugates that are 
unaffected with regard to the overall biological activity of the ligand.  
Thiol coupling utilizes exchange reactions between thiol and active disulfide groups 
(Figure 10). The active disulfide moiety may be introduced either on the dextran 
matrix (to exchange with a thiol group on the ligand, referred to as the ligand thiol 
approach) or on the ligand molecule (to exchange with a thiol group introduced on the 
dextran matrix, referred to as the surface thiol approach). A recommended reagent for 
introducing active disulfide groups is  2-(2-pyridinyldithio) ethaneamine (PDEA). The 
amine group in PDEA can be used to attach the molecule to activated carboxyl groups 
on either the surface or the ligand. Thiol coupling can be a valuable approach if the 
ligand is inactivated by amine coupling in the analyte binding site. The thiol approach 
can also help to immobilize ligands in a defined orientation, since the number of 
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potential attachment sites is often less than with amine coupling, and in many cases is 
reduced to one single site.  
 
Figure 10. Chemistries for immobilizing (bio)molecules onto the surface of CM-series 
(carboxymethylated dextran) sensor chips. 
 
Ligands containing aldehyde groups (either native or introduced by oxidation of cis-
diols) can be immobilized after activating the surface with hydrazine or 
carbohydrazine. Alternative approaches for immobilizing glycoproteins and other 
glycoconjugates include aldehyde-amine coupling, thiol-ene click chemistry, and the 
use of unnatural amino acids to allow specific conjugation reactions that are 
orthogonal to the reactivity of all naturally occurring amino acids, e.g. via azide-
alkyne click chemistry (Hermanson, 2008). 
Although the CM5 biosensor chip is used most frequently, other sensor chips are 
available for special purposes. The CM4 sensor chip has a lower degree of 
carboxymethylation than CM5 (less negatively charged) resulting in reduced 
nonspecific binding. The CM3 sensor chip, with shorter carboxymethylated dextran 
than CM5, which works well with whole cells. The C1 chip has a  flat 
carboxymethylated surface and no dextran matrix and works well for whole cells and 
viruses. The AU chip contains bare gold. The NTA (nitrilotriacetic acid) chip is 
designed to bind histidine-tagged molecules. The SA chip which is a CM5 chip with 
covalently immobilized streptavidin for capturing biotinylated molecules. The HPA 
chip is essentially a "blank" chip that lacks the carboxymethyl dextran of the CM5 
chip. The surface is composed of hydrophobic alkanethiol groups. This chip can be 
used to mimic conditions of an ELISA (hydrophobic adsorption of protein), or to lay 
down lipid monolayers of various compositions. The latter can be used to study 
protein-lipid interactions or protein-protein interactions using a membrane-associated 
protein/receptor.  
Introduction 
 
 
34 
For drug residue detection, the CM5 biosensor chip is most frequently applied 
(Johansson, 2004). In the present study, antibodies, antibiotic-protein conjugates, 
antibiotic-derivatives and antibiotics themselves were immobilized on CM5 biosensor 
chips using the routine NHS-based amine coupling chemistry. For the immobilization 
of macromolecules, such as antibodies and drug-protein conjugates (Part III), 
electrostatic attraction is used for concentrating the ligand at the surface. The 
carboxymethylated surface of the sensor chip has a pKa of around 4. The surface is 
fully charged at pH values above 7. Below pH 7, the charge is gradually reduced, with 
roughly 30% of the groups charged at a pH of 3.5. To achieve efficient pre-
concentration of the ligand, the pH of the buffer used during the immobilization 
should be higher than 3.5 and lower than the IP of the ligand. Due to this pre-
concentration, relatively low ligand concentrations (of the order of 20 – 50 μg ml-1) 
can be applied. Such electrostatic pre-concentrations are usually ineffective for small 
molecules and high concentrations (typically 5-10 mM) are used during the 
immobilizations to compensate for this effect (Part II). Due to contamination 
problems in the IFC, the direct immobilization of small molecules into the different 
flow channels (Fcs) is not recommended. Sensor chip whole surfaces were coupled 
with small molecules outside the instrument. For the immobilizations to the surfaces 
in the different Fcs, lower concentrations of protein-conjugates were used (Haasnoot 
et al., 2000b). Nowadays, a device (Surface Prep Unit) is available for the Biacore 
3000 that makes it possible to immobilize small molecules on the chip surface in the 
different Fcs avoiding the use and contamination of the IFC. This device was used for 
the immobilization of the different aminoglycosides in the different Fcs (Chapter 8). 
In the case of the immobilization of carboxylated-sulfonamide derivatives (Chapter 5) 
or flumequine via its carboxyl group (Chapter 9), ethylenediamine (EDA) was used 
during the two-steps coupling procedure in which the carboxylated chips surface was 
reacted with EDA to create an amino-group containing surface which reacted with the 
esterified carboxylated ligands (O’Shannessy et al., 1992). 
1.4 ANTIBODIES 
1.4.1. Antibody classes 
The central ingredient of any immunoassay (IA) is the antibody molecule. Antibodies 
belong to the family of macromolecules known as immunoglobulins, which are 
present at 12-15 mg ml-1 in blood serum, amounting to nearly one fifth of its total 
protein content (Harlow and Lane, 1988). Immunoglobulins appear as a very diverse 
group of proteins, also named globulins, that share key structural and functional 
features. Functionally, they can be characterized by their ability to bind both to 
antigens and to specialized cells or proteins of the immune system. Structurally, 
antibodies are composed of one or more copies of a characteristic unit that can 
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typically be visualized as forming a Y shape (Figure 11). Each Y contains four 
polypeptides – two identical copies of a polypeptide known as the heavy chain and 
two identical copies of a polypeptide called the light chain. There are two forms of 
light chains and a single antibody will have light chain subunits of either lambda (λ) 
or kappa (κ) variety, but not both types in the same molecule. In mammals five 
immunoglobulin classes (IgG, IgM, IgA, IgD and IgE) are distinguished by the type 
of heavy chains found in the molecule. Where IgG molecules have heavy chains 
known as γ-chains, IgMs have μ-chains, IgAs have α-chains, IgEs have ε-chains, and 
IgDs have δ-chains. The sequences of the IgG heavy chains have also shown that 
there are four subclasses of γ-chains known as IgG1, IgG2a, IgG2b and IgG3. The 
differences in the heavy-chain polypeptides, primarily in the Fc fragment (for the 
fragment that crystallizes), allow these proteins to function in different types of 
immune responses and at particular stages of the maturation of the immune response. 
Different classes of antibodies may also vary in the number of Y-like units that join to 
form the complete protein. IgM antibodies have five Y-shaped units and IgA 
antibodies have one, two or three units. The sites for association between the different 
Y units, the J-chain - a very acidic polypeptide of MW 15000 that is very rich in 
carbohydrate -, are also found in the Fc region. 
 
Figure 11. Schematic representation of a typical immunoglobulin-G molecule. The 
organization of the variable portions of the heavy and light-chains depicting the framework 
regions (FR) and the complementarity determining regions (CDRs) is shown in the lower 
portion of the figure. 
In mammals, IgM constitutes about 10% of the antibodies. It is produced early in the 
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immune response and reacts quite strongly with an antigen due to the combined 
strength of the multiple bond interaction, which is called the avidity (Tijssen, P., 
1985). The multivalent IgM has an avidity of 102-104 times higher than the affinity of 
the isolated sites (its Fab fragments). However, the pentameric IgM is particularly 
sensitive to mild reduction by thiol reagents at neutral pH (splitting into monomers) 
and losing its high avidity. 
IgG represents 70% of the serum immunoglobulins and constitutes the majority of the 
secondary immune response to most antigens. IgG molecules have three domains (two 
Fab domains and one Fc domain; see Figure 11). The Fab domains (fragment that 
carries the antigen binding site) - forming the arms of the Y shape - are identical, 
which makes IgG molecules bivalent. The domain that is involved in immune 
regulation is the Fc fragment, and this forms the base of the Y structure. The two 
heavy (H-chain) polypeptides (each 440 amino acids [approximately 55,000 Daltons]) 
in the Y-structure are identical. The two light (L)-chains (each about 220 amino acids 
(about 25,000 Daltons)) are also identical. One L-chain associates with the amino-
terminal region of one H-chain to form an antigen-binding site. The carboxy-terminal 
regions of the two H-chains fold together to make the Fc domain. The four 
polypeptide chains are held together by disulphide bridges and noncovalent bonds. L-
chains can be divided into two regions, the variable (V) and the constant (C) region 
(each about 110 amino acids in length) and H-chains can be divided into four regions 
(1 V and 3 C regions). The V regions (located at the amino end) of one H-chain and 
one L-chain combine to form one antigen binding site. The V regions of both chains 
are organized into three hyper-variable or complementarity determining regions 
(CDRs) separated by four framework regions (FR) (Figure 11, lower panel). The 
greatest amino acid sequence variation occurs within the CDRs whereas the 
framework regions are less variable. The association of the CDRs, three from the H- 
and three from the L-chains, form the antigen-binding site. The heterogeneity in the 
V-regions of both L- and H-chains confer the capability to respond to a very large 
number of antigens. The diversity of the mammalian immune response is maximally 
105-106 different antibodies. 
1.4.2 Antibody-antigen interaction 
The ability of an antibody molecule to specifically bind an antigen, or ligand 
molecule, is controlled by structural and chemical interactions that occur within the 
antigen-binding site. The antigen-antibody interaction is a reversible interaction 
dominated by thermodynamic control (Equation 5), and does not involve formation of 
covalent bonds. The binding is the result of a variety of interactions including 
hydrophobic, ionic, hydrogen bonds, π-π electron interaction, and van der Waals 
forces. Typically, the binding energy (relative affinity) of the antibody is larger with 
an increasing number of specific chemical interactions that occur between an analyte 
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and the amino acid residues in the antigen binding site. Thus the specificity and 
sensitivity of an immunoassay are controlled by the precise nature of the antigen-
antibody binding process and small changes in antigen structure can profoundly affect 
the strength (or affinity) of the antibody-antigen interaction.  
The affinity of an antibody describes the amount of antibody-antigen complex that 
will be found at equilibrium. High-affinity antibodies (i.e. KA = 1012 mol-1) will bind 
larger amounts of antigen in a shorter period of time than low-affinity antibodies (i.e. 
KA = 104 mol-1). High-affinity antibodies perform better in all immunochemical 
techniques. Whereas the affinity of an antibody reflects its binding energy to a single 
epitope, avidity reflects the overall binding intensity between antibodies and a 
multivalent antigen presenting multiple epitopes. Avidity is determined by the affinity 
of the antibody for the epitope, the number of antibody binding sites, and the 
geometry of the resulting antibody-antigen complexes. Avidity is also assay specific, 
and differs when the same antibodies are used in different techniques (Lipman et al., 
2005).  
 
1.4.3 Antibodies towards haptens 
The principal function of the immune system is to protect the organism from 
infectious organisms and from their toxic products. The immune system contains 
more than 109 antibody-producing cells (lymphocytes) distributed throughout the 
body. They travel through the blood and lymphatic systems, pausing and 
accumulating in specialized structures known as lymphoid organs, which in mammals 
are the lymph nodes and spleen. Many types of lymphocytes with different functions 
have been identified. The immune system has two basic components that respond to a 
challenge of a foreign substance: a cellular response mediated by T lymphocytes and a 
humoral response mediated by antibodies secreted by B lymphocytes (Figure 12).  
 
Figure 12. General simplified graphic of the process of antibody production showing the 
necessary physical link between the cells involved. B cell is a cell that secretes antibodies, T 
cell activates B cells and antigen is the substance recognized by the immune system. 
Interactions in the graphic:1. antigen is bound, 2. antigen is degraded in the cell, 3. B cell 
presents an antigen fragment, 4.T cell recognizes the antigen fragment, 5. T cell activates the 
B cell to produce antibodies,  6. the B cell secretes antibodies (Harlow and Lane, 1988). 
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The B cells recognize antigens through cell-surface immunoglobulins that bind to 
discrete chemical and structural epitopes on the antigen molecule. Each B cell 
possesses surface immunoglobulins of a single type (i.e., is monoclonal) and has a 
binding capacity that is directed against a discrete epitopic target. Most of the cellular 
functions of the immune system can be described by grouping lymphocytes into three 
basic types – B cells, cytotoxic T cells and helper T cells. All three carry cell-surface 
receptors that can bind antigens. B cells secrete antibodies, and carry a modified form 
of the same antibody on their surface, where it acts as a receptor for antigens. 
Cytotoxic T cells lyse foreign or infected cells, and they bind to these target cells 
through their surface antigen receptor, known as the T-cell receptor. Helper T cells 
play a key regulatory role in controlling the response of B cells and cytotoxic T cells, 
and they also have T-cell receptors on their surface. Two fundamental requirements 
must be met by a molecule to be immunogenic: (i) it should be foreign to activate the 
defense mechanism; and, (ii) it must be of a certain complexity to react with the 
different components of the immune system necessary to induce the immune response 
(immunogenicity). In general, for a compound to elicit a primary antibody response 
and a strong secondary response, it must contain an epitope that can bind to the cell-
to-cell communication between B cells and helper T cells. This is achieved by 
providing a physical link between these two cells (Figure 12). When an antigen binds 
to the antibodies on the surface of the B cell, this antigen/antibody complex is taken 
up by the B cell and processed by proteolysis into peptides. These fragments migrate 
to the surface, where they bind to receptors known as class II proteins. This complex 
attracts a matching helper T cell, which releases lymphokines and activates the B cell. 
As the activated B cell then begins to divide, its offspring (plasma cell) secretes 
millions of copies of the antibody that recognizes this antigen in the blood. The 
physical link between the B and T cells is formed by the antigen fragment and is an 
essential step in the differentiation of a B cell into a plasma cell. The site for class II-
T-cell receptor binding does not need to be related structurally to the epitope for 
surface antibody binding, but the two sites must occur on the same molecule or 
physical complex. This requirement for both an epitope and a class II-T-cell receptor 
binding site imposes a minimum size limit on an immunogen, and molecules of less 
than about 3000-5000 Daltons are generally not good immunogens. Compounds 
smaller than this can often bind to surface antibodies on the B cell but may not have 
suitable sites for the simultaneous binding of a class II protein and a T-cell receptor. 
Physical coupling of small molecules to larger immunogenic molecules overcomes 
this problem by providing the missing class II-T-cell receptor binding sites and allows 
the induction of a strong antibody response against the small molecules. Small 
molecules showing this behavior are defined as haptens. The large molecules that 
render them immunogenic are defined as carriers. 
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1.4.4 Conjugation of haptens 
Haptens are coupled to proteins for the preparation of immunogenic hapten-carrier 
complexes. A foreign protein administered in vivo by any one of a number of potential 
routes nearly ensures the stimulation of an immune response. In addition, protein 
carriers are chosen for their solubility and functional groups that could facilitate easy 
conjugation with a hapten molecule. The most common carrier proteins are keyhole 
limpet hemocyanin (KLH; MW 4.5 x 105 to 1.3 x 107), bovine serum albumin (BSA; 
MW 67,000), the highly positive charged aminoethylated (or cationized) BSA (cBSA 
- prepared by modification of its carboxylate groups with ethylene diamine to increase 
the immunogenicity compared to BSA), thyroglobulin (MW 660,000) and ovalbumin 
(OVA; MW 43,000).  
The coupling chemistry used to prepare an immunogen from a hapten and carrier 
protein is an important consideration for the successful production and correct 
specificity of the resultant antibodies. The choice of linking methodology is governed 
by the functional groups present on both the carrier and the hapten, as well as on the 
orientation of the hapten desired for appropriate presentation to the immune system 
(Hermanson,1996). 
Antisera (blood serum of immunized animals) to sulfadimidine and other 
sulfonamides have been raised using hapten conjugates prepared by diazotization of 
the aromatic amino group (Ram et al., 1991; Renson et al., 1993) or by introducing 
spacers such as glutaraldehyde (Fleeker and Lovett, 1985; Dixon-Holland and Katz, 
1988; Märtlbauer et al., 1992) or a succinyl group (Jackman, 1992; Haasnoot et al., 
1996). However, antibodies developed by these procedures were very specific in 
relation to other sulfonamides. In this research, this was confirmed during the 
evaluation of polyclonal antibodies raised against eight different sulfonamides, 
coupled to carrier proteins via different procedures (succinylation, glutaraldehyde 
coupling, epoxy activation, periodate cleavage and diazo-coupling), which were all 
very specific (Chapter 3).  
Ideally, it would be more efficient to develop a more general immunoassay that could 
detect a number of different sulfonamides (a multi-sulfonamide assay). Sheth and 
Sporns (1991) were the first who reported about the development of such an ELISA 
based on polyclonal antibodies. They chemically linked a sulfathiazole derivative 
(TS) to proteins in such a way that the aromatic amino group, common to all 
sulfonamides was distal to the protein (Figure 13). TS was coupled to the carrier 
proteins via the carboxyl group which was esterified with N-hydroxysuccinimide 
(NHS) and reacted with the amines of the carrier proteins. A similar approach was 
described by Assil et al. (1992) who used another sulfonamide derivative (PS, see 
Figure 13). In this study, the NHS coupling of TS and PS to the carrier proteins KLH 
and BSA was used prior to the immunization of mice. Pabs were obtained and Mabs 
were developed and they were both tested in an ELISA format (Part I).  
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The aminoglycoside dihydrostreptomycin (DHS) was coupled to the carrier proteins 
via two reactions (Chapter 7). The one-step glutaraldehyde coupling (Hermanson, 
1996) was performed at two pH values (7.3 and 8.5) because of observed differences 
in solubility of the proteins. Glutaraldehyde is a homobifunctional cross-linking 
reagent that reacts with primary amine groups of the proteins and the aminoglycoside 
to form Schiff bases, which can be reduced to form stable secondary amine linkages. 
The other procedure used succinic anhydride pre-activated carrier proteins in order to 
introduce additional coupling sites and to reduce the chance of creating inter-protein 
cross-links. Subsequently, the conjugate reaction between the protein carboxyl groups 
and the amino groups of the aminoglycoside was performed with the carbodiimide 
reaction (EDC) forming an amide bond. 
The mixed anhydride procedure (Tijssen, 1985) was followed for the coupling of 
flumequine to the carrier proteins (Chapter 9). Here, the carboxyl groups of 
flumequine were converted to acid anhydrides that react smoothly with the amino 
groups of proteins to again form amide bonds.  
 
Figure 13. Molecular structures of the immunogens used for the development of generic Pabs 
and Mabs). TS = N1-[4-(carboxymethyl)-2-thiazolyl]sulfanilamide; PS = N1-[4-methyl-5-[2-
(4-carboxyethyl-1-hydroxyphenyl)]-azo-2-pyridyl]sulfanilamide. 
1.4.5 Immunization 
In accordance with the Amsterdam protocol on animal protection and welfare of 1997 
(http://eur-lex.europa.eu/en/treaties/dat/11997D/htm/11997D.html (approached on 
2009-03-30)) and a recent proposal of the European Commission, of 5 November 
2008 to revise Directive 86/609/EEC (http://ec.europa.eu/environment/chemicals/lab 
_animals/home_en.htm (approached on 2009-03-30)), animal experiments must be 
replaced with alternatives wherever possible, the number of animals used should be 
minimized and suffering of animals must be avoided or kept to a minimum. The 
animal experiments applied in this study were subject to strict legal controls and  
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submitted for examination to an Animal Experiments Committee that checked 
whether the purpose of the experiment is proportionate to the distress caused to the 
animal.  
Immunizing and bleeding of animals for the production of polyclonal sera or to act as 
donors for hybridoma fusions (Chapter 1.4.6) is a technically straightforward 
procedure. To obtain good antibody responses, healthy and well-cared-for animals are 
essential. To inject and bleed animals safely and painlessly requires skill, patience, 
and practical training. In this study, the facilities at the Laboratory of Hormonology 
(Marloie, Belgium) were used for the immunization and bleeding of rabbits to obtain 
polyclonal antisera. For the immunizations and bleedings of mice and the subsequent 
removal of the spleens for the production of monoclonal antibodies, the facilities of 
the Centre for Small Experimental Animals (Wageningen, the Netherlands) were 
used. 
The production of antibodies relies on the in vivo humoral response of the animal 
(Harlow and Lane, 1988). After the primary injection of antigen, an increase in B cells 
bearing surface antibodies specific for the inoculated antigens is first detected after 5-
6 days. Antibodies are usually detected in the serum from around 7 days after the 
injection and persists at a low level for a few days, typically reaching peak titer 
around day 10. Primary responses often are very weak and the sera contain a 
substantial proportion of IgMs. A minimum delay of 2 or 3 weeks is required before 
reintroducing the antigen. The number of B cells bearing antigen-specific cell-surface 
antibodies increases exponentially after the second injection and high levels of 
antibody persist for about 2-4 weeks after the second injection. The responses to the 
subsequent injections, given every 4-6 weeks, mirror that of the secondary injection. 
Higher titers of antibody are reached, and the nature (more IgG) and quality (higher 
affinity) of the antibodies changes during these injections which is known as 
maturation of the immune response. Levels of 1 mg ml-1 of antigen-specific IgG are 
possible, which is about 10% of the total IgG content of serum. 
During these immunizations, adjuvants (e.g. Freund’s or Specol) are used to improve 
or enhance an immune response to the antigen. There are two types of Freund’s 
adjuvants: Freund’s Complete Adjuvant (FCA) and Freund’s Incomplete Adjuvant 
(FIA). FCA is a water-in-oil emulsion that localizes antigen for release periods up to 6 
months. It is formulated with mineral oil, the surfactant mannide monoleate and heat-
killed Mycobacterium tuberculosis, Mycobacterium butyricum or their extracts. This 
potent adjuvant stimulates both cell-mediated and humoral immunity with preferential 
induction of antibodies against epitopes of denatured proteins. Although FCA has 
historically been the most widely used adjuvant, it is one of the more toxic options 
due to the use of non-metabolizable mineral oil, while it also induces granulomatous 
reactions. Its use is limited to laboratory animals and it should be used only with weak 
antigens. In addition, it should not be used more than once in a single animal, since 
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multiple FCA inoculations can cause severe systemic reactions and decreased immune 
response. FIA has the same formulation as FCA but does not contain mycobacterium 
or its components. FIA usually is limited to booster doses of antigen since it is 
normally much less effective than FCA for primary antibody production. FCA and 
FIA are normally mixed with equal parts of antigen preparations to form stable 
emulsions.  
Specol is a water-in-oil adjuvant composed of defined and purified light mineral oil 
(Stills, 2005). It has been suggested as an alternative to Freund's adjuvant for 
hyperactivation of the immune response in rabbits (Leenaars et al., 1994). Specol can 
be used for antigens of low immunogenicity and can be administered equally 
effectively by the subcutaneous or intraperitoneal routes.  
In the present research, rabbits (n=12) and mice (n=10) were immunized using 
Freund’s adjuvants or specol (Chapters 2, 3, 7 ,9). 
1.4.6 Polyclonal, monoclonal and recombinant antibodies. 
In immunoassays for residue analysis in food, polyclonal (Pabs), monoclonal (Mabs) 
and occasionally recombinant antibodies (Rabs) are used. All three antibody-types 
were applied during this research and some relevant background is described below. 
 
Pabs are antibodies that are derived from different B cell lines each with one 
specificity i.e. the clonotype. An immunized animal produces generally a random 
number of clonotypes and its antiserum becomes polyclonal. It has been estimated 
that 10-40 × 106 distinct clonotypes can theoretically be generated by a mouse which 
contains 2 × 108 B cells (Tijssen, 1985). About 1 out of every 10000 clonotypes 
seems to recognize a given epitope with varying degrees of affinity. Thus, in theory, 
several thousand clonotypes could be produced by an animal against a given epitope. 
In practice, however, only a random few (up to about ten) B-cell clones are activated 
and only few distinct antibodies against an epitope are generated out of this large 
repertoire of randomly formed specificities (Briles and Davie, 1980). It is therefore 
practically impossible to make reproducible Pabs against any epitope. Even antisera 
from the same animal taken at different times differ in their properties. Pabs are 
typically produced by immunization of a suitable mammal, such as a mouse, rat, 
guinea pig, hamster, rabbit, goat, sheep, donkey or horse. However, rabbits are the 
most commonly used laboratory animals for this purpose. They are easy to keep and 
handle, can be safely and repeatedly bled, and the antibodies they produce are well 
characterized and easily purified. With careful management, a few hundred ml of 
serum can be obtained from one rabbit through the course of an immunization regime 
and from different bleedings. The concentration of specific antibody in polyclonal 
sera is typically 50 to 200 μg ml-1, and the range of total IgG concentration in sera is 
between 5 and 20 mg ml-1 (Lipman et al., 2005). Goats, sheep or horses are generally 
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used when large quantities of antisera are required. When using rabbits, young adult 
animals (2.5–3.0 kg) should be used for the primary immunization because of the 
vigorous antibody response. Immune function peaks at puberty and primary responses 
to new antigens decline with age. Female rabbits are generally preferred because they 
are more docile and are reported to mount a more vigorous immune response than 
males. At least two animals per antigen should be used to reduce the change of 
potential total failure resulting from non-responsiveness to antigens of individual 
animals. Some investigators favor chickens because they transfer high quantities of 
IgY (equivalent to mammalian IgG antibodies) into the egg yolk, and harvesting 
antibodies from eggs eliminates the need for the invasive bleeding procedure 
(Albrecht et al. (1996); Pichler et al., (2004); Schneider et al. (2004)).  
So far, in residue assays, Pabs are applied most frequently. The main problem with 
polyclonal antisera is the batch quantity and the batch-to-batch variation. Therefore 
the amount of tests is limited. However, with for instance a batch of 25 ml of a 
polyclonal antiserum and a usually optimum dilution of 40,000 times (total volume = 
1,000,000 ml of which 2.5 ml is used per microtiter plate), 400,000 microtiter plate 
tests kits can be prepared. For most of the drug residue test kits, this is much more 
than the world-wide market needs for 50 or more years. In special circumstances, e.g. 
for high volume (on-line) testing, test strips, immunoaffinity chromatography (IAC) 
and for “best-sellers”, more antibodies are necessary. Increased volumes of Pabs can 
be obtained by mixing different batches of (rabbit) antisera obtained after different 
boosters or from different rabbits. However, in most cases, the quality of antisera 
improves after several boosters (antibody maturation) and mixing with lower-quality 
batches might reduce the test performance. Other possibilities are the immunization of 
larger animals (goat, sheep, donkey, etc.) or the use of chicken eggs. 
In the present study, Pabs were developed in rabbits against sulfonamides (Part I) and 
flumequine (Chapter 9).  
 
Mabs. The preparation of a homogeneous population of antibodies was achieved with 
the development of the technology for hybridoma production. Antibodies that are 
produced by hybridomas are known as monoclonal antibodies (Mabs). In the animal, 
antibodies are synthesized primarily by plasma cells (B lymphocytes), which cannot 
be grown in tissue culture and cannot be used as an in vitro source of antibodies. 
Köhler and Milstein (1975), developed a technique that allows the growth of clonal 
populations of cells secreting antibodies with a defined specificity. In this technique 
an antibody-secreting cell, isolated from an accumulating organ of an immunized 
animal (e.g. from the spleen), is mixed with a myeloma cell, a type of B-cell tumor, 
centrifuged to generate good cell-to-cell contact, and fused with polyethylene glycol 
(PEG) as a fusing agent. These hybrid cells or hybridomas can be prepared by fusing 
myelomas and antibody-producing cells isolated from different species, but the 
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number of viable hybridomas increases dramatically when closely related species are 
used. Even in the most efficient hybridoma fusions, only about 1% of the starting cells 
are fused, and only about 1 in 105 form viable hybrids. This leaves a large number of 
unfused cells still in the culture. The cells from the immunized animal do not continue 
to grow in tissue culture, and so do not disturb further work. However, the unfused 
myeloma cells are well adapted to tissue culture and must be killed, which is achieved 
by drug selection (e.g. aminopterin) in which the synthesis of nucleotides is blocked. 
The hybridomas can be maintained in vitro and will continue to secrete antibodies 
with a defined specificity. Approximately one week after the fusion, colonies of 
hybrid cells will be ready to screen. During the screening, samples of tissue culture 
media are tested for the presence of the desired antibodies using for instance antibody 
capture assays with antigen-coated 96-wells microtiter plates (Chapters 2 and 7). 
After a positive well has been identified, the cells are cloned. The original positive 
well will often contain more than one clone of the hybridoma cells and single-cell 
cloning has to be performed. In cloning by limiting dilution (Goding, 1986), cells are 
distributed over a number of wells at a dilution so that some wells should not show 
cellular growth. By repeating this process two or three times (recloning), single-cell 
clones are obtained and medium volumes can be expanded. The antibody 
concentration in the medium is about 2-50 μg/ml (Tijssen, 1985). Standard procedures 
for the preparation, purification and characterization of Mabs are described in 
laboratory manuals (e.g. Harlow and Lane, 1988, Campbell, 1984, and Goding, 1986).  
The usefulness of Mabs stems from three characteristics: their specificity of binding, 
their homogeneity, and their ability to be produced in unlimited quantities. The 
production of Mabs allows the isolation of reagents with a unique, chosen specificity. 
Because all of the antibodies produced by descendants of one hybridoma cell are 
identical, Mabs are powerful reagents for testing for the presence of a desired epitope. 
In addition, one unique advantage of hybridoma production is that impure antigens 
can be used to produce specific antibodies. The limitations of hybridoma technology 
include the extensive commitment of time, labor and expense, the requirement for 
animal use and specialized cell culture facilities, and the expertise needed to prepare 
and screen large number of hybridomas to select the best ones (Lipman et al., 2005).  
Compared with the development of Pabs, the developments of Mabs is laborious and 
this technology is applicable only for tests that are intended for a large (worldwide) 
and stable market (i.e. pesticide, mycotoxin and beta-lactam assays). Pabs can be 
generated much more rapidly, at less expense, and with less technical skills than is 
required to produce Mabs. One can reasonably expect to obtain Pabs within several 
months of initiating immunizations, whereas the generation of hybridomas and 
subsequent production of Mabs can take up to a year or longer in some cases (Lipman 
et al., 2005), with no guarantee for a better performance. Märtlbauer et al. (1994) 
compared Mabs and Pabs for the detection of antibiotics and sulfonamides and with 
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most Pabs (five out of six) a better sensitivity was obtained. 
In the present study, Mabs were developed against sulfonamide-derivatives (Part I) 
and dihydrostreptomycine (Chapter 7). Kohen et al. (2000) raised another Mab against 
sulfamethazine with the purpose to produce anti-idiotype antibodies (recognizing the 
binding site of the Mab). This Mab was also identified as an antibody recognizing 
several important sulfonamides (Haasnoot et al., 2000b), and was used in this research 
to develop a fast multi-sulfonamide biosensor immunoassay for the analysis of broiler 
sera (Chapter 4).  
Rabs. Until the late 1980s, the production of antibodies relied primarily on animal 
immunisation. From then, the development of molecular methods for the expression 
of recombinant antibody fragment in bacteria and techniques for production and 
screening of combinatorial libraries has opened a wide range of opportunities for the 
selection of recombinant antibodies and their engineering (Maynard and Georgiou, 
2000). Several in vitro methods have been developed for the production of antibodies  
(Bradbury et al., 2003), but the most commonly used technology is phage display 
(Brichta et al., 2005). Phage display refers to the display of functional foreign 
peptides, proteins or antibody fragments on the surface of a bacteriophage. This is 
accomplished by fusion of the DNA coding sequences of the protein to be displayed 
into the phage genome to the gene encoding one of the phage surface proteins. 
Surface display of the antibodies allows affinity selection of antibodies by exposing 
the phage library to immobilized antigen molecules. The captured phage particles are 
eluted from the antigen, amplified by infecting Escherichia coli host cells and used in 
a subsequent round of affinity selection. After the final round of affinity selection, 
phage particles are amplified in order to prepare and characterize their displayed 
antibodies individually and the monoclonal phage population with the desired binding 
specificities can be isolated.  
With regard to antigenic specificity, different types of phage libraries are used for 
selection of specific recombinant antibodies: (1) a specific library sourced from 
immunized animals, (2) a single-pot (general) library created with no specificity 
against a particular analyte which avoids the use of laboratory animals (Willats, 
2002). The most popular recombinant antibody format is the single-chain variable 
fragment (scFv), containing the variable domains of the heavy and light chain (Figure 
11) linked to a single protein by a polypeptide linker. It contains a complete binding 
site and it is the smallest effective antibody fragment (26-27 kDa). Spinks et al. 
(1996) used this technique to study the development of broad-specificity (generic) 
antibodies to beta-lactams and aminoglycosides. Other Rab applications are described 
for pesticides (Kramer, Hock, 1996 and 2003) and potato glycoalkaloids (Kamps-
Holtzapple, Stanker, 1996). In comparison to Pabs and Mabs, Rabs, using the phage 
display technique, can be prepared faster, in more automatic process and with reduced 
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consumption of laboratory animals (Brichta et al., 2005). 
The multi-sulfonamide Mab 27G3 producing hybridoma cell line (Chapter 2) was 
used by Korpimäki et al. (2002, 2003 and 2004a,b) for the development and 
modification of multi-sulfonamide scFv molecules. Random mutant libraries were 
created with error-prone PCR over the whole scFv coding region. Several of the 
obtained mutants had significantly altered binding properties and improved broad 
specificity. In a competitive time-resolved fluoroimmunoassay, one of the first 
selected mutants (A.3.5) showed an improved sensitivity towards several 
sulfonamides compared with the wild-type Mab (Korpimäki et al., 2002).  However, 
they displayed a low sensitivity towards important sulfonamides, such as 
sulfamethazine, sulfadimethoxine and sulfaquinoxaline. In the following study these 
authors generated new antibody libraries by recombining the previously enriched 
libraries with DNA-shuffling and introducing new mutations with error-prone PCR 
and oligonucleotide-directed mutagenesis (Korpimäki et al., 2003). In the time-
resolved fluoroimmunoassay, the selected mutant from that study (M.3.4) showed an 
improved sensitivity for all 13 sulfonamides tested, and even sulfamethazine, 
sulfadimethoxine and sulfaquinoxaline could be measured below the 100 ng/ml level 
(Korpimäki et al, 2004b). Both Rabs (A.3.5 and M.3.4) were used in the present study 
for the development and evaluation of multi-sulfonamide inhibition biosensor 
immunoassays (Chapters 5 and 6). 
 
1.5 PERFORMANCE OF ANALYTICAL METHODS 
With the publication of Commission Decision 2002/657/EC from 12 August 2002 
(EC, 2002a), new defined analytical parameters came into force which, until then, 
were to a large extent unknown to the analytical community. The decision limit (CCα) 
means the limit at and above which it can be concluded with an error probability of α 
that a sample is non-compliant and it replaced terms as limit of detection, limit of 
determination etc. The detection capability (CCβ) was defined as the smallest content 
of a substance that may be detected, identified and/or quantified in a sample with an 
error probability of β. The minimum required performance limit  (MRPL) was defined 
as the minimum content of an analyte in a sample which at least has to be detected 
and confirmed. According to the definitions described in this decision, the biosensor 
immunoassays (BIAs) used in this study are quantitative screening methods because 
they determine, by means of calibration curves, the amount of substances expressed as 
numerical values of appropriate units (ng ml-1 or g‐1). Furthermore, the BIAs are 
classified as screening methods that are used to detect the presence of a substance or 
class of substances at the level of interest. These methods have the capability for a 
high sample throughput, and are used to sift large numbers of samples for potential 
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non-compliant results and should be designed to avoid false compliant results. Only 
those analytical techniques for which it can be demonstrated that they are validated 
and have a false compliant rate of <5% at the level of interest shall be used for 
screening purposes in conformity with Directive 96/23/EC (EC, 1996b). In the case of 
a suspected non-compliant result, this result should be confirmed by a confirmatory 
method which provides information on the chemical structure of the analyte. In the 
case of substances for which no permitted limit has been established, the CCα can be 
established for quantitative and qualitative assays by analyzing at least 20 blank 
materials per matrix to be able to calculate the signal-to-noise ratio and three times the 
signal-to-noise ratio can be used as the decision limit. In the case of substances with 
an established permitted limit such as an MRL (section 1.1), CCα can be established 
by analyzing at least 20 blank materials per matrix fortified with the analyte at the 
permitted limit. The concentration at the permitted limit plus 1.64 times the 
corresponding standard deviation equals the decision limit. The detection capability 
(CCβ) can be established by analyzing 20 blank samples spiked with analyte(s) at the 
decision limit. The value of CCα plus 1.64 times the standard deviation of the within-
laboratory reproducibility of the measured content equals the detection capability. In 
Chapter 9 of this thesis, these new parameters were established for the detection of 
flumequine in tissue and serum. 
 
1.6 AIMS AND SCOPE 
Within this research, SPR-based biosensors from Biacore were used to develop and 
study the application of multiplex  biosensor immunoassays (using multi-component 
antibodies and/or combined immunoassays with serially connected flow channels) in 
the animal food chain for the detection of antibiotics classified within three different 
groups; (i) sulfonamides, (ii) aminoglycosides and (iii) quinolones. Different types of 
antibodies (polyclonal, monoclonal and recombinant mutants) were compared in 
different assay formats (direct and inhibition) and combined (multiplexed) assays 
were developed and tested with different sample materials (milk, serum and tissue). 
Sulfonamides were chosen as model compounds to study the development and 
performance of group-specific or multi-component antibodies (Part I and II).  
The scientific challenges of this part of the study were: (i) the development, selection 
and improvement of multi-sulfonamide antibodies raised against the generic structure 
of sulfonamides, (ii) the study of the performance of the different antibodies and 
optimize their application for the multi-sulfonamide detection in the optical 
biosensors, and (iii) the development of a well-based answer to the questions whether 
biosensor immunoassays can be used to analyze blood serum for the prediction of the 
levels in tissue, and whether such assays can be combined with serological assays 
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for anti-pathogens. To this aim, two sulfonamide derivatives were prepared and linked 
to carrier proteins in such a way that the common sulfonamide group was distal to the 
proteins (Chapter 2). The performances of Mabs and/or Pabs against these derivatives 
were compared with those of compound-specific Pabs in ELISA (Chapter 3). Multi-
sulfonamide biosensor immunoassays for the fast detection of sulfonamides in 
chicken sera were developed and are described in Part II. These assays used multi-
sulfonamide monoclonal antibodies (Chapter 4) and recombinant mutated antibodies 
(Chapter 5). Mutant antibodies were applied for the biosensor detection of 
sulfonamides in sera of treated broilers and, to predict the levels in tissue, results were 
compared with tissue levels as determined by LC-MS (Chapter 6).  
Mabs against aminoglycosides were used to study the performance of different 
biosensor immunoassay formats for the analysis of milk samples (Part III). In this part 
of the study the scientific challenges were: (i) the investigation of different assay 
formats (direct, inhibition and combined (multiplexed)) and discovery of the best 
assay format for the multiplex detection of antibiotics in milk, (ii) the development of 
the easiest and still effective sample preparation procedure to deal with the foreseen 
matrix interferences from milk, and (iii) the clarifications of the interactions and 
interferences of combined immunoassays in the multiplexed format. In the direct 
assay format, the antibodies were immobilized onto the sensor chip surface and the 
binding of aminoglycosides was measured directly and compared with the inhibition 
assay format, using chips coupled with antibiotic-protein conjugates in which 
solutions for the observed matrix effects from milk were studied (Chapter 7). The 
inhibition assay format, with chips directly immobilized with the aminoglycosides, 
was applied in an assay in which four flow channels were serially connected to 
develop a multiplex immunoassay for the simultaneous detection of five 
aminoglycosides in milk (Chapter 8). For the detection of fluoroquinolones, a multi-
quinolones antiserum was developed previously. However, flumequine has a 
deviating structure and the cross-reactivity in the multi-quinolones assay towards 
flumequine was low. For that reason, a biosensor immunoassay for flumequine in 
serum and muscle was developed in Chapter 9. In a subsequent study (outside the 
scope of this thesis), this assay was combined with the multi-quinolones assay to 
obtain a dual-assay format for the detection of all interesting fluoroquinolones in 
muscle (Marchesini et al., 2007). 
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ABSTRACT 
 
To prepare monoclonal antibodies (Mabs) against the generic part of sulfonamides, a 
sulfathiazole derivative was chemically linked to carrier proteins in such a way that 
the aromatic amino group, common to all sulfonamides, was distal to the proteins. 
Four mice were immunized with the sulfathiazole-protein derivatives. The spleen cells 
of one of the mice were fused with myeloma cells to produce hybridomas of which 
the supernatants were screened in an indirect ELISA (iELISA) for the presence of 
sulfathiazole antibodies. After cloning, positive supernatants were tested in a 
competitive iELISA (ciELISA) for inhibition with 18 sulfonamides. This resulted in 
four different Mabs (all IgG1 kappa light chain) which recognized several 
sulfonamides. By use of the best Mab (27G3) and an optimized ciELISA protocol, 
eight structurally different sulfonamides showed 50% inhibition at concentrations less 
than 100 ng ml–1 or 5 ng/well. However, other relevant sulfonamides (such as 
sulfadimidine, sulfatroxazole and sulfachloropyrazine) were detected at a high level 
only with this Mab. This means that the ciELISA (with the best Mab) showed a broad 
specificity for sulfonamides but the sensitivity towards the different sulfonamides 
varied too much to call it a generic sulfonamide ELISA. 
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INTRODUCTION 
 
The sulfonamides are a group of antimicrobial agents applied in veterinary as well as 
human medicine for the treatment and prophylaxis of bacterial infections 
(Saschenbrecker & Fish, 1980). As a result, foods derived from animals treated with 
sulfonamides may be contaminated with these drugs. Maximum residue limits 
(MRLs) for sulfonamides have been established in many countries. In Canada, the 
European Union and the USA, an MRL of 100 μg kg–1 is set for total sulfonamides in 
edible tissues (Food and Drug Regulations, 1991; EU Regulation, 1999); in Japan, an 
MRL of 20 μg kg–1 is applied for total sulfonamides. In the Netherlands, at least nine 
sulfonamides are allowed to be used in veterinary medicine and, ideally, control 
methods should detect the presence of the total sulfonamides.  
Today, Integral Production Chain Systems demand faster on-site (farmhouses) and/or 
on-line (slaughterhouses) test systems. Immunoassays are capable of detecting low 
amounts of residues in many samples in a short time. Such a high-volume ELISA 
system for slaughterhouse screening of sulfadimidine (= sulfamethazine) in swine 
plasma/serum (approximately 2400 serum/plasma samples in an 8 h working day) has 
been described (Ram et al., 1991). Antisera to sulfadimidine and other sulfonamides 
have been raised using hapten conjugates prepared by diazotization of the aromatic 
amino group (Ram et al., 1991; Renson et al., 1993) or by introducing spacers such as 
glutaraldehyde (Fleeker & Lovett, 1985; Dixon-Holland & Katz, 1988; Märtlbauer et 
al., 1992) or a succinyl group (Jackman, 1992; Haasnoot et al., 1996). However, 
antibodies developed by these procedures are very specific in relation to other 
sulfonamides. Ideally, it would be more efficient to develop an immunoassay that 
could detect a number of different sulfonamides. Sheth & Sporns (1991) were the first 
who reported about the development of such an ELISA based on polyclonal 
antibodies (Pabs). They chemically linked a sulfathiazole derivative to proteins in 
such a way that the aromatic amino group, common to all sulfonamides, was distal to 
the protein. A subset of the Pabs developed against this hapten was competitive with 
different sulfonamides. By use of the best competitive ELISA protocol, nine 
structurally different sulfonamides showed 50% inhibition at concentrations of less 
than 5 μg ml–1. Assil et al. (1992) used a similar approach to develop such an ELISA 
for longer sulfonamides with N1-[4-methyl-5-[2-(4-carboxyethyl-1-hydroxyphenyl)]-
azo-2-pyridyl]-sulfanilamide linked to proteins as the immunization agent. By the 
application of an affinity-purified fraction of the polyclonal serum, they produced an 
ELISA which showed 50% inhibition with seven sulfonamides at concentrations less 
than 10 μg ml–1.  
Muldoon et al. (1999) were the first who reported about the development of generic 
monoclonal antibodies (Mabs) against sulfonamides and use a N-sulfanilyl-4-
aminobenzoic acid hapten-protein conjugate as the immunogen. The sensitivities of 
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their best Mab, referred to as Sulfa-1, for sulfanitran, sulfapyridine and sulfathiazole 
(expressed as IC50 values), were 1.41, 22.8 and 322 ng ml–1. However, the sensitivities 
towards other sulfonamides ranged from 3 to 100 μg ml–1. The detection of 
sulfonamides at the μg ml–1 level is not very useful for the screening of sample 
materials at the MRL levels (20–100 ng ml–1/g–1).  
In this study, we report about the results of experiments in which we followed the 
approach of Sheth and Sporns (1991) and used a sulfathiazole derivative coupled to 
carrier proteins [keyhole limpet haemocyanin (KLH) and bovine serum albumin 
(BSA)] as immunogens. Instead of Pabs, as applied by Sheth & Sporns (1991), we 
investigated the possibility of producing generic Mabs to develop an ELISA in which 
several sulfonamides could be detected at the ng ml–1 level. 
 
 
MATERIALS AND METHODS 
 
Materials 
Bovine serum albumin (BSA), keyhole limpet haemocyanin (KLH), ovalbumin 
(OVA), N-hydroxysuccinimide, polyethylene glycol 1500 (PEG 1500, 50%), 
ammonium bicarbonate, dimethyl sulfoxide (DMSO), sulfadimidine (= sulfametha-
zine), sulfamethoxazole, sulfamethoxypyridazine, sulfamerazine, sulfaguanidine, 
sulfadimethoxine, sulfadiazine, sulfachloropyridazine, sulfacetamide, sulfapyridine, 
sulfathiazole, sulfamethizole and sulfisoxazole were obtained from Sigma-Aldrich 
Chemie BV (Zwijndrecht, the Netherlands). Sulfadoxine, sulfachloropyrazine, 
sulfaquinoxaline and Visking dialysis tube were supplied by Serva (Heidelberg, 
Germany) and sulfamethoxydiazine by Bayer (Leverkusen, Germany). Sulfatroxazole 
was a gift from Leo Pharmaceutical Products (Weesp, the Netherlands). (2-Amino-4-
thiazolyl)-acetic acid, N-acetylsufanilyl chloride and 1,3-dicyclohexylcarbodiimide 
were obtained from Aldrich Chemie (Zwijndrecht, the Netherlands). Magnesium 
sulfate, methanol, sodium hydrogen carbonate, sodium chloride, ethyl acetate, urea, 
glycerol, phosphoric acid, pyridine, iso-propanol, chlorotrimethylsilane and 
dimethylformamide were supplied by Merck (Darmstadt, Germany).  
Rabbit anti-mouse immunoglobulins-horseradish peroxidase (RAM-HRP) was 
purchased from DAKO (Denmark). ELISA microtiter plates, tissue culture plates (96- 
and 24-wells) and culture flasks (5 and 20 ml) were obtained from Costar (Cambridge, 
MA, USA). Dulbecco modified Eagle’s medium (DMEM) and hybridocult were 
obtained from Bio Whittaker (Verviers, Belgium) and Fetal Clone I (FCI) was from 
HyClone (Logan, Utah, USA). Hypoxanthine/thymidine (HT; 50x) and aminopterin 
(A; 100x) were obtained from Life Technologies (Breda, the Netherlands).  
Solutions of tetramethylbenzidine (TMB) peroxidase substrate and peroxide were 
obtained from Kirkegaard and Perry Labs (Gaithersburg, MD, USA). Specol was 
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obtained from DLO Institute for Animal Science and Health (ID-DLO, Lelystad, the 
Netherlands). The BCA protein assay reagents were obtained from Pierce (Rockford, 
ILL, USA). 
 
Preparation of the sulfathiazole derivative 
The sulfathiazole derivative N1[4-(carboxymethyl)-2-thiazolyl] sulfanilamide (TS) 
was prepared according to a modified procedure previously described by Sheth and 
Sporns (1991). 
 
(2-Amino-4-thiazolyl)-acetic acid methyl ester 
A solution of (2-amino-4-thiazolyl)-acetic acid (7.8 g) in dry methanol (100 ml) was 
treated at 0 °C with 20 ml of chlorotrimethylsilane and thereafter refluxed for 2 days. 
Solvents were removed on a Rotavapor and the residue was dissolved in ethyl acetate 
(250 ml). The solution was washed four times with 50 ml of an aqueous saturated 
solution of sodium hydrogen carbonate, until the pH of the carbonate solution was > 7, 
followed by a two times washing with 30 ml of an aqueous saturated solution of 
sodium chloride. The solution was dried by the addition of magnesium sulfate which 
was removed by filtration and the solvent evaporated under reduced pressure on a 
Rotavapor. The solid residue was recrystallized from a mixture of ethyl acetate (30 
ml) and methanol (5 ml) to give 2.5 g of (2-amino-4-thiazolyl)-acetic acid methyl 
ester. Thin layer chromatography (TLC) on silica gel 60 plate (Merck, Germany) with 
ethyl acetate/ether/ethanol (65/30/5) as eluent resulted in one spot and the melting 
point was determined as 122–125 °C. The product was confirmed by NMR: 1H NMR 
(DMSO-d6, 200 MHz): δ 3.46 (d, J = 0.4 Hz, 2H); 3.60 (s, 3H); 6.32 (s, 1H); 6.92 (br 
s, 2H). 13C NMR (DMSO-d6, 50 MHz); δ 36.8 (t); 51.6 (q); 103.2 (d); 144.3 (s); 168.3 
(s); 170.6 (s).  
 
N4-Acetyl-N1-[4-[(methoxycarbonyl)methyl]-2-thiazolyl]-sulfanilamide  
To a solution of (2 amino-4-thiazolyl)-acetic acid methyl ester (1.27 g) in dry pyridine 
(5 ml) was added N-acetylsulfanilyl chloride (1.8 g) at 0 °C. This mixture was stirred 
thereafter for 24 h at room temperature. To this mixture, 2 ml of ethanol was added 
and the pH was adjusted to 3 by the addition of 4 M hydrochloric acid. The precipitate, 
which was formed after 10–20 min, was filtered off and dried under vacuum which 
resulted in 2.1 g of product with a melting point of 225 °C. N4-Acetyl-N1-[4-
[(methoxycarbonyl)methyl]-2-thiazolyl]-sulfanilamide was confirmed by NMR: 1H 
NMR (DMSO-d6, 200 MHz): δ 2.05 (s, 3H); 3.61 (s, 3H); 3.62 (d, J = 8.4 Hz, 2H); 
6.60 (s, 1H); 7,65 (s, 4H); 10.28 (s, 2H). 13C NMR (DMSO-d6, 50 MHz): δ 24.1 (q); 
32.7 (t); 52.1 (q); 105.6 (d); 118.4 (d); 127.0 (d); 130.7 (s); 136.7 (s); 142.5 (s); 168.3 
(s); 168.9 (s); 169.1 (s). 
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N1-[4-(Carboxymethyl)-2-thiazolyl]sulfanilamide (TS)  
N4-Acetyl-N1-[4-[(methoxycarbonyl)methyl]-2-thiazolyl]-sulfanilamide (1 g) was 
dissolved in 25 ml of 2 M sodium hydroxide. This solution was refluxed for 5 h and 
after cooling to room temperature, the pH was lowered to 4 by the addition of 4 M 
hydrochloric acid. The solution was extracted three times with 25 ml of ethyl acetate. 
The ethyl acetate was dried over magnesium sulfate and evaporated which resulted in 
0.2 g of the product. The product was confirmed by NMR: 1H NMR (DMSO-d6, 400 
MHz): δ 3.43 (d, J = 7.2Hz, 2H); 6.50 (s, 1H); 6.57 (d, J = 8.4Hz, 2H); 7.42 (d, J = 8.4 
Hz, 2H). 
 
Coupling of TS to proteins 
 
Preparation of N-hydroxysuccinimide (NHS) ester  
TS (62 mg), N-hydroxysuccinimide (34 mg) and 1,3-dicyclohexyl carbodiimide (44 
mg) were reacted overnight in 1.5 ml of dry dimethylformamide at 4 °C. The 
dicyclohexylurea precipitate was removed by filtration and the clear solution was used 
for coupling to proteins. 
 
Coupling to proteins  
Protein (KLH, BSA and OVA) solutions (1 ml of 5 mg ml–1 of PBS) were cooled in 
an ice bath, 0.5 ml of the NHS ester solution was added and the pH was adjusted to 
7.6. The mixture was stirred for 21 h at 4 °C, thereafter transferred to a dialysis tube 
and dialyzed against 8 M urea (1 l) followed by dialyzing against 0.5 M ammonium 
bicarbonate (4 l) and finally against 0.25 M ammonium bicarbonate (4 l). The protein 
concentrations (0.41, 0.28 and 2.19 mg ml–1 for BSA, KLH and OVA, respectively) 
were determined with the BCA test. The protein solutions were lyophilized and stored 
at –20 °C before use. 
 
Production of Mabs 
 
Immunization of mice  
Four female mice (Balb/c Ola Hsd), 10–12 weeks old, were immunized 
subcutaneously (sc) with 50 μg of BSA- or KLH-hapten conjugates in 100 μl of PBS 
emulsified with 100 μl of Specol. Booster injections (sc) with 25 μg of the 
immunogen in 100 μl of PBS emulsified with 100 μl of Specol were given at 2-week 
intervals. Blood was taken from each mouse prior to the first immunization (pre-
immune) and 1 week after each booster injection. The sera were tested by an indirect 
ELISA for antibodies against TS coupled to OVA. 
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Fusion and cloning  
The four mice were primed intraperitoneally with 25 μg of immunogen in 200 μl PBS 
4–5 days before spleen cell isolation. One mouse was selected for the production of 
hybridomas and the spleen cells of the other mice were stored in liquid nitrogen. 
Hybridoma cells secreting Mabs to the sulfathiazole derivative were prepared using 
murine myeloma P3/NS-1/1-Ag4–1 (NS-1), non-secreting mouse myeloma 
(American Type Culture Collection, Rockville, MA, USA) as the fusion partner. The 
myeloma cells were fused with splenocytes prepared from mouse 98008 at a ratio of 
1:2 using PEG 1500 precipitation. Cells were suspended in HAT selection medium 
[culture medium (DMEM, supplemented with 8% FCI + 1% hybridocult + 0.5% P/S) 
+ 1% HT + 1% A] and plated in 96-well tissue cell culture plates at 100000 cells/well. 
After one week, the medium was changed to HT medium (culture medium + 1% HT) 
and five days thereafter, by culture medium. From day 12 to 14, hybridoma 
supernatants were tested for antibodies to the sulfathiazole derivative using the 
indirect ELISA (iELISA). Cultures containing cells secreting antibodies to the 
conjugate were further tested in the iELISA for antibodies recognizing free 
sulfonamides. Positive cultures were immediately cloned by limiting dilution (average 
0.5 cells/well; Goding, 1986) until stable (2–3 clonings). The Mab-producing clones 
of interest were transferred from the culture in the 96-well plate to 0.5 ml of culture 
medium in a 24-well plate. After the 24-well culture became dense, the culture was 
transferred to 5 or 20 ml culture flasks. Colonies were propagated, frozen (overnight 
at –80 °C in a freezing container filled with isopropyl alcohol) in culture media 
containing 12% dimethyl sulfoxide and stored in nitrogen. The immunoglobulin 
subclass of Mabs secreted by each clone was determined by the Mouse Monoclonal 
Antibody Isotyping Kit (IsoStrip) of Boehringer Mannheim (Germany).  
 
Indirect ELISA (iELISA) 
 
Determination of antibody titers  
TS-OVA in coating buffer (50 ng/100 μl/well) was used as the solid-phase 
immobilized agent. After overnight incubation at 4 °C or 1 h at room temperature, the 
wells were emptied and blocked with 0.1% OVA in coating buffer (50 mmol l–1 
sodium carbonate; pH 9.6) for at least 1 h at room temperature. The plate was emptied 
and stored in 25% glycerol in coating buffer. Prior to use, the plate was washed four 
times with washing buffer. To each well, 100 μl of a serial dilution of serum or 
culture supernatant were added. The plate was incubated at room temperature for 1 h 
and washed four times with washing buffer. Subsequently, 100 μl of rabbit anti-
mouse IgG-HRP (RAM-HRP) in a 1:2500 dilution in PBST were added to each well 
and incubated for 1 h at room temperature. After washing the plate, the bound 
peroxidase was assessed by adding 100 μl of a tetramethylbenzidine peroxidase 
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substrate system (a freshly prepared mixture of solution of TMB peroxidase substrate 
and peroxidase; 1/1; v/v). After incubation in the dark for 20–30 min at room 
temperature, the reaction was stopped by adding 100 μl aliquots of 1 mol l–1 
phosphoric acid and the colored product of the peroxidase reaction was measured at 
450 nm using an Argus 400 microplate reader (Canberra Packard, Downers Grove, IL, 
USA). Serum titers were defined as the final dilution which resulted in an absorbance 
of 2.0.  
 
Competitive iELISA (ciELISA) for characterization of antibody specificity  
After washing the coated and blocked plate (see determination of antibody titers), 50 
μl of a standard solution of sulfonamides was added to the well followed by 50 μl of 
diluted serum or culture supernatant dilutions. The plates were treated further as 
described before. In total 18 sulfonamides were used for competition (see Figure 1). 
In the case of testing culture supernatants, the individual sulfonamides were added to 
the ELISA in amounts of 0.01, 0.1, 1 and 10 μg ml–1 which corresponds to 0.5, 5, 50 
and 500 ng well–1. In the case of competition in blood serum, standard solutions of 
1000 μg ml–1 (5000 ng well–1) were included also.  
 
Optimization experiments for the ciELISA  
A calibration curve of sulfathiazole (0.1–100 ng ml–1) was used during the 
optimization experiments of the ciELISA with the Mabs. Three concentrations of 
coating (TS-OVA) of the microtiter plate (5, 25 and 50 ng of protein 100 μl–1 well–1) 
were compared. The concentration of the Mabs was varied. The conditions of the first 
incubation were varied in time (0.5, 1, 2 and 4 h and overnight) and in temperature 
(4–6 °C, room temperature and 37 °C). These incubations were performed with and 
without mild shaking. The concentration of HRP-labeled second antibody was varied 
and the conditions of the second  incubation were varied as with those applied for the 
first incubation. 
 
 
RESULTS 
 
Synthesis of sulfathiazol derivative 
The synthetic route for the sulfathiazol derivative (TS) is shown in Figure 2. TS was 
prepared according to a modified procedure previously described by Sheth & Sporns 
(1991). The (2 amino-4-thiazolyl)-acetic acid methyl ester was prepared in another 
way by using a chlorotrimethylsilane mediated esterification procedure. The so-
prepared ester had a melting point of 122–125 °C. Sheth & Sporns reported a melting 
point of 169–171 °C. They probably measured the melting point of the hydrochloric 
acid salt.  
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Figure 1. Molecular structures of the sulfonamides used in the competition experiments. 
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Figure 2. Synthetic route to the sulfathiazole derivative N1[4-(carboxymethyl)-2-thiazolyl]-
sulfanilamide (TS). 
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For the synthesis of N4-acetyl-N1-[4-[(methoxycarbonyl)methyl]-2-thiazolyl]-
sulfanilamide, Sheth & Sporns (1991) refluxed the reactants in pyridine for 1.5 h and 
extracted the product in hot water. In our hands this resulted in tarry products. 
Therefore, we performed the synthesis at room temperature by stirring for 24 h and 
the product formed was precipitated at pH 3 and filtered. 
The TS–protein ratios were estimated according to Erlanger et al. (1957) and by the 
presence of free aromatic amino groups measured by the modified Bratton Marshall 
(BM) test as was described by Garden & Sporns (1994). For the BSA conjugates, the 
ratio determined according to Erlanger et al. was 15 mol of hapten mol–1 of protein 
and 33 mol mol–1 with the BM reaction.  
For the KLH conjugate, the ratio was 276 mol mol–1 (Erlanger) and 203 mol mol–1 
(BM) (estimated molecular weight of KLH 3000 kDa).  
 
Determination of antisera titer and specificity 
Antisera from the four mice (98005–98008) immunized with KLH- and BSA-hapten 
recognized the hapten conjugated to OVA.  
 
Table 1. The concentration of sulfonamide (μg ml–1) required to result in a 50% inhibition 
using the bleeding sera of the four mice in the ciELISA 
Sulfonamide Mouse 
98005 
Mouse 
98006 
Mouse 
98007 
Mouse 
98008 
Sulfathiazole 0.9 0.2 1.5 0.6 
Sulfamethizole 0.9 0.4 4 0.5 
Sulfachloropyridazine 2 0.8 5 2 
Sulfamethoxypyridazine 3 5 7 3 
Sulfamethoxazole 15 15 50 8 
Sulfadimethoxine 50 5 >100 50 
Sulfapyridine 50 9 50 20 
Sulfamethoxydiazine 90 5 >100 >100 
Sulfamerazine 90 10 90 50 
Sulfadiazine 100 8 >100 50 
Sulfaquinoxaline 100 15 >100 >100 
Sulfadoxine >100 >100 >100 >100 
Sulfachloropyrazine >100 80 >100 >100 
Sulfisoxazole >100 >100 >100 >100 
Sulfatroxazole >100 >100 >100 >100 
Sulfaguanidine >100 >100 >100 >100 
Sulfadimidine >100 >100 >100 >100 
Sulfacetamide >100 >100 >100 >100 
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No reaction was observed when pre-immune sera were reacted with OVA hapten or 
when sera from immunized mice were tested against ovalbumin. Thus, a specific 
reaction to the hapten was apparent. For mice immunized with KLH-TS (98005 and 
98006) the titers ranged from 1/3000 (mouse 98005) and 1/9000 (mouse 98006) after 
the first injection to 1/200000 (98005) and 1/400000 (98006) after the fourth injection. 
For mice immunized with BSA-TS (98007 and 98008) the titers ranged from 1/3500 
(98007) and 1/5000 (98008) after the first injection to 1/50000 (98008) after the third 
injection and 1/150000 (98007) after the fourth injection.  
The optimum final dilutions of the bleeding sera were determined as 1/400000 
(98005), 1/800000 (98006), 1/400000 (98007) and 1/150000 (98008). Using these 
optimum final dilutions, the bleeding sera of the four mice were tested in the ciELISA 
for competition with 18 sulfonamides (see Table 1). With all sera, free sulfathiazole 
and sulfamethizole competed at the lowest concentration (0.2–4 μg ml–1 at 50% 
inhibition), followed by sulfachloropyridazine (0.8–5 μg ml–1) and sulfamethoxy-
pyridazine (3–7 μg ml–1). Of the mice immunized with KLH-TS, the bleeding serum 
of mouse 98006 showed competition at the lowest concentration. Of the mice 
immunized with BSA-TS, the bleeding serum of mouse 98008 showed competition at 
the lowest concentration. The spleen cells of mouse 98008 were used for the fusion 
experiment. 
 
Production of Mabs 
After two booster injections, one of the mice (98008) was primed with a final booster 
injection. Four days later, spleen cells were isolated. One month later, and with an 
extra booster injection, the same procedure was performed with the other three mice 
(98005, 98006 and 98007) of which the spleen cells were stored in liquid nitrogen. 
The fresh spleen cells of mouse 98008 were used for fusion with myeloma cells. 
Screening of 550 wells in the iELISA resulted in 21 wells with culture supernatant 
reactive to the OVA-TS coated plate. These supernatants were screened with the 
iELISA for optimum dilution and with the ciELISA for competition with sulfathiazole. 
Competition was found in five of these supernatants (3A1; 4E10; 14G11; 26E5 and 
27G3). These hybridoma cells were cloned by limiting dilutions (2–3 times). This 
procedure resulted in four stable clones (27G3; 14G11; 26E5 and 4E10) and 
supernatants of 20 ml culture flasks were tested for optimum dilution. The 
supernatants of clones 27G3, 14G11, 4E10 and 26E5 could be used in final dilutions 
of 1/12000, 1/10000, 1/10000 and 1/750, respectively. This means that three of the 
clones produce high amounts of Mabs and one is a less producer.  
The subclass of the Mabs present in the four supernatants was determined by the 
Mouse Monoclonal Antibody Isotyping Kit and all were identified as IgG1 with 
kappa light chain. Of the four Mabs, 27G3 showed the best sensitivity towards 
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sulfathiazole and was used in experiments to increase the sensitivity of the ciELISA 
using a sulfathiazole calibration curve. 
 
 
Figure 3. Sulfathiazole calibration curves (n = 4) obtained with the four Mabs in the 
optimized ciELISA (B0 = maximum absorbance and B = absorbance of standards). Error 
bars are ± standard deviation. 
 
Decreasing the amount of immobilized OVA-TS (2 and 10 times) did not result in an 
improved sensitivity. The conditions of the first incubation (temperature, time and 
with or without mild shaking) were varied. The best results were obtained with short 
incubation times (1 h) at 4–6 °C under mild shaking conditions. Then the conditions 
of the second incubation step were varied. Here the optimum conditions were 1 h at 
4–6 °C under mild shaking conditions. Under these optimized conditions, the 
sensitivity of the ciELISA for sulfathiazole improved six times. Using the other three 
Mabs under optimum incubation conditions, the sensitivity of the ciELISA towards 
sulfathiazole increased also. However Mab 27G3 showed the best sensitivity with a 
working range (20–80% inhibition) between 3.5 and 50 ng ml–1 (see Figure 3).  
In the optimized ciELISAs, the competition with 18 sulfonamides was tested and the 
results are shown in Table 2. Mab 14G11 is most sensitive for sulfathiazole, 
sulfamethoxypyridazine, sulfamethizole and sulfachloropyridazine. The other 
sulfonamides showed much less competition (< 2–6% cross-reactivity compared to 
sulfathiazole). Mab 26E5 is the most sensitive for competition with sulfisoxazole and 
sulfamethizole followed by sulfaquinoxaline, sulfathiazole and sulfadimethoxine. 
Mab 4E10 is the most sensitive for competition with sulfamethizole and six other 
sulfonamides showed 50% inhibition at a concentration <100 ng ml–1. Of the four 
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Mabs, 27G3 is the most sensitive towards sulfathiazole and seven other sulfonamides 
showed 50% inhibition below 100 ng ml–1 and this Mab was selected as the best of 
the four Mabs. 
 
Table 2. The concentration of sulfonamide (ng ml–1) required to result in a 50% inhibition 
using the Mabs obtained from mouse 98008 in the ciELISA and as described by Sheth & 
Sporns (1991) using a sub-population of a polyclonal antiserum (Pab) 
Sulfonamide Mab
27G3
Mab
4E10
Mab
14G11
Mab 
26E5 
Pab*
 
Sulfathiazole 10 130 180 250 5000
Sulfamethizole 0.6 2 250 80 1300
Sulfachloropyridazine 4 4 300 1500 –
Sulfamethoxypyridazine 15 13 210 1500 –
Sulfamethoxazole 150 30 3000 3000 3300
Sulfadimethoxine 250 100 > 10000 500 4700
Sulfapyridine 30 150 3000 > 10000 1300
Sulfamethoxydiazine 30 30 > 10000 > 10000 –
Sulfamerazine 500 250 > 10000 > 10000 > 25000
Sulfadiazine 80 80 > 10000 > 10000 1600
Sulfaquinoxaline 1200 3000 > 10000 200 –
Sulfadoxine 30 800 > 10000 > 10000 –
Sulfachloropyrazine 1800 8000 > 10000 > 10000 –
Sulfisoxazole 250 80 > 10000 50 –
Sulfatroxazole 7000 2000 > 10000 3000 –
Sulfaguanidine 500 > 10000 > 10000 > 10000 –
Sulfadimidine 8000 7000 > 10000 > 10000 > 25000
Sulfacetamide 1800 > 10000 > 10000 > 10000 18 000
–not tested; * as described by Sheth & Sporns (1991) 
 
 
DISCUSSION 
 
Sheth & Sporns (1991) produced Pabs in rabbits which were immunized with TS 
conjugated to LPH and to BSA. Indirect ELISA’s performed on collected sera, using 
TS conjugated OVA as the coating, resulted in high titers in each pair of rabbits. 
Serum dilutions of 1/200000 gave three times background absorbance. In our study, 
the bleeding sera of the four mice resulted also in high titers. Serum dilutions of 
1/50000 to 1/400000 still resulted in an absorbance of 2.0. This means that the 
immunogens (TS-BSA and TS-KLH) are well recognized by the mice. 
Sheth & Sporns (1991) tested their rabbit sera in a ciELISA with high concentrations 
(25 μg ml–1) of the different sulfonamides and no significant decrease in absorbance 
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was noted. Free sulfonamides at high concentrations could not compete with bound 
hapten and they concluded that most of the antibodies had greater affinity for the TS-
protein than for free TS and other sulfonamides. 
In our study, using the bleeding sera of the four mice, we noticed a significant  
decrease of absorbance due to the competition with sulfathiazole, sulfamethizole, 
sulfachloropyridazine, sulfamethoxypyridazine and sulfamethoxazole at the 25 μg  
ml–1 level or lower (see Table 1). 
As expected, sulfathiazole (part of the immunogen) and sulfamethizole (with an extra 
nitrogen and methyl group only) showed competition at the lowest concentration. 
Sheth & Sporns (1991) selected a sub-population of antibodies with specificity for the 
aromatic amino portion of sulfonamides by the use of a deviating sulfonamide 
derivative coupled to proteins as the coating in the ELISA. This procedure resulted in 
a ciELISA in which nine structurally different sulfonamides showed 50% inhibition at 
concentrations ranging from 1.3 to 22 μg ml–1 (see Table 2). Assil et al. (1992) used a 
similar approach, with another immunogen, but applied an affinity-purified fraction of 
the polyclonal serum to obtain an ELISA which showed 50% inhibition with seven 
sulfonamides at concentrations less than 10 μg ml–1. 
In our study, the production of generic Mabs against a sulfathiazole derivative, four 
Mabs were obtained and one of them (27G3, see Table 2) showed 50% inhibition 
below the 10 μg ml–1 ( = 10000 ng ml–1) level with all sulfonamides tested. Eight of 
these sulfonamides showed 50% inhibition below the 100 ng ml–1 level. 
In general, we see major improvements with respect to the sensitivity and cross-
reactivity by the use of two of the Mabs (27G3 and 4E10; see Table 2) compared with 
our Pabs (see Table 1) and those described by Sheth & Sporns (1991; see Table 2). 
However, even with our best Mab (27G3), some essential sulfonamides (like 
sulfadimidine, sulfatroxazole, sulfaquinoxaline and sulfachloropyrazine) are detected 
at a high level only. Therefore, although one of the Mabs showed a broad specificity 
and a nice sensitivity towards several sulfonamides, the ciELISA was not considered 
to be generic towards all sulfonamides. On the basis of the results obtained in this 
study, the authors think that the production of a generic competitive assay, based on 
just one Mab, for the detection of sulfonamides will be very difficult. Future 
experiments will be focused on the application of this Mab in immunoaffinity 
chromatography to investigate its use as a generic sulfonamide antibody in non-
competitive systems. 
 
 
ACKNOWLEDGEMENTS 
 
This research was supported by the European Commission under the Agriculture and 
Monoclonal antibodies against a sulfathiazole derivative 
 72 
Fisheries Research Programme (FAIR3 CT96–2059) and the Dutch Ministry of 
Agriculture, Nature Management and Fisheries to whom thanks are due. 
 
 
REFERENCES 
 
- Assil, H.I., Sheth, H., Sporns, P. (1992) An ELISA for sulfonamide detection using 
affinity-purified polyclonal antibodies, Food Res. Intern., 25, 343– 353. 
- Dixon-Holland, D.E., Katz, S.E. (1988) Competitive direct enzyme-linked 
immunosorbent assay for detection of sulfamethazine residues in swine urine and muscle 
tissue. J.AOAC., 71, 1137-1140. 
- Erlanger, B.F., Borek, F., Beister, S.M.,  Lieberman, S. (1957) Steroid– protein 
conjugates. Preparation and characterisation of conjugates of bovine serum albumin with 
testosterone and with cortisone. J. Biol. Chem., 228, 713–727. 
- EU Regulation (1999) no. 508/1999, L60(9–3–1999), pp. 16– 52.  
- Fleeker, J.R., Lovett, L.J. (1985) Enzyme immunoassay for screening sulfamethazine 
residues in swine blood, J.AOAC., 68, 172–174. 
- Food and Drug Regulations (1991) Table III, Division 15, Part B., Canada Gazette Part II, 
125, 1478–1480. 
- Garden, H.B., Sporns, P. (1994) Development and evaluation of an enzyme immunoassay 
for sulfamerazine in milk. J. Agric. Food Chem., 42, 1379–1391. 
- Goding, J.W. (1986) Monoclonal Antibodies: Principles and Practice, 2nd ed., Academic 
Press, London, pp. 59–103. 
- Haasnoot, W., Korsrud, G.O., Cazemier, G., Maneval, F., Keukens, H.J., Nouws, J.F.M. 
(1996) Application of an enzyme immunoassay for the determination of sulfamethazine 
(sulfadimidine) residues in swine urine and plasma and their use as predictors of the level 
in edible tissue, Food Add. Cont., 13, 811– 822. 
- Jackman, R. (1992) Approaches to the development of enzyme immunoassays for the 
detection of residues in meat offal and milk, in Food Safety and Quality Assurance. 
Applications of Immunoassay Systems (Morgan, M.R.A., Smith, C.J., Williams, P.A., 
Eds), Elsevier, London, pp. 215– 226.  
- Märtlbauer, E., Meier, R., Usleber, E., Terplan, G. (1992) Enzyme immunoassays for the 
detection of sulfamethazine, sulfadiazine, sulfamethoxypyridazine and trimethoprim in 
milk, Food Agric. Immunol., 4, 219–228. 
- Muldoon, M.T., Font, I.A., Beier, R.C., Holtzapple, C.K., Young, C.R., Stanker, L.H. 
(1999) Development of a cross-reactive monoclonal antibody to sulfonamide antibiotics: 
Evidence for structural conformation-selective hapten recognition, Food Agric. Immunol., 
11, 117–134.  
- Ram, B.P., Singh, P., Martins, L., Brock, T., Sharkov, N., Allison, D. (1991) High-
volume enzyme immunoassay test system for sulfamethazine in swine, J.AOAC., 74, 43– 
46.  
- Renson, C., Degand, G., Maghuin-Rogister, G., Delahaut, Ph. (1993) Determination of 
sulphamethazine in animal tissues by enzyme immunoassay, Anal. Chim. Acta, 275, 323– 
328. 
- Saschenbrecker, P.W., Fish, N.A. (1980) Sulfamethazine residues in uncooked edible 
tissues of pork following recommended oral administration and withdrawal, Can. J. Comp. 
Med., 44, 338–345.  
- Sheth, H.B., Sporns, P. (1991) Development of a single ELISA for the detection of 
sulfonamides, J. Agric. Food Chem., 39, 1696–1700. 
Chapter 3  
 73
 
 
Chapter 3 
 
 
 
 
 
Sulfonamide antibodies: from specific 
polyclonals to generic monoclonals 
 
 
 
 
 
 
 
 
 
 
 
Published in Food and Agricultural Immunology (2000) 12, 15-30 
 
Willem Haasnoot, Geert Cazemier, Jolanda du Pré, Anniek Kemmers-Voncken, 
Monique Bienenmann-Ploum and Ron Verheijen 
 
 
State Institute for Quality Control of Agricultural Products (RIKILT), Bornsesteeg 45, 6708 
PD Wageningen, the Netherlands 
Sulfonamide antibodies: from specific polyclonals to generic monoclonals 
 74 
ABSTRACT 
 
Polyclonal antibodies (Pabs) against eight different sulfonamides were raised in 
rabbits. The aromatic amino group, common to all sulfonamides, was used for linking 
the different sulfonamides to the carrier proteins (bovine serum albumin (BSA) and 
keyhole limpet haemocyanin (KLH)) and enzyme (horseradish peroxidase (HRP)), 
using different coupling procedures. The competitive direct ELISAs (cdELISAs) 
developed with these antisera and HRP-conjugates showed high sensitivity (0.2–8.0 
ng ml–1 at 50% inhibition) and high specificity. The performances of these antibodies 
were compared with Pabs raised in mice against two sulfonamide derivatives (N1-[4-
(carboxymethyl)-2-thiazolyl]sulfanilamide (TS) and N1-[4-methyl-5-[2-(4-carboxy-
ethyl-1-hydroxyphenyl)]-azo-2-pyridyl]sulfanilamide (PS)) linked to proteins (BSA 
and KLH) in such a way that the common aromatic amino group was distal to the 
protein. In competitive indirect ELISAs (ciELISAs), these Pabs recognized several 
structurally different sulfonamides. The Pabs from mice immunized with TS–BSA 
reacted with sulfonamides containing thiazolyl, thiadiazolyl, pyridazinyl and 
isoxazolyl groups. The Pabs from mice immunized with PS–KLH reacted with 
sulfonamides containing pyrimidinyl, pyridazinyl, quinoxalinyl and pyridinyl groups. 
The spleen cells of the mice were fused with myeloma cells to obtain monoclonal 
antibodies (Mabs) producing hybridomas. So far, with only one of the mice 
(immunized with TS–BSA), this resulted in four different Mabs which recognized 
several sulfonamides. By use of the best Mabs (27G3 and 4E10) and an optimized 
ciELISA protocol, eight structurally different sulfonamides showed 50% inhibition at 
concentrations less than 100 ng ml–1 or 5 ng/well. However, other relevant 
sulfonamides (such as sulfadimidine, sulfatroxazole and sulfachloropyrazine) were 
detected at a high level only. 
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INTRODUCTION 
 
Sulfonamides are antimicrobial agents applied in veterinary as well as human 
medicine for the treatment and prophylaxis of bacterial infections. As a result of 
veterinary application, foods derived from animals treated with sulfonamides may be 
contaminated with these drugs. In the Netherlands and the USA (1998), at least nine 
different sulfonamides are approved for veterinary application and maximum residue 
limits (MRLs) in edible tissues have been established for total sulfonamides (100 μg 
kg–1 in Canada, the USA and the European Union and 20 μg kg–1 in Japan). 
Sulfonamides are derivatives of sulfanilamide (p-aminobenzene sulfonic acid). They 
can be described as N1- or N4-substituted sulfanilamides depending on whether the 
substitution is on the amido or aromatic amino group, respectively. Substitution in the 
benzene ring of sulfonamides usually yields inactive compounds such as the main 
metabolites (N4-acetylated sulfonamides). Substitutions at the amido group with 
heterocyclic aromatic nuclei yields compounds with varying degrees of anti-microbial 
activity.  
Immunoassays are capable of detecting low amounts of residues in many samples in a 
short time. For most immunoassays, antisera to sulfonamides have been raised using 
hapten conjugates prepared by diazotization of the aromatic amino group (Ram et al., 
1991, Renson et al., 1993) or by introducing spacers such as glutaraldehyde (Fleeker 
& Lovett, 1985; Dixon-Holland & Katz, 1988; Märtlbauer et al., 1992) or a succinyl 
group (Jackman, 1992; Haasnoot et al., 1996) which resulted in specific assays. 
Another approach is to raise antibodies against the aromatic amino group which is 
common to all sulfonamides. Sheth and Sporns (1991) were the first who reported 
about the development of such antibodies. They chemically linked a sulfathiazole 
derivative (N1-[4-(carboxymethyl)-2-thiazolyl] sulfanilamide) to proteins in such a 
way that the aromatic amino group was distal to the protein. Polyclonal antibodies 
(Pabs) were raised in rabbits and by the use of a subset of the antibodies, nine 
structurally different sulfonamides showed 50% inhibition at concentrations of less 
than 5 μg ml–1. Assil et al. (1992) used a similar approach to develop such an ELISA 
for longer sulfonamides with (N1-[4-methyl-5-[2-(4-carboxyethyl-1-hydroxyphenyl)]-
azo-2- pyridyl]-sulfanilamide) linked to proteins as the immunisation agent. By the 
application of an affinity-purified fraction of the polyclonal antiserum, they produced 
an ELISA which showed 50% inhibition with seven sulfonamides at concentrations 
less than 10 μg ml–1. 
Muldoon et al. (1999) used an N-sulfanilyl-4 aminobenzoic acid–protein conjugate to 
develop cross-reactive antibodies to sulfonamide antibiotics. Most of the antibodies 
that were detected in the blood of immunized mice (n = 5) recognized the free hapten 
but only the antibodies from one mouse recognized other free sulfonamides also. The 
spleen cells of this mouse were used for hybridoma production which resulted in one 
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monoclonal antibody (Mab)-producing clone. This Mab recognized eight sulfonamide 
drugs at levels below 1 μg/well or 10 μg ml–1. 
Haasnoot et al. (2000) followed the approach of Sheth and Sporns (1991) to prepare 
Mabs against the aromatic amino group of sulfonamides. By use of the best Mab in a 
competitive indirect ELISA (ciELISA), all sulfonamides tested (n = 18) showed 50% 
inhibition at concentrations less than 0.5 μg/well or 10 μg ml–1 and eight of them at 
concentrations less than 5 ng/well or 0.1 μg ml–1. However, other relevant 
sulfonamides were detected at a high level only. Therefore, to date, true generic 
antibodies against sulfonamides are not available and to detect sulfonamides of 
interest, either specific antibodies (poly- or monoclonal) have to be used or new 
generic antibodies have to be developed. 
In this study, the development of competitive direct ELISAs (cdELISA), using Pabs 
raised against eight different sulfonamide-conjugates, is described. The performances 
of these ELISAs (sensitivity and cross-reactivity towards 18 sulfonamides (see Figure 
1)) are compared with those obtained by ciELISAs in which Pabs raised against two 
different sulfonamide derivatives (prepared according to Sheth & Sporns (1991) and 
Assil et al.  (1992)) are used. The performances of the different Pab-based ELISAs 
are compared with those obtained with the previously developed ‘generic’ Mabs 
(Haasnoot et al., 2000) and suggestions for improvements are given. 
 
 
MATERIALS AND METHODS 
 
Materials 
Bovine serum albumin (BSA), keyhole limpet haemocyanin (KLH), ovalbumin 
(OVA), succinic anhydride, polyethylene glycol 1500 (PEG 1500, 50%), dimethyl 
sulfoxide (DMSO), 1-ethyl-3[3-(dimethyl amino)propyl] carbodiimide (EDC), 
Freund’s Complete Adjuvant (FCA), Freund’s Incomplete Adjuvant (FIA), sodium 
azide, sulfadimidine (= sulfamethazine), sulfamethoxazole, sulfamethoxypyridazine, 
sulfamerazine, sulfaguanidine, sulfadimethoxine, sulfadiazine, sulfachloropyridazine, 
sulfacetamide, sulfanilamide, sulfapyridine, sulfathiazole, sulfamethizole and 
sulfisoxazole were obtained from Sigma-Aldrich Chemie BV (Zwijndrecht, the 
Netherlands). Sulfadoxine, sulfachloropyrazine, sulfaquinoxaline, sodium periodate, 
sodium borohydride and Visking dialysis tubing (36/32) were obtained from Serva 
(Heidelberg, Germany) and sulfamethoxydiazine from Bayer (Leverkusen, Germany). 
Sulfatroxazole was a gift from Leo Pharmaceutical Products (Weesp, the Netherlands).  
Dioxane, Tween-20, pyridine, sodium hydroxide, di-sodium hydrogen phosphate 
dihydrate, sodium dihydrogen phosphate monohydrate, potassium dihydrogen 
phosphate, sodium chloride, sodium carbonate, sodium hydrogen carbonate, ethanol, 
saccharose, tris(hydroxymethyl)-aminomethane (Tris), glutaraldehyde, phosphoric 
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acid, hydrochloric acid, sodium acetate, glycerol and sodium nitrite were obtained 
from Merck (Darmstadt, Germany). 
Horseradish peroxidase (HRP) was obtained from Boehringer (Mannheim, Germany). 
Solutions of tetramethylbenzidine (TMB) peroxidase substrate and peroxide were 
obtained from Kirkegaard and Perry Labs (Gaithersburg, MD, USA). Goat anti-rabbit 
IgG (GAR) was obtained from Caltag Laboratories (Burlingame, CA, USA) and 
rabbit anti-mouse immunoglobulins–horseradish peroxidase (RAM-HRP) from 
DAKO (Denmark). Ammonium sulfamate was supplied by Fluka Chemie 
(Zwijndrecht, the Netherlands). 1,4-Butanediol diglycidyl ether, deuterium oxide and 
sodium deuterium oxide were supplied by Acros Chimica (‘s Hertogenbosch, the 
Netherlands). 
Centriprep concentrators (30) were supplied by Amicon, Inc. (Beverly, MA, USA). 
Specol was obtained from DLO Institute for Animal Science and Health (ID-DLO, 
Lelystad, the Netherlands). Dulbecco modified Eagle’s medium (DMEM) and 
hybridocult were obtained from Bio Whittaker (Verviers, Belgium) and Fetal Clone I 
(FCI) was from HyClone (Logan, Utah, USA). Hypoxanthine/thymidine (HT; 50x) 
and aminopterin (A; 100x) were obtained from Life Technologies (Breda, the 
Netherlands). ELISA microtiter plates, tissue culture plates (96- and 24-wells) and 
culture flasks (5 and 20 ml) were obtained from Costar (Cambridge, MA, USA). 
 
Linking of sulfonamides to proteins via the aromatic amino group 
 
Several procedures for the coupling of sulfonamides, via the aromatic amine group, to 
the carrier proteins (BSA and KLH) and the enzyme (HRP) were applied. 
 
Succinylation  
Succinylated sulfonamides were coupled to carrier proteins and HRP according to a 
previous described procedure for the preparation of sulfamethazine–protein 
conjugates (Haasnoot et al., 1996). A mixture of the sulfonamide (1 g) and succinic 
anhydride (0.5 g) was refluxed for 1.5 h in anhydrous ethanol containing 10 μl of 
anhydrous pyridine. The mixture was then evaporated to dryness and refluxed for 30 
min in 10.5 ml of a mixture of ethanol and water (6:4.5; v:v) and again evaporated to 
dryness. The residue was dissolved in 10.5 ml of a mixture of ethanol and water 
(6:4.5; v:v) and filtered through a sintered glass filter. The filtrate was allowed to 
crystallize overnight at –20 °C. The crystals were collected by filtration (0.45 μM 
filter; Millipore) and washed with a cold (–10 to –20 °C) mixture of ethanol: water 
(6:4.5; v:v). The collected crystals were dried and stored at –20 °C until used. 
 
Coupling to BSA. The succinylated sulfonamide (50 mg) was dissolved in 10 ml of a 
mixture of Tris buffer (0.05 M; pH 7.5) and dioxane (1:1; v:v). 1-Ethyl-3[3-
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(dimethylamino)- propyl] carbodiimide (EDC (40 mg dissolved in 0.5 ml water)) was 
added. This solution was added to a BSA solution (10 mg dissolved in 0.5 ml of 
phosphate buffer (0.5 mM)) and mixed for 1 h on a magnetic stirrer. The mixture was 
dialyzed against phosphate buffer (5 mM, pH 7) for 3 days (two changes of buffer per 
day). The sulfonamide–hemisuccinate–BSA was stored at –20 °C until used. 
 
Coupling to HRP. The succinylated sulfonamide (5 mg) was dissolved in 0.5 ml of the 
mixture of the Tris buffer and dioxane (1:1; v:v) and 25 mg of EDC, dissolved in 0.5 
ml of water, was slowly added. This solution was added to a HRP solution (58 mg 
dissolved in 3 ml of a mixture of PBS and water (1:2; v:v). The mixture was stirred on 
a magnetic stirrer for 3 h and dialyzed against PBS for 3 days (two changes of buffer 
per day). The dialyzed solution was stored at –20 °C until used. 
 
Glutaraldehyde coupling  
Sulfonamides were coupled to BSA via glutaraldehyde as described by Dixon-
Holland & Katz (1988). The sulfonamide (350 mg) and BSA (600 mg) were dissolved 
in 75 ml of 2:1 solution of phosphate buffer (pH 7.2) and dioxane. To the mixture, 
0.35 ml of 25% glutaraldehyde was added and stirred for 3 h at room temperature. 
The mixture was dialyzed for 6 days against PBS with buffer changes twice a day. 
The dialyzed solution was lyophilized and stored under desiccation at 4 °C until used. 
 
Epoxy (bisoxirane) activation 
Sulfonamides were coupled to epoxy activated BSA and HRP according to a 
previously described procedure (Lommen et al., 1995). 
 
Coupling to BSA. BSA (360 mg) was dissolved in D2O (6 ml), 1,4-butanediol 
diglycidyl ether (93 mg) was added and the pH was adjusted to 10.9 with 0.5 M 
NaOD. After incubation (24 h at 27 °C) the reaction was stopped by the addition of 
NaH2PO4 (100 mg). The free 1,4-butanediol glycidyl ether was removed by applying 
the following procedure three times; dilution with phosphate buffer followed by 
concentration with a Centriprep (end volume 6 ml). To this epoxy activated BSA 
solution (6 ml), Na2CO3 (63 mg) was added. To 0.6 ml of this epoxy-activated BSA, 
0.06 mM of a sulfonamide was added and the pH was adjusted to 10.8 ± 0.1 with 
sodium hydroxide (0.1 M) and, after a four days reaction at 27–30 °C, the solution 
was dialyzed against PBS for three days. The dialyzed solution was stored at –20 °C 
until used. 
 
Coupling to HRP. HRP (200 mg) was dissolved in D2O (4.5 ml), 0.5 ml of a solution 
of 1,4-butanediol diglycidyl ether (20 mg ml-1 D2O) and the pH was adjusted to 10.9 
with 0.5 M NaOD. After 24 h at 27 °C, the reaction was stopped by the addition of 
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NaH2PO4 (20 mg). The free 1,4-butanediol glycidyl ether was removed (see coupling 
to BSA). Sulfonamides were dissolved in 0.1 M Na2CO3 (10 mg ml-1) and 0.5 ml of 
the sulfonamide solution was mixed with 0.5 ml of the epoxy-activated HRP solution. 
For reaction conditions and purification, the same procedure as described for the 
coupling to BSA was applied. 
 
Periodate cleavage  
For the coupling of some sulfonamides to HRP, the method described by Thomson 
and Sporns (1995) was followed. HRP (4 mg) was dissolved in 1.0 ml water; 0.2 ml 
of 0.1 M aqueous sodium periodate were added and the mixture stirred for 20 min at 
room temperature, transferred to dialysis tubing and dialyzed overnight against 4 l of 
1 mM sodium acetate buffer (pH 4.4) at 4 °C. To dialysis tubing contents were added 
40 μl of 200 mM carbonate buffer (pH 9.5), one drop of 1 M sodium hydroxide and 
10 mg of the sulfonamide and the reaction mixture was stirred for 2 h at 4 °C. Sodium 
borohydride (4 mg ml–1, 100 μl) was added and the mixture stirred for 2 h at 4 °C. 
The reaction mixture was dialyzed against three changes of PBS. The contents of the 
dialysis tubing were recovered and frozen at –20 °C. 
 
Diazo-coupling  
For the coupling of some sulfonamides to KLH, the diazo derivative coupling as 
described by Renson et al. (1993) was applied. The sulfonamide (10 mg) was 
dissolved in 2 ml hydrochloric acid (3.5 M) and 0.6 ml of a solution of sodium nitrite 
(10 mg ml–1) was added dropwise to this mixture with stirring in the dark at 4°C. 
After 30 min, the reaction was stopped by addition of 0.75 ml of a solution of 
ammonium sulfamate (33 mg ml–1). To a solution of KLH (10 mg in 6 ml PBS) 0.1 ml 
of the diazo derivative solution was slowly added and the pH was adjusted to 9.5 ± 
0.5 by the addition of a few drops of sodium hydroxide (1 M). The reaction mixture 
was left for 6 h at 4 °C and unreacted material was removed by dialysis against PBS. 
The dialyzed solution was stored at –20 °C until used. 
 
Linking of sulfonamide derivatives to proteins 
 
Two sulfonamide derivatives were coupled to proteins in such a way that the common 
aromatic amino group was distal to the proteins. 
 
Coupling of a sulfathiazole derivative  
The synthesis of the sulfathiazole derivative N1[4-(carboxymethyl)-2-thiazolyl]-
sulfanilamide (TS) and the coupling to proteins (KLH, BSA and OVA) was described 
before (Haasnoot et al., 2000). 
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Coupling of N1-[4-methyl-5-[2-(4-carboxyethyl-1-hydroxyphenyl)]-azo-2-pyridyl]-
sulfanilamide (PS)  
For the synthesis of PS and the coupling to proteins (KLH, BSA and OVA), the 
procedures as described by Assil et al. (1992) were applied. 
 
Immunization 
 
Rabbits  
The sulfonamide–protein conjugates (0.75 ml of solutions of 0.5 mg ml–1 PBS (0.4 
mg of conjugate)) were mixed with 0.75 ml of Freund’s complete adjuvant. The 
emulsions were injected subcutaneously (s.c.) into New Zealand White rabbits. After 
4 weeks, the rabbits were subcutaneously injected every 6 weeks with 0.4 mg of 
conjugate in Freund’s incomplete adjuvant (booster injection) and blood samples were 
taken 1 and 2 weeks after the respective immunizations. The collected sera were 
stored at –20 °C. 
 
Mice  
Female mice (Balb/c Ola Hsd), 10–12 weeks old, were immunized (s.c.) with 50 μg of 
BSA- or KLH-TS or -PS conjugates in 100 μl of PBS emulsified with 100 μl of 
Specol. Booster injections (sc) with 25 μg of the immunogens in 100 μl of PBS 
emulsified with 100 μl of Specol were fiven at 2-week intervals. Blood was taken 
from each mouse prior to the first immunization (pre-immune) and 1 week after each 
booster injection. The sera were stored at –20 °C until used for testing for antibodies 
against TS or PS coupled to OVA by an indirect ELISA. 
 
Production of Mabs 
 
The mice were primed intraperitoneally with 25 μg of immunogen in 200 μl PBS 4–5 
days before spleen cell isolation. Hybridoma cells secreting Mabs were prepared 
using murine myeloma P3/NS-1/1-Ag4–1 (NS-1), non-secreting mouse myeloma 
(American Type Culture Collerction, Rockville, MD, USA) as the fusion partner. The 
myeloma cells were fused with splenocytes at a ratio of 1:2 using PEG 1500 
precipitation. Cells were suspended in HAT selection medium (culture medium 
[DMEM, supplemented with 8% FCI + 1% hybridocult + 0.5% P/S] + 1% HT + 1% 
A) and plated in 96-wells tissue culture plates at 100000 cells/well. After one week, 
the medium was changed to HT medium (culture medium + 1% HT) and five days 
thereafter, by culture medium. From days 12–14, hybridoma supernatants were tested 
for antibodies to TS or PS (conjugated to OVA) using the indirect ELISA. Cultures 
containing cells secreting antibodies to the conjugates were further tested in the 
competitive indirect ELISA for antibodies recognizing free sulfonamides. Positive 
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cultures were immediately cloned by limiting dilution (average 0.5 cells/well) until 
stable (2–3 clonings). 
The Mab-producing clones of interest were transferred from the culture in the 96-well 
plate to 0.5 ml of culture medium in a 24-well plate. After the 24-well culture became 
dense, the culture was transferred to 5 or 20 ml culture flasks. Cultures were 
centrifuged and the supernatants stored at –20 °C until used. Colonies of interest were 
propagated, frozen (overnight at –80 °C in a freezing container filled with 2- 
propanol) in culture medium containing 12% dimethyl sulfoxide and stored in 
nitrogen. 
 
ELISAs 
 
(Competitive) direct ELISA  
For the validation of the rabbit sera (antisera titers) and to determine the optimum 
dilution of the HRP-conjugates the direct ELISA was applied. Thereafter, when 
optimum dilutions of the reagents were known, the competitive direct ELISA was 
applied to determine the sensitivity and cross-reactivity towards other sulfonamides. 
 
Direct ELISA (dELISA). Microtiter plates were coated overnight at 4–6 °C with 100 μl 
aliquots of goat anti-rabbit IgG (5 μg IgG ml–1) in coating buffer (35 mmol l–1 sodium 
hydrogen carbonate + 15 mmol l–1 sodium carbonate (pH 9.6)). Plates were washed 
four times with PBS (pH 7.2) containing 0.05% Tween-20 (PBST) with a microplate 
washer (Wellwash Model 4 microplate washer, Denley Instruments, Billinghurst, 
Sussex, UK). For the determination of antibody titers, aliquots (50 μl) of serial 
dilutions (101 till 106) in PBST of the raw antiserum were pipetted (in columns 1–6 or 
7–12 for another serum) in the microtiter plates. Aliquots (50 μl) of serial dilutions 
(101 till 106) in PBST of a sulfonamide–HRP conjugate were pipetted (in rows B–G). 
To rows A and H, 50 μl of PBST were added. The plate was incubated for 1 h at 4–
6 °C and washed four times with PBST. The bound peroxidase was assessed by 
adding 100 μl of a TMB peroxidase substrate system (a freshly prepared mixture of 
solutions of TMB peroxidase substrate and peroxide; 1:1; v:v). After incubation in the 
dark for 20 min at room temperature, the reaction was stopped by adding 100 μl 
aliquots of 1 mol l–1 phosphoric acid and the colored product of the peroxidase 
reaction was measured at 450 nm using an Argus 400 microplate reader (Canberra 
Packard, Downers Grove, IL, USA). The antiserum titer was defined as the maximum 
dilution which resulted in an absorbance of 1.0 at the most possible dilution of the 
sulfonamide–HRP conjugate. 
 
cdELISA. To the wells of the microtiter plate, 50 μl aliquots of buffer or standard 
solutions of sulfonamides were added followed by 25 μl quantities of diluted 
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antiserum and sulfonamide–HRP conjugate. The plates were treated further as 
prescribed above. 
 
(Competitive) indirect ELISA  
TS– or PS–OVA in coating buffer (50 ng/100 μl/well) was used as the solid-phase 
immobilized agents. After overnight incubation at 4 °C or 1 h at room temperature, 
the wells were emptied and blocked with 0.1% OVA in coating buffer. The plate was 
emptied and stored in 25% glycerol in coating buffer until used. Prior to use, the plate 
was washed four times with washing buffer. 
 
Determination of antibody titers. To each well, 100 μl of a serial dilution of serum or 
culture supernatant was added. The plate was incubated at room temperature for 1 h 
and washed four times with washing buffer. Subsequently, 100 μl aliquots of rabbit 
anti-mouse IgG–HRP (RAM–HRP) in a 1:2500 dilution in PBST were added to each 
well and the plate incubated for 1 h at room temperature. After washing the plate, the 
bound peroxidase was assessed by adding 100 μl of a TMB peroxidase substrate 
system (a freshly prepared mixture of a solution of TMB peroxidase substrate and 
peroxidase; 1:1; v:v). After incubation in the dark for 20–30 min at room temperature, 
the reaction was stopped by adding 100 μl aliquots of 1 mol l–1 phosphoric acid and 
the coloured product was measured at 450 nm using an Argus 400 microplate reader 
(Canberra Packard, Downers Grove, IL, USA). Serum titers were defined as the final 
dilution which resulted in an absorbance of 1.0. 
 
ciELISA. After washing the coated and blocked plate, 50 μl of a standard solution of 
sulfonamides (in PBST) was added to the well followed by 50 μl of a diluted serum or 
culture supernatant dilutions. The plates were treated further as described above. 
 
 
RESULTS 
 
ELISAs based on specific Pabs 
 
The method described by Jackman (1992), using succinic anhydride to convert the 
aromatic amine group of the sulfonamide into a carboxylate group with a four-carbon 
spacer, worked well with sulfadimidine. This carboxylate group is used to couple the 
sulfonamide to the amine groups of the carrier proteins. As described before 
(Haasnoot et al., 1996), the same procedure was used to produce the enzyme-
conjugate. Other enzyme-conjugates (periodate cleavage and epoxy activation) were 
tested but a difference in ELISA performance was not observed. The different batches 
of antisera obtained after the 19 booster injections of rabbit 464 were analyzed for 
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optimum dilution and a high variation was observed. The titers increased in time from 
20000 (after the first booster) till 200000 (after the 12th booster) and thereafter the 
titers fluctuated between 100000 and 200000. To obtain a larger batch of antiserum of 
constant quality, the different antisera obtained after the several booster injections 
were mixed to one batch of about 700 ml. In the cdELISA, this batch was used in a 
final dilution of 1:40000 which resulted in a calibration curve for sulfadimidine with 
50% inhibition at 0.5 ng ml–1. The ELISA showed cross-reactivity towards 
sulfamerazine (16%) and sulfadimethoxine (0.12%) and no cross-reactivity ( < 0.1%) 
with the other sulfonamides (see Table 1). 
Succinylated sulfadiazine coupled to BSA did result in an antiserum (rabbit 466) with 
a low titer. Another rabbit (474) was immunized with a BSA conjugate in which 
sulfadiazine was coupled via glutaraldehyde and this resulted in low titers also. The 
same rabbit was used for immunization with sulfadiazine coupled to epoxy activated 
BSA and an increase in titer (between 30 000 and 140 000) was observed. The 
antisera obtained after the seven booster injections were combined to obtain a larger 
batch of antiserum (280 ml). The performance of this batch in the cdELISA was poor 
(low maximum signal and bad sensitivity). 
New immunizations (rabbit code MH3) with the diazo derivative of sulfadiazine 
coupled to KLH were more successful. The antiserum titer of the different blood 
samples obtained after the booster injections started at 20000 and rose to 320000 after 
the fifth booster injection and then varied from 50000 to 200000. The serum obtained 
after the fifth booster injection was used in the cdELISA in combination with 
sulfadiazine–HRP prepared according to the epoxy activation procedure and this 
resulted in a calibration curve with a 50% inhibition at 0.5 ng ml–1. This ELISA 
showed cross-reactivity towards sulfathiazole (10%) and low cross-reactivity towards 
five other sulfonamides (see Table 1).  
For the development of the sulfadoxine-ELISA, sulfadoxine was coupled to BSA via 
glutaraldehyde coupling. This immunogen (in rabbit 478) resulted in antisera with low 
titers and after the ninth booster the same rabbit was immunized with sulfadoxine 
coupled to epoxy-activated BSA. This resulted in an increase in antibody titer (up to 
200000). A batch of antiserum (280 ml) was prepared of serum obtained after seven 
booster injections. This batch was used in the ELISA (final dilution of 1:4000) in 
combination with sulfadoxine–HRP (periodate coupling). This resulted in a 
calibration curve for sulfadoxine with 50% inhibition at 3.3 ng ml–1 and the ELISA 
showed no cross-reactivity towards other sulfonamides (see Table 1). 
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Table 1. The concentration of sulfonamide (ng ml-1) required to result in a 50% inhibition 
(IC50) in the different cdELISAs based on Pabs (% cross-reactivity).  
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For the development of the sulfadimethoxine-ELISA, a rabbit (no. 477) was first 
injected nine times with sulfadimethoxine–BSA prepared according to the 
glutaraldehyde coupling. However, the titers were low and from the ninth booster 
injection another immunogen (sulfadimethoxine coupled to epoxy activated BSA) was 
used. An increase in antisera titers was observed (1:75000 to 1:250000). The antisera 
obtained after the seven booster injections were combined to obtain a batch with a 
volume of 280 ml. This batch could be used in the ELISA in a final dilution of 1:5000. 
In combination with sulfadimethoxine–HRP (prepared according the epoxy activation 
procedure) this resulted in an ELISA with a calibration curve for sulfadimethoxine 
with 50% inhibition at 1.1 ng ml–1. The ELISA showed no cross-reactivity towards 
the other sulfonamides tested (see Table 1). 
For the development of the sulfachloropyrazine-ELISA, the immunogen was prepared 
according to the epoxy activation method. The serum of rabbit 503 obtained after the 
fifth booster was used in the sulfachloropyrazine-ELISA (final dilution 1:2400) in 
combination with the HRP-conjugate prepared according to the epoxy activation 
procedure. This resulted in a calibration curve for sulfachloropyrazine which showed 
50% inhibition at 8.0 ng ml–1 and cross-reactivity towards other sulfonamides was not 
observed (see Table 1). 
For the preparation of antisera against sulfatroxazole and sulfamethoxazole, rabbits 
(nos 496 and 502) were injected with BSA-conjugates prepared according to the 
epoxy coupling procedure. The response towards these immunogens was low and 
after increasing the amount of injected immunogen (from 0.45 to 0.9 mg/injection) the 
response slowly increased. For both ELISA’s, the sera obtained after the 10th booster 
injections were used (final dilution 1:1000) in combination with the HRP-conjugate 
prepared according to the periodate method. The calibration curve for sulfatroxazole 
showed 50% inhibition at 3.0 ng ml–1. Cross-reactivities were seen for 
sulfachloropyridazine (8.6%) and sulfisoxazole (6.7%) and low cross-reactivities 
(0.1–1.1%) for some other sulfonamides (see Table 1). The calibration curve for 
sulfamethoxazole showed 50% inhibition at 1.2 ng ml–1 and this sulfamethoxazole-
ELISA showed a 100% cross-reactivity with sulfamethizole and low cross-reactivity 
(0.1–1.3%) towards some other sulfonamides (see Table 1). 
Sulfisoxazole was coupled to KLH according to the diazo-coupling procedure and the 
serum obtained after the tenth booster was used in the ELISA (final dilution 1:10 000) 
in combination with sulfisoxazole–HRP (periodate coupling). This resulted in an 
ELISA which showed 50% inhibition for sulfisoxazole at 0.2 ng ml–1. This ELISA 
showed cross-reactivity towards sulfatroxazole (20%) and low cross-reactivity 
towards some other sulfonamides (0.2–3.8%, see Table 1).  
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Figure 1. Molecular structures of the 18 sulfonamides used for cross-reactivity studies. 
 
ELISAs based on generic Pabs 
 
The sulfonamide derivatives TS and PS (see Figure 2) were coupled to BSA and KLH 
and these immunogens, with the aromatic amine group distal from the proteins, were 
used to immunize eight mice. Mice 98005 and 98006 were immunized with TS 
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coupled to KLH and mice 98007 and 98008 with TS coupled to BSA. Mice 98012 
and 98013 were immunized with PS coupled to KLH and mice 98014 and 98015 with 
PS coupled to BSA. For the determination of antibody titers, the ciELISAs were used. 
Antisera from the mice immunized with TS-immunogens (98005–98008) recognized 
the hapten conjugated to OVA and no reaction was observed when pre-immune sera 
were added or when sera from the immunized mice were tested against OVA. Thus, a 
specific reaction to the hapten was apparent and the antisera showed high titers 
(130000–1200000 after the third or fourth booster injection) with both carrier proteins. 
This means that TS coupled to the proteins is very immunogenic.  
The sera obtained after immunization with PS–protein conjugates showed acceptable 
titers with KLH as the carrier (120000 and 230000 after the fourth injection) and low 
titers with BSA as the carrier (3000 and 4000 after the fourth injection).  
The six bleeding sera from the mice with acceptable titers were used in the ciELISAs 
in which 18 different sulfonamides (see Figure 1) were added at the 10 ppm level. The 
sera from mice 98005–98008 all showed comparable cross-reactivities towards the 18 
sulfonamides. The cross-reactivities of the sera from mice 98012 and 98013 were also 
similar. 
 
 
 
Figure 2. Molecular structures of the immunogens used for the development of generic Pabs 
and Mabs (A and B) and the structure of the hapten used by Muldoon et al. (1999; C). (A) = 
N1-[4-(carboxymethyl)-2-thiazolyl]sulfanilamide (TS); (B) = N1-[4-methyl-5-[2-(4-
carboxyethyl-1-hydroxyphenyl)]-azo-2-pyridyl]sulfanilamide (PS); (C) = N-sulfanyl-4-
aminobenzoic acid. 
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In Figure 3 the results are shown for two of these antisera. The Pabs from mouse 
98008 (immunized with TS–BSA) showed good competition (> 50%) with five 
sulfonamides and the Pabs from mouse 98013 (immunized with PS-KLH) with nine 
sulfonamides. It is obvious that the blood obtained from the mouse immunized with 
TS reacted the best with those sulfonamides containing similar structures 
(sulfathiazole and sulfamethizole) but there is also a strong reaction with 
sulfonamides containing a pyridazinyl group (like sulfachloropyridazine and 
sulfamethoxypyridazine) or an isoxazolyl group (like sulfamethoxazole). 
The antisera obtained from mouse 98013 showed a good reaction with sulfonamides 
containing a pyrimidinyl group (sulfadimidine, sulfamerazine, sulfadiazine, 
sulfamethoxydiazine and sulfadimethoxine), a pyridazinyl group (sulfamethoxy-
pyridazine and sulfachloropyridazine), a quinoxalinyl group (sulfaquinoxaline) and a 
pyridinyl group (sulfapyridine). This serum was less reactive towards the 
sulfonamides containing a thiadiazolyl group (sulfamethizole) and an isoxazolyl 
group (sulfisoxazole).  
 
 
Figure 3. Inhibition (%) by 18 sulfonamides (at the 10 ppm level) in the ciELISA using 
bleeding sera of mouse 98008 (immunized with TS-BSA) and mouse 98013 (immunized with 
PS-KLH). 
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ELISAs based on generic Mabs 
 
The spleen cells of mice 98008 and 98013 were used for fusion with myeloma cells. 
The hybridomas obtained with mouse 98013 did not produce antibodies specific for 
PS–OVA coated plates and this fusion was considered as failed. After the fusion with 
the spleen cells of mouse 98008, the culture supernatant of 21 wells showed reaction 
with TS–OVA coated plates. Competition with sulfonamides was found in five of 
these supernatants.  
 
Table 2. Comparison of the inhibition concentrations at 50% (IC50), expressed as ng/well, for 
the different sulfonamides used in ciELISA’s with two of our Mabs (clone 27G3 and 4E10) 
with TS (see Figure 2) as the immunogen and the Mab (SULFA-1) of Muldoon et al. (1999) 
with N-sulfanyl-4-aminobenzoic acid (SUL; see Figure 2) as the immunogen. 
IC50 (ng/well)  
Sulfonamide 
 
Clone 
27G3 
Clone 
4E10 
Clone 
SULFA-1 
Sulfamethizole 0.03 0.1 7000 
Sulfachloropyridazine 0.2 0.2 436 
Sulfathiazole 0.5 6.5 32 
Sulfamethoxypyridazine 0.7 0.6 - 
Sulfapyridine 1.5 7.5 2.3 
Sulfamethoxydiazine 1.5 1.5 - 
Sulfadoxine 1.5 40 - 
Sulfadiazine 4 4 976 
Sulfamethoxazole 7.5 1.5 6000 
Sulfadimethoxine 12.5 5 1572 
Sulfisoxazole 12.5 2 20000 
Sulfamerzine 25 12.5 374 
Sulfaguanidine 25 >500 - 
Sulfaquinoxaline 60 150 2500 
Sulfachloropyrazine 90 400 - 
Sulfacetamide 90 >500 1435 
Sulfatroxazole 350 100 - 
Sulfadimidine 400 350 7000 
Sulfanitran - - 0.14 
SUL - - 6.8 
Sulfisomidine - - 314 
Sulfasalazine - - 430 
Sulfanilamide - - 6000 
Sulfabenzamide - - 10000 
–Not tested 
 
These hybridoma cells were brought into limiting dilution (two or three times) and 
this procedure resulted in four stable clones (27G3; 14G11; 26E5 and 4E10) which all 
produced IgG1 kappa light chain antibodies. The preparation and evaluation of these 
Mabs were described before (Haasnoot et al., 2000). By use of the best Mabs (27G3 
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and 4E10) and an optimized ciELISA protocol, eight structurally different 
sulfonamides showed 50% inhibition at concentrations less than 100 ng ml–1 or 5 
ng/well (see Table 2). However, other relevant sulfonamides (such as sulfadimidine, 
sulfatroxazole and sulfachloropyrazine) were detected at a high level only. 
 
 
DISCUSSIONS AND CONCLUSIONS 
 
Most of the described immunoassays for sulfonamide detection are focused on one 
sulfonamide in which different coupling procedures for the preparation of the 
immunogens and enzyme conjugates are applied. In exception, Jackman et al. (1993) 
used succinylation for the coupling of 12 different sulfonamides to OVA and used 
these immunogens to raise Pabs in sheep. Although antisera titers were not described, 
the individual cdELISA (using sulfonamide–hemisuccinate–HRP) showed 50% 
inhibition in the range 0.2–5 ng ml–1. In the present study, the succinylation worked 
well with sulfadimidine (high antibody titers and an high sensitivity ELISA) but with 
other sulfonamides the results were not so successful (low titers and low sensitivity). 
Trying several couplings, in our hands, the best general procedure for the coupling of 
the different sulfonamides seemed to be the use of epoxy-activated BSA. 
A high variation of antibody titers in the sera obtained after the several booster 
injections was observed after all immunizations. Such variations in titers were 
reported also by Singh et al. (1989) who developed an enzyme immunoassay for 
screening sulfamethazine (= sulfadimidine). To obtain larger batches of Pabs with 
constant quality, some antisera obtained after different boosters were pooled. 
Using the Pabs, the dose–response curves of the eight cdELISA’s showed 50% 
inhibition between 0.2 and 8 ng ml–1. These sensitivities are comparable to those 
reported by Jackman (1993) for his sulfonamide ELISA’s. 
Three of our cdELISA’s (like the sulfadoxine-, sulfadimethoxine- and sulfachloro-
pyrazine-ELISA) were very specific towards the sulfonamide used as the immunogen 
and cross-reactivities towards other sulfonamides were not observed (see Table 1). 
The sulfadimidine-ELISA cross-reacted with sulfamerazine (16%). Fodey et al. 
(1997), Fleeker and Lovett (1985) and Märtlbauer et al. (1992) described a cross-
reactivity for sulfamerazine of 10, 30 and 56%, respectively, in their sulfadimidine-
ELISA’s. The sulfadiazine-ELISA showed cross-reactivity towards sulfathiazole 
(10%) and low cross-reactivity towards sulfamerazine (2.5%) and sulfapyridine (1%). 
Märtlbauer et al. (1992) also reported cross-reactivities to sulfathiazole (10.9%), 
sulfamerazine (11%) and sulfapyridine (1.1%) in the sulfadiazine-ELISA. The 
sulfatroxazole-ELISA showed low cross-reactivities towards three sulfonamides (see 
Table 1) and the sulfisoxazole-ELISA cross-reacted with sulfatroxazole (20%) and 
showed low cross-reactivity with four other sulfonamides (see Table 1). The 
sulfamethoxazole-ELISA showed 100% cross-reactivity with sulfamethizole due to 
the similarity in structure. In general, these ELISA’s based on Pabs are very specific 
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and for the detection of several sulfonamides, different ELISA’s have to be used 
simultaneously. 
A better approach would be the development of generic antibodies by the 
immunization of animals with conjugates in which the common aromatic amino group 
is distal to the carrier protein. Such immunogens were described before. Sheth and 
Sporns (1991) described the use of TS and Assil et al. (1992) the use of PS. 
For the synthesis of TS–protein conjugates, the method as described by Sheth and 
Sporns (1991) was followed although some modifications were applied during the 
syntheses (Haasnoot et al., 2000). In the ciELISA, with TS–protein immobilized to 
the ELISA plate, Sheth and Sporns found no competition with high amounts (25 ppm) 
of free sulfonamides probably due to the greater affinity of antibodies for the protein-
bound hapten. In our ciELISA, with the Pabs of the mice immunized with TS–
proteins, all sulfonamides added at the 10 ppm level showed inhibition and five of 
them showed high inhibition (> 50%) (see Figure 3). Sheth and Sporns had to use 
another sulfonamide derivative (NS-conjugated OVA) bound to the microtiter plate to 
select a small subpopulation of the Pabs. In this ELISA, 11 sulfonamides showed 
50 % inhibition below 25 ppm.  
Using the Pabs of the mice immunized with PS–KLH, the ciELISA showed inhibition 
with all sulfonamides added at the 10 ppm level and nine of them showed high 
inhibition (> 50%; see Figure 3). Assil et al. (1992) used the same procedure and they 
found no competition with free sulfonamides added to the ELISA at the 10 ppm level. 
They had to select a subpopulation of the Pabs by affinity chromatography 
purification using OVA–TS bound to Sepharose. This fraction of the antiserum was 
used in a ciELISA with OVA-TS bound to the microtiter plate. In this ciELISA, seven 
sulfonamides showed inhibition when added at a level lower or equal to 10 ppm.  
Instead of selecting subpopulations of the Pabs by using a deviating coating (Sheth & 
Sporns, 1991) or an affinity purified fraction (Assil et al., 1992), we continued with 
the preparation of Mabs. To date we have succeeded in producing four Mabs 
producing hybridoma’s after the fusion of myeloma cells with spleen cells of a mouse 
immunized with TS–BSA (Haasnoot et al., 2000). As described in Table 2, we 
compared the generic performances of two of these Mabs with one recently described 
by Muldoon et al. (1999). Muldoon et al. used N-sulfanyl-4 aminobenzoic acid (see 
Figure 2) coupled to KLH as the immunogen to develop cross-reactive Mabs to 
sulfonamide antibiotics. The sensitivities of the Mab for sulfanitran, sulfapyridine and 
sulfathiazole (expressed as IC50 values) were 0.14, 2.3 and 32 ng/well, respectively. 
However, the sensitivity for other sulfonamides was much less (314–10000 ng/well). 
In general, our Mabs (27G3 and 4E10) showed a higher sensitivity towards more 
sulfonamides (see Table 2). The binding of Mab 27G3 to OVA–TS coated microtiter 
plates was inhibited (50%) by all sulfonamides added at a level below 500 ng/well. 
Although these Mabs are unique, the difference in sensitivity towards the different 
sulfonamides is too high to call them true generic antibodies. Future experiments will 
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be focused on the development of Mabs against the PS-conjugate. As shown in Figure 
3, this immunogen resulted in Pabs with high sensitivity towards interesting 
sulfonamides (sulfadimidine, sulfamerazine, sulfadiazine, sulfaquinoxaline, 
sulfadoxine and sulfadimethoxine) which were less detectable with the Pabs and Mabs 
obtained from TS immunized mice. 
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ABSTRACT 
 
A monoclonal antibody (Mab) raised against sulfamethazine (21C7) was applied in an 
optical biosensor (Biacore Q) to develop a rapid biosensor immunoassay (BIA) for the 
detection of several sulfonamides in chicken serum. The performance of this Mab was 
compared with two polyclonal antibodies (Pabs) raised against sulfamethazine (Qflex 
sulfamethazine binding protein (SBP) and RIKILT 464b). Using these Pabs, the limits 
of detection (LODs) in 10 times diluted chicken serum were approximately 30 ng ml-1 
and the two BIAs were found to be specific for sulfamethazine. Using Mab 21C7, the 
LOD for sulfamethazine in 10 times diluted chicken serum was lower (10 ng ml-1), 
high cross-reactivities were measured for sulfisoxazole (149%), sulfachloropyridazine 
(112%), sulfachloropyrazine (94%), sulfamerazine (87%), sulfadiazine (56%), 
sulfatroxazole (56%) and sulfathiazole (50%) and low cross-reactivities (11-25%) 
were measured with six other sulfonamides.  
Compared with the Pabs, the Mab-based BIA resulted in a better sensitivity and was 
found suitable for the detection of 8 sulfonamides in 10 times diluted chicken serum 
with LODs between 7 and 20 ng ml-1. The total run time for each cycle was 7 min. 
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INTRODUCTION 
 
The sulfonamides are a group of antibacterial agents commonly given to food animals 
for prophylactic or therapeutic purposes. In the Netherlands, at least nine different 
sulfonamides are approved for veterinary application and for the medication of 
chicken, five sulfonamides (sulfamethazine, sulfadiazine, sulfachloropyridazine, 
sulfaquinoxaline and sulfamethoxazole) are approved. Intensive use of these drugs in 
animal breeding can lead to unwanted residues in food and to establish safe limits for 
human consumption, maximum residue limits (MRLs) for sulfonamides have been 
established in many countries. In the Netherlands and the European Union an MRL of 
100 µg kg-1 for the total amount of sulfonamides is set for edible tissue [1].  
For the detection of sulfonamides in edible tissue, many methods based on different 
technologies (microbial inhibition assays [2-3], immunoassays [4-6], liquid 
chromatography (LC) [7], LC-mass spectrometry (MS) [8], etc.) have been described. 
These methods are mainly used in laboratories and animal carcasses are processed 
before analytical results are available. For the "real-time" detection of sulfonamides in 
slaughterhouses, body fluids (bile, urine and blood serum) can be employed as 
markers for residue presence in tissue [4, 9-11]. These body fluids can normally be 
analyzed directly without extraction. Currently the most rapid technology for 
performing "real-time" analysis is based on a commercially available surface plasmon 
resonance (SPR) biosensor (BiacoreTM).  
Sternesjö et al. [12] were the first who described an SPR-based biosensor 
immunoassay (BIA) for the determination of sulfamethazine residues in milk. 
Sulfamethazine was covalently immobilized to a carboxymethylated dextran-modified 
gold film. Polyclonal antibodies (Pab) raised against sulfamethazine were added to the 
sample and the immobilized surface was used to determine the amount of free 
antibodies. The limit of detection (LOD) of this inhibition assay in raw and defatted 
milk was <1 µg kg-1, which was better than those obtained with microbiological, 
immunochemical and physical methods [13]. Other advantages of the biosensor assay 
they described were the lack of a sample preparation, its fully automated operation, 
the short time for analysis (20 min) and the specificity.  
Elliott et al. [11] developed a more rapid immunobiosensor screening assay for the 
detection of sulfadiazine in pig bile. Pabs to sulfadiazine were added to 20 times 
diluted bile samples and the level of antibody binding to a sulfadiazine immobilized 
biosensor chip was determined after 20 s. The surface of the chip was then 
regenerated over a 1-min period prior to another sample injection. They found that an 
action level of 600 ng g-1 in pig bile could be used to control for the presence of 
sulfadiazine in edible tissue at the MRL level (100 ng g-1). Crooks et al. [10] applied 
the same system and procedure to detect both sulfamethazine and sulfadiazine in pig 
bile on two separate biosensor chips and they found that the BIAs showed more 
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reliable results than conventional immunoassay methods. However, due to the 
specificity of the antibodies used, these BIAs were all specific for one of the 
sulfonamides and, to detect several sulfonamides, different BIAs had to be used. For 
the screening of more sulfonamides at the same time, several investigations were 
focused on the development of generic antibodies detecting the group of sulfonamides 
[14-16]. However, these approaches were not so successful and important 
sulfonamides (such as sulfamethazine) were not detected or at a high level only. 
A Mab (21C7) raised against sulfamethazine [17] was identified as an antibody 
recognizing several important sulfonamides dissolved in buffer [18]. This Mab was 
used for the development of anti-idiotype antibodies and was applied in a BIA for the 
detection of sulfamethazine in urine [19] but was not used before for the detection of 
several sulfonamides in sample materials. 
In the present study we aimed for a BIA suitable for the detection of several 
relevant sulfonamides in chicken blood. In a Dutch research project ("Development of 
monitoring and surveillance systems in the poultry meat chain", financed by the 
Dutch Ministry of Agriculture, Nature Management and Fisheries within research 
program no. 389) such a BIA should be combined with a BIA for the detection of 
Salmonella antibodies in chicken blood. The Biacore Q biosensor was used in 
combination with the Qflex Kit Sulfamethazine and the performance of the 
sulfamethazine binding protein (SBP), as supplied in the kit, was compared with an 
in-house developed polyclonal antiserum (464b) and with Mab 21C7.  
 
 
EXPERIMENTAL 
 
Materials 
The N4-acetyl-sulfonamide kit (containing N4-acetyl-metabolites from sulfadiazine, 
sulfamethazine (sulfadimidine), sulfathiazole, sulfamethizole, sulfaquinoxaline, 
sulfanilamide and sulfamerazine), N4-acetyl-sulfamethoxazole, N4-acetyl-sulfadoxine, 
N4-acetyl-sulfadimethoxine, sulfadoxine, sulfachloropyrazine and sulfaquinoxaline 
were obtained from Serva (Heidelberg, Germany). Sulfamethazine, sulfamethoxazole, 
sulfamethoxypyridazine, sulfamerazine, sulfaguanidine, sulfadimethoxine, 
sulfadiazine, sulfachloropyridazine, sulfapyridine, sulfathiazole, sulfamethizole and 
sulfisoxazole were obtained from Sigma-Aldrich Chemie BV (Zwijndrecht, the 
Netherlands). Sulfatroxazole was a gift from Leo Pharmaceutical Products (Weesp, 
the Netherlands). 
The Qflex Kit Sulfamethazine (containing SBP, sulfamethazine derivative, HBS-EP 
buffer (composition: 0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA and 0.005% 
Surfactant P20), a CM5 sensor chip and kit accessories), the Qflex Kit Sulfamethazine 
handbook and the amine coupling kit (containing 0.1 M N-hydroxysuccinimide (NHS), 
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0.4 M N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 1 
M ethanolamine hydrochloride-NaOH (pH 8.5)) were supplied by Biacore AB 
(Uppsala, Sweden). The CM-dextran sodium salt was obtained from Fluka Chemie 
(Zwijndrecht, the Netherlands) and dimethyl sulfoxide (DMSO) was from VWR 
International (Amsterdam, the Netherlands). The anti-sulfamethazine polyclonal 
antiserum (464b) was raised in a rabbit immunized with sulfamethazine-
hemisuccinate-bovine serum albumine (BSA) and the performance of this antiserum 
in an enzyme-linked immunosorbent assay (ELISA) was described previously [4]. 
The raw serum was stored at -80 ºC until used. The preparation of the anti-
sulfamethazine Mab (21C7) was also described previously [17]. Lyophilized ascites 
(0.5 ml) was dissolved in 0.5 ml of water and the solution was diluted 20 times in 
HBS-EP buffer and stored in 1 ml portions at -20 ºC until used. 
 
Equipment 
The Biacore Q biosensor was loaned from Biacore Benelux (Breda, the Netherlands). 
A Sigma Model 302K centrifuge was supplied by Salm en Kipp BV (Breukelen, the 
Netherlands) and the microtiter plate Varishaker-Incubator was obtained from 
Dynatech (Guernsey, UK). 
  
Solutions 
The sulfonamides and the N4-acetyl-sulfonamides were dissolved in methanol (1 mg 
ml-1) and stored at -20 ºC until used. Of each standard, a first intermediate standard 
solution with a concentration of 27 µg ml-1 was prepared in water. From this 
intermediate standard solution, calibrant solutions (27, 9, 3 and 1 ng ml-1), solutions 
used for the determination of the cross-reactivity (270, 27 or 2.7 ng ml-1) and 
solutions used for the addition to chicken serum samples (20 and 50 ng ml-1) were 
prepared in extraction buffer. The extraction buffer consisted of 20 mM sodium 
phosphate buffer and 0.15 M sodium chloride to which 0.3 g L-1 of CM-dextran 
sodium salt was added. This buffer was filtered though a 0.2 µm filter. The running 
buffer was ready-to-use HBS-EP buffer and the regeneration solution consisted of 
20% acetonitrile in 0.2 M sodium hydroxide. The SBP stock solution provided in the 
kit was diluted in running buffer (one part stock solution to four parts HBS-EP).  
 
Preparation of the biosensor chip 
The sensor chip (CM5) consists of a gold surface coated with a carboxymethylated 
dextran matrix. The ready-to-use sulfamethazine derivative (supplied in the Qflex Kit) 
was immobilized on the sensor surface using the amine coupling kit and the 
Immobilization Wizard of the Biacore Q software. To eliminate the risk of carry-over 
of ligand from the immobilization procedure in the Integrated µ-Fluidic Cartridge 
(IFC) channels of the biosensor, immobilization was performed in the Surface Prep 
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unit, separate from the IFC. The Surface Prep unit is a sensor chip holder that fits 
directly onto the auto sampler rack base of the Biacore Q. Flow channels are formed 
on the sensor chip surface by docking a plastic block (the flow cell carrier) onto the 
chip. Solutions were injected directly into the flow channels with the auto sampler 
needle and effluents from the flow channels were collected in a small waste beaker.  
At first, the sensor chip surface was activated by injecting a mixture of 0.4 M EDC 
and 0.1 M NHS (1:1; v/v) at a flow rate of 10 µl min-1 and with a contact time of 7 
min. After washing with 0.1 M sodium hydroxide, the sulfamethazine derivative was 
injected over the surface during 7 min at a flow rate of 5 µl min-1. To deactivate the 
remaining active sites, 1 M ethanolamine was injected during 3 min at a flow rate of 
10 µl min-1. An extra wash step with 50% DMSO was used to remove any adsorbed 
chemicals from the immobilization procedure. 
 
Biosensor Immunoassays (BIAs) 
The Qflex Kit Sulfamethazine was used in combination with the Biacore Q. The assay 
was designed as an inhibition (indirect) assay. The sensor chip, with immobilized 
sulfamethazine derivative, was used to bind antibodies against sulfamethazine (Qflex  
SBP). A known concentration of the SBP was mixed (1:1; v/v) with the sample 
(chicken serum which was ten times diluted in extraction buffer) in a microtiter plate 
automatically by the instrument. The mixture was injected over the sensor surface for 
60 s at a flow rate of 40 µl min-1 and the response from free SBP was measured. The 
surface was regenerated by injecting a solution of 0.2 M sodium hydroxide containing 
20% acetonitrile during 60 s at 40 µl min-1 and the sensor was ready for the next 
analysis cycle. The total run time under these conditions was 7 min. In the 
Concentration Analysis Wizard of the Biacore Q software, the responses for a set of 
calibration solutions (1, 3, 9 and 27 ng ml-1 sulfamethazine in dilution buffer) were 
used to generate a calibration graph (using the four-parameter equation as fitting 
function) and unknown samples were determined with reference to the calibration 
graph. 
Applying Mab 21C7 (a 20 times dilution of the 20 times pre-diluted ascites (400 times 
diluted ascites)) instead of the SBP, the same procedure as described above could be 
applied. 
When using Pab 464b instead of the SBP, a two-step regeneration (injecting 50 mM 
hydrochloric acid for 30 s, followed by 0.2 M sodium hydroxide containing 20% 
acetonitrile during 30 s) was necessary to clean the sensor surface from bound 
antibodies (run time 7 min). 
 
Determination of cross-reactivities 
For each of the three antibodies, calibration graphs of sulfamethazine in extraction 
buffer (27, 9, 3 and 1 ng ml-1) were prepared.  
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With the rather specific polyclonal anti-sulfamethazine antibodies, standard solutions 
of the sulfonamides and the N4-acetyl-metabolites (27 and 270 ng ml-1) in extraction 
buffer were injected and the concentrations were calculated by means of the 
calibration results in extraction buffer. For N4-acetyl-sulfamethazine, a lower 
concentration (2.7 ng ml-1) was also injected. For each of the sulfonamides, the 
percentage of cross-reactivity was calculated (the calculated concentration 
(sulfamethazine equivalents) divided by the injected concentration times 100 %).  
For the less specific Mab 21C7, standard solutions of the sulfonamides with 
concentrations of 2.7 and 27 ng ml-1 in extraction buffer were injected and cross-
reactivities were calculated as described above.  
For the calculation of the cross-reactivity in diluted chicken serum (10 or 4 times 
diluted), a chicken serum was spiked at the 100 ng ml-1 level with each of the 
sulfonamides. Of the sulfonamides, standard solutions of 20 and 50 ng ml-1 were 
prepared in extraction buffer. In the case of 10 times diluted chicken serum, 20 µl of 
chicken serum (mixture of 10 different blank chicken sera) was mixed in a microtiter 
plate with 100 µl of the sulfonamide standard solutions (20 ng ml-1) and 80 µl of 
extraction buffer. The sulfamethazine equivalents were calculated with a calibration 
graph for sulfamethazine in chicken serum (10, 30, 90 and 270 ng ml-1) which was 
also 10 times diluted. In the case of the 4 times diluted chicken sera, 50 µl of the 
chicken serum was mixed in a microtiter plate with 100 µl of the sulfonamide 
standard solutions (50 ng ml-1) and 50 µl of extraction buffer. The sulfamethazine 
equivalents were calculated with a calibration graph for sulfamethazine in chicken 
serum (4, 12, 36 and 108 ng ml-1) which was also 4 times diluted.  
 
Samples 
Blank chicken sera samples (n=66) were obtained from the Institute for Animal 
Science and Health (ID-Lelystad, Lelystad, the Netherlands). Of these samples, 42 
were taken from 21-day-old chickens and 24 were taken from 44-day-old broilers. 
 
 
RESULTS AND DISCUSSION 
 
Calibration graphs obtained with the three antibodies. 
In the Biacore Q, the performance of the antibody (SBP) supplied in the Qflex Kit 
Sulfamethazine was compared with a Pab developed in RIKILT (464b) and with the 
Mab developed in the Weizmann Institute of Science (Mab 21C7). All three 
antibodies were developed against sulfamethazine. During this comparison, the 
conditions prescribed in the Qflex Kit Sulfamethazine handbook (flow rate, injection 
volume, regeneration, etc.) were used (see Experimental section). These conditions 
worked well for the SBP and also for Mab 21C7. However, applying Pab 464b, the 
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regeneration conditions had to be adjusted to a two step regeneration with 50 mM 
HCL (20 µl), followed by 0.2 M NaOH containing 20% acetonitrile (20 µl). 
Under the conditions prescribed in the kit handbook, the SBP was diluted in running 
buffer and, prior to the injection, mixed in the Biacore with extraction buffer (1:1; 
v/v), which resulted in an average maximum response of 807 ± 31 RU. A comparable 
average maximum response in buffer (783 ± 34 RU) was obtained with a 385 times 
dilution of Pab 464b. In an ELISA [4], this antiserum could be used in a 2500 times 
dilution (25 µl). This means that the BIA consumes approximately 10 times more 
antibodies than the ELISA. The 20 times pre-diluted Mab 21C7 containing ascites 
could be diluted another 20 times (400 times diluted ascites) to obtain an average 
maximum response in buffer of 726 ± 12 RU. Using these antibody dilutions mixed 
(1:1; v/v) with standard solutions of sulfamethazine (1, 3, 9 and 27 ng ml-1), the 
calibration graphs showed 50% inhibition at 11.5, 9.5 and 8 ng ml-1 for the Qflex SBP, 
Pab 464b and Mab 21C7, respectively (see Figure 1).  
 
 
 
Figure 1. Normalized calibration graphs of sulfamethazine in buffer using the three different 
antibodies in the BIA. 
 
The limits of detection (LOD = the concentration of sulfamethazine corresponding to 
the average maximum response minus three times standard deviation (S.D.)), obtained 
with the three calibrations for sulfamethazine in buffer were 3.0, 3.5 and 1.5 ng ml-1 
for the SBP, 464b and Mab 21C7, respectively. The inhibition of the response at the 
highest calibration standard (27 ng ml-1) was also less for the calibration using the 
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SBP. This means that the calibration graph for the BIA could be improved if the SBP 
was replaced by Pab 464b or Mab 21C7.  
 
Performance of the BIAs in chicken sera. 
Table 1: Performances of the three BIAs (using the Qflex SBP, Pab 464b and Mab 21C7) in 
the Biacore Q for the determinations of sulfamethazine in 10 times diluted blank chicken sera 
samples (n=66) and these samples spiked with sulfamethazine (100 ng ml-1). 
ANTIBODY  
Qflex  
SBP 
Pab 
464B 
Mab 
21C7 
Maximum response with buffer (RU) 807±31 783±34 726±12 
Maximum response with blank chicken sera (RU) 833±27 828±31 773±15 
LOD in 10 x diluted chicken sera (ng ml-1) 30 28 10 
LDM in 10 x diluted chicken sera (ng ml-1) 45 43 18 
Response with sulfamethazine spiked 
(100 ng ml-1) chicken sera (RU) 
465±47 341±45 323±9 
Inhibition of maximum response with 
sulfamethazine spiked chicken sera (%) 
44.2 58.8 58.2 
Recovery of sulfamethazine (%) 89±5 103±9 93±3 
 
 
Figure 2. Comparison of sulfamethazine calibration graphs in buffer and chicken serum (10 
and 4 times diluted) obtained with Mab 21C7 in the BIA. 
 
Of each blank chicken serum (n=66), 20 µl were pipetted into a microtiter plate well 
and 180 µl of extraction buffer was added. After 2 min of mixing on a microtiter plate 
shaker, the chicken sera were analyzed without the addition of antibody (1:1 dilution 
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with running buffer; v/v) to investigate the average background response (nonspecific 
binding) which was low (21 ± 10 RU).  
Thereafter, the 10 times diluted chicken sera (n=66) were analyzed after mixing (1:1; 
v/v) with the three different antibodies (diluted in running buffer). The average 
maximum responses obtained with the three antibodies in the diluted chicken sera 
were somewhat higher than those obtained in buffer (see Table 1), which could only 
be partly explained by the small background obtained from the chicken sera without 
the addition of antibodies. After the addition of sulfamethazine to the chicken sera 
(100 ng ml-1), the average responses obtained with the 10 times diluted chicken sera in 
the three BIAs were strongly decreased compared to the maximum responses. The 
average inhibitions of the maximum responses were between 44 - 59 % (see Table 1).  
 
Table 2: Cross-reactivities of the antibodies towards several sulfonamides and N4-acetyl-
metabolites in buffer and chicken serum (4 and 10 x diluted). 
CROSS-REACTIVITY (%) 
Mab 21C7 
SULFONAMIDE 
Pab 
Qflex SBP 
buffer 
Pab 
 464B 
buffer 
 
buffer 
SERUM 
(10x ) 
SERUM 
(4x) 
Sulfamethazine (sulfadimidine) 100 100 100  100  100 
N4-Acetyl-sulfamethazine 81 79 70  68  73  
Sulfadiazine 1 2 63  56  52  
N4-Acetyl-sulfadiazine 1 2 50  52  43  
Sulfamerazine 7 8 86  87  85  
N4-Acetyl-sulfamerazine 10 10 83  70  73  
Sulfachloropyrazine 2 2 127  94  86  
Sulfisoxazole <0.4 <0.4 130  149  >108  
Sulfachloropyridazine <0.4 <0.4 100 112  99  
Sulfatroxazole <0.4 <0.4 47  56  51  
Sulfathiazole <0.4 1 48  50  37  
N4-Acetyl-sulfathiazole   0.4 1 26  30  19  
Sulfamethizole <0.4 <0.4 30  15  12  
N4-Acetyl-sulfamethizole <0.4 <0.4 11  <10  <4  
Sulfadimethoxine 1 3 22  20  20  
N4-Acetyl-sulfadimethoxine 1 3 7  <10  5  
Sulfamethoxypyridazine <0.4 <0.4 22  25  26  
Sulfamethoxydiazine <0.4 <0.4 21  22  23  
Sulfapyridine 1 1 15  13  17  
Sulfamethoxazole <0.4 <0.4 8  11  14  
N4-Acetyl-sulfamethoxazole <0.4 1 2  <10  <4  
Sulfaquinoxaline <0.4 <0.4 0.9  <10  <4  
N4-Acetyl-sulfaquinoxaline   0.4 <0.4 <0.4  <10  <4  
Sulfadoxine <0.4 <0.4 <0.4  <10  <4  
N4-Acetyl-sulfadoxine <0.4 <0.4 <0.4  <10  <4  
Sulfaguanidine <0.4 <0.4 <0.4  <10  <4  
 
Calculating the concentration in the spiked sera by means of the calibration graph in 
buffer resulted in average recoveries between 89 and 103 % (see Table 1). 
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Calibration graphs in chicken serum were prepared for the three BIAs and compared 
with the calibrations in buffer. The responses obtained with those in 10 times diluted 
chicken sera were somewhat higher than those obtained in buffer. With the Mab-
based BIA, a calibration graph in four times diluted chicken serum was also prepared. 
As shown in Figure 2, the responses obtained were again slightly higher, which 
proved the influence of the chicken serum, and, for quantitative results, calibration 
graphs in chicken serum should be used to calculate the concentrations in the sample. 
Using the calibration plots in 10 times diluted chicken serum, the limits of detection 
(LOD = concentration of sulfamethazine corresponding with the average response of 
blank chicken sera minus three times the S.D.) of the two Pab-based BIAs in 10 times 
diluted chicken sera were calculated as 28 and 30 ng ml-1 (see Table 1). The limits of 
determination (LDM = concentration of sulfamethazine corresponding with the 
average response of blank chicken sera minus six times S.D.) were 43 and 45 ng ml-1 
(see Table 1). With the Mab-based BIA, the LOD and LDM in 10 times diluted 
chicken sera were lower (10 and 18 ng ml-1, respectively). These lower values were 
obtained due to a smaller variation in the responses obtained with the blank chicken 
sera and due to a more sensitive calibration graph. With this Mab, the LOD and LDM 
in four times diluted chicken sera were 5 and 9 ng ml-1, respectively.  
Therefore, of the three antibodies used in this study, the Mab showed the best results 
in the  BIA for the determination of sulfamethazine in chicken sera. 
 
Cross-reactivity. 
The cross-reactivities of the three antibodies in the BIAs were compared using 
standard solutions of different sulfonamides and N4-acetyl-metabolites of some of the 
sulfonamides dissolved in buffer. As shown in Table 2, the SBP and the Pab 464b 
were very specific towards sulfamethazine and its N4-acetyl metabolite. With both 
antibodies, low cross-reactivities were observed for sulfamerazine and its N4-acetyl-
metabolite.  
Mab 21C7 showed high cross-reactivity (47 - 130%) with eight sulfonamides and 
with the N4-acetyl-metabolites of three of these sulfonamides, medium cross-
reactivity (15-30%) with five sulfonamides and low cross-reactivity (8%) with one of 
the sulfonamides. These cross-reactivities obtained with the Mab were also 
determined in chicken sera (10 and 4 times diluted) and the results were almost the 
same with those obtained in buffer (see Table 2). The different sulfonamides were 
added at the 100 ng ml-1 level (MRL in tissue) to a mixture of the blank chicken sera 
and the samples were 10 and 4 times diluted in extraction buffer. As shown in Figure 
3, the responses obtained with the spiked serum samples were compared with the 
average responses obtained with the blank chicken sera (n=66) which were calculated 
as 773 ± 15 RU for 10 times diluted sera and 798 ± 15 RU for 4 times diluted sera. 
From these average responses obtained with blank sera, threshold levels (average 
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response minus six times the standard deviation) were calculated as 683 RU (10 times 
diluted sera) and 708 RU (4 times diluted sera). As shown in Figure 3A, the addition 
of 8 of the sulfonamides at the 100 ng ml-1 level resulted in strongly reduced 
responses using 10 times diluted samples. With 4 times diluted samples the responses 
obtained with 14 of the sulfonamides were below the threshold (Figure 3B). 
 
 
 
Figure 3. Responses obtained in the Mab-based BIA with a blank chicken serum towards 
different sulfonamides were added at the 100 ng ml-1level, after a 10 times dilution (A) and 
after a 4 times dilution in extraction buffer (B). The thresholds (dotted lines) were calculated 
from the average responses (minus six times the standard deviation) obtained with the blank 
chicken sera (n=66).   
 
Of the five sulfonamides allowed to be used in chicken in the Netherlands, this Mab 
recognized three of them (sulfamethazine, sulfadiazine and sulfachloropyridazine) 
with high cross-reactivity (see Table 2) which makes it a unique antibody. However, 
the cross-reactivities with the other two sulfonamides allowed for the treatment of 
chicken were low (11% for sulfamethoxazole and <10% for sulfaquinoxaline in 10 
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times diluted serum) and additional research is needed to include these sulfonamides 
into the assay. An option might be the use of a multi-channel approach in which one 
or two antibodies are added to the assay in combination with immobilized 
sulfonamides in additional flow channels. Such a multi-channel approach on a high-
throughput biosensor was recently described for the simultaneous determination of 
sulfamethazine and sulfadiazine in porcine bile [20]. 
 
 
CONCLUSIONS 
 
The Qflex Kit Sulfamethazine in combination with the Biacore Q resulted in a fast 
BIA (total run time of 7 min) that could be used for the detection of sulfamethazine in 
10 times diluted chicken sera with an LOD of 30 ng ml-1. This BIA and the BIA based 
on Pab 464b were very specific for sulfamethazine and its N4-acetyl metabolite. The 
BIA could be improved by the application of Mab 21C7. The Mab-based BIA resulted 
in a lower LOD for sulfamethazine in 10 times diluted chicken sera (10 ng ml-1) and 
could detect 8 sulfonamides at comparable sensitivities (LODs between 7 and 20 ng 
ml-1). During the experiments described in this study, the biosensor chip with the 
immobilized sulfamethazine derivative was used for approximately 1100 cycles and 
no significant change in performance was observed using the same antibody, which 
makes this BIA very robust. 
Future experiments with medicated chicken are necessary to investigate the 
relationship between concentrations of the sulfonamides in blood serum and edible 
tissue to establish an action level in blood serum of chicken. 
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ABSTRACT 
 
Three different group-specific anti-sulfonamide antibodies were compared in 
inhibition assay formats in an optical biosensor (Biacore 3000) using CM5 sensor 
chips coated with three different sulfonamide derivatives. The antibodies used were 
an anti-sulfamethazine monoclonal antibody (Mab) 21C7, the sulfonamide binding 
protein (SBP) in the Qflex Kit Sulfonamides and a recently developed mutant 
antibody (M.3.4). Each of these antibodies showed interactions with all 17 
sulfonamides tested and one (Mab 21C7) was sensitive for the N4-acetyl metabolites 
also. The limits of detection of the different sulfonamides in chicken serum varied 
between 7 and >1000 ng ml−1 (Mab 21C7), 15 and 340 ng ml−1 (Qflex) and 4 and 82 
ng ml−1 (mutant M.3.4). The mutant M.3.4-based assay was found to be the most 
sensitive towards most of the sulfonamides whereas the Qflex Kit Sulfonamides 
detected the five sulfonamides registered for application in poultry in the Netherlands 
within the narrowest measurement range. 
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INTRODUCTION 
 
One of the aims of the Dutch research project “Development of monitoring and 
surveillance systems in the poultry meat chain” is to evaluate the on-line detection of 
drug residues in slaughterhouses and the detection of sulfonamides was chosen as a 
first model. In the Netherlands, at least nine different sulfonamides are approved for 
veterinary application. For the medication of poultry, five sulfonamides 
(sulfamethoxazole, sulfadiazine, sulfamethazine, sulfachloropyridazine and 
sulfaquinoxaline) are approved of which the first two are most frequently applied. 
Intensive use of these drugs in animal breeding can lead to unwanted residues in food 
and to establish safe limits for human consumption, the European Union established a 
maximum residue limit (MRL) of 100 μg kg−1 for the total amount of sulfonamides in 
edible tissue [1].  
For the detection of sulfonamides in edible tissue, many methods based on different 
technologies (microbial inhibition assays [2,3], immunoassays [4–6], LC [7], LC–MS 
[8], etc.) have been described. These methods are mainly used in laboratories and 
animal carcasses are processed before analytical results are available. For the 
detection of sulfonamides in slaughterhouses, body fluids (bile, urine and blood 
serum) can be employed as markers for residue presence in tissue [4,9–11]. These 
body fluids can normally be analyzed directly without extraction. Currently the most 
rapid technology for performing analysis is based on a commercially available surface 
plasmon resonance (SPR) biosensor (BiacoreTM). Applications were described for the 
determination of sulfamethazine residues in milk [12,13] and the detection of 
sulfamethazine and sulfadiazine in pig bile [10,11]. However, due to the specificity of 
the antibodies used, these biosensor immunoassays (BIAs) were all specific for one of 
the sulfonamides and, to detect several sulfonamides, different BIAs had to be used. 
As an example, a two-channel approach on a high-throughput biosensor was 
described for the simultaneous determination of sulfamethazine and sulfadiazine in 
porcine bile [14].  
For the screening of more sulfonamides at the same time, several investigations were 
focused on the development of multi-sulfonamide antibodies detecting the group of 
sulfonamides [15–18]. However, these approaches were partly successful because 
important sulfonamides (such as sulfamethazine) were not detected or at a high level 
only.  
A monoclonal antibody (Mab) 21C7 raised against sulfamethazine [19] was identified 
as an antibody recognizing several important sulfonamides dissolved in buffer [20]. 
This Mab was applied in BIAs for the detection of sulfamethazine in urine [21] and 
for the detection of eight sulfonamides in chicken serum with limit of detections 
(LODs) between 7 and 20 ng ml−1 [22]. However, the sensitivity of this assay for the 
detection of important sulfonamides, such as sulfamethoxazole and sulfaquinoxaline 
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was less. A mutant antibody (A.3.5) was selected after protein engineering of a broad 
specificity sulfonamide binding monoclonal antibody (Mab 27G3 [17]). In a 
competitive time-resolved fluoroimmunoassay this mutant showed an improved 
sensitivity towards several sulfonamides compared with the wild-type Mab [23]. 
However, the sensitivity towards important sulfonamides such as sulfamethazine, 
sulfadimethoxine and sulfaquinoxaline was low. In order to improve the properties of 
the antibodies, mutants from the previous study [23] were recombined and more 
mutations introduced [24]. In the time-resolved fluoroimmunassay, the selected 
mutant from that study (M.3.4) showed an improved sensitivity for all 13 
sulfonamides tested and even sulfamethazine, sulfadimethoxine and sulfaquinoxaline 
could be measured below the 100 ng ml−1 level.  
In the present study, the performance of the new mutant M.3.4 was compared with 
that of Mab 21C7 and with a recently launched multi-sulfonamide kit (Qflex® Kit 
Sulfonamides) of Biacore (Uppsala, Sweden) in the Biacore 3000 using chicken 
serum as sample material. The performances of these antibodies in the biosensor are 
compared for (i) sensitivities towards 26 sulfonamides and N4-acetyl metabolites 
added to chicken serum and (ii) the influence of chicken serum on the assays.  
 
 
MATERIALS AND METHODS 
 
Materials and instrument 
Sulfatroxazole was a gift from Leo Pharmaceutical Products (Weesp, the Netherlands). 
All other sulfonamides, including an N4-acetyl-sulfonamide kit (not available 
anymore) were obtained from Serva (Heidelberg, Germany) or Sigma–Aldrich 
(Zwijndrecht, the Netherlands). Biacore AB (Uppsala, Sweden) delivered the Biacore 
3000, the Qflex Kit Sulfamethazine, the Qflex Kit Sulfonamides, HBSEP buffer, CM5 
biosensor chips and an amine coupling kit (containing 0.1 M N-hydroxysuccinimide 
(NHS), 0.4 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) 
and 1 M ethanolamine-hydrochloride (pH 8.5)). All other chemicals were obtained 
from Sigma–Aldrich. The preparation of N1-[4-(carboxymethyl)-2-thiazolyl] 
sulfanilamide (TS) [17], the development of Mab 21C7 [19] and the application in the 
biosensor [22] and the development of mutant M.3.4 were described previously [24].  
 
Biosensor immunoassays (BIAs) 
 
Preparation of the biosensor chips. 
For each of the three assays, a different sulfonamide derivative was bench top  
immobilized onto the surface of a CM5 sensor chip. In the Mab 21C7-based assay, a 
sulfamethazine derivative as supplied in the Qflex Kit Sulfamethazine was 
immobilized [22]. Using the Qflex Kit Sulfonamides, another sulfonamide derivative 
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(supplied in the kit) was immobilized. During both immobilizations, the procedures as 
prescribed by the manufacturer were followed.  
For the application of mutant M.3.4, the chip was coated with TS using the following 
procedure. The chip surface was activated with 50 μl of a mixture of 0.4 M EDC and 
0.1 M NHS (1:1; v/v) during 15 min at RT. The chip surface was washed with water 
and dried under a stream of nitrogen gas. To the chip, 50 μl of 0.1 M ethylene diamine 
(pH of 8.5) was added and after 15 min incubation at RT, the chip was washed with 
water and dried under a stream of nitrogen gas.  
The sulfonamide derivative (TS) was immobilized on the activated sensor surface 
using the following procedure. TS (2 mg) was dissolved in 0.2 ml dimethylsulfoxide 
(DMSO) and 0.8 ml of sodium carbonate buffer (1.59 g Na2CO3 + 2.93 g NaHCO3 in 
1 l water, adjusted to pH 9.6) was added. Of this TS solution, 50 μl was mixed with 
50 μl 0.4 M EDC and 50 μl 0.1 M NHS and after an incubation at RT for 1 h, this 
mixture (50 μl) was added to the activated chip. After an incubation of 1 h at RT, the 
chip was washed with water, dried under a stream of nitrogen and docked into the 
Biacore 3000.  
 
Assays for serum samples 
In the Mab 21C7-based and mutant M.3.4-based assays, chicken serum (20 μl) was 
pipetted into a 96-well microtiter plate and 80 μl of extraction buffer (20 mM sodium 
phosphate and 0.15 M sodium chloride; pH 7.2) was added. Using the Qflex Kit 
Sulfonamides, 60 μl of extraction buffer and 20 μl of a concentrated Hepes buffer (0.1 
M Hepes, 34 mM EDTA, 1 M NaCl and 0.01% P20) were added to chicken serum (20 
μl) in the well of the microtiter plate. Prior to injections, the diluted samples were 
mixed with diluted antibody (1:1; v/v) in the Biacore 3000. The antibody solutions 
were diluted to result in maximum responses between 700 and 1200 response units 
(RU) applying injection volumes of 50 μl at a flow rate of 20 μl min−1 (Mab 21C7 or 
mutant M.3.4) or 27 μl at a flow rate of 80 μl min−1 (according to the Qflex Kit 
Sulfonamide manual) with HBS-EP as the running buffer. For the regenerations, 10 μl 
of 0.1 M HCl followed by 5 μl of 0.1 M NaOH (mutant M.3.4) or 20 μl of 0.1 M 
NaOH (Qflex) or 20 μl of 0.2 M NaOH plus 20% acetonitrile (21C7) were injected at 
a flow rate of 20 μl min−1. 
 
Sample materials 
Blank chicken serum samples (n = 66) were obtained from the Animal Sciences 
Group (ASG, Lelystad, the Netherlands). Of these samples, 42 were taken from 21-
days-old chicken and 24 were taken from 44-days-old broilers. These samples were 
mixed to create a large batch (approximately 100 ml) of blank chicken serum.  
An animal experiment with 4-weeks-old broilers was performed at ASG and started 
on 18-02-2003. One group of broilers (10 male and 10 female) was not treated with 
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sulfonamides and served as blanks. These broilers were slaughtered on the first day of 
the experiment and serum samples were stored at −20 ◦C until analyzed. 
To obtain incurred samples, another group of chickens (15 male and 15 female) was 
given an oral treatment with Trimethosulfmix 50% (80 mg trimethoprim and 420 mg 
sulfadiazine sodium per g; Eurovet Animal Health BV, Bladel, the Netherlands) using 
a dose of 0.45 g l−1 of drinking water. The average water consumption was 
determined as 200 ml (approximately 38 mg of sulfadiazine) per kg body weight. 
During the 4 days treatment, two groups of six chickens each were slaughtered at days 
2 and 4 and after the treatment three groups of six chickens each were slaughtered at 
days 7, 10 and 14 (3, 6 and 10 days after treatment) and serum samples were stored at  
−20 °C until analyzed. 
 
 
RESULTS AND DISCUSSION 
 
Assay conditions 
The performances of the three inhibition assays were, as much as possible, tested 
under comparable conditions. Chicken serum samples were five times diluted in 
extraction buffer and, prior to the injection, the sample solutions were mixed with the 
antibody solutions (1:1; v/v) in the Biacore. The final dilutions of the antibodies in the 
three assays were adjusted to result in maximum responses between 700–1200 RU 
using an injection volume of 50 μl at a flow rate of 20 μl min−1 with HBS-EP as the 
running buffer. However, the performance of the Qflex Kit Sulfonamides increased 
(better sensitivity) using the protocol described in the kit handbook (for pork muscle 
only) in which a concentrated Hepes buffer was added to the sample solution and 
short injections (20 s) at a high flow rate (80 μl min−1) were applied. 
During the comparison, these conditions were applied with the Qflex kit only. In all 
assays, the relative responses obtained 30 s after the sample injections were used for 
the calculations as described below. Due to the different sulfonamide derivatives 
immobilized onto the chip surface and the different antibodies used, the regeneration 
conditions of the three assays varied also (see  materials and methods section). These 
differences in assay conditions are visualized in the sensorgrams obtained with the 
three different assays (Fig. 1). The total time of analysis using the Qflex kit was 8 and 
10 min for the other two assays. Of this time, about 3 min were used for mixing the 
sample with the antibodies, 1–2.5 min for sample injection and 0.5–1 min for the 
regeneration. The rest of the analysis time was used by the Biacore during washing 
steps. Due to the addition of concentrated Hepes buffer, resulting in a higher bulk 
response (BR), and the short injection at a high flow rate, the sensorgram obtained 
with the Qflex kit was deviating from the sensorgrams obtained with the other two 
assays (Fig. 1). 
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Figure 1. Sensorgrams obtained in the three different assays with a blank chicken serum. In 
the Mab 21C7-based and mutant M.3.4-based assay, 50 μl was injected at a flow rate of 20 μl 
min-1 and for the Qflex Kit Sulfonamides, 27 μl was injected at a flow rate of 80 μl min-1 
(according to the kit handbook). For the regeneration conditions, see Materials and methods. 
BR = bulk response. 
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Sensitivity of the three assays towards different sulfonamides 
The batch of blank chicken serum samples was spiked with 26 different sulfonamides 
and metabolites (100 ng ml−1) and analyzed in the three different assays. The 
responses were compared with the average responses obtained after analyzing the 
blank chicken serum and percentages of inhibition were calculated. As shown in Fig. 
2, the assay based on Mab 21C7 was sensitive towards the N4-acetyl-metabolites of 
some sulfonamides and the other two assays showed minor reactions with these 
metabolites (showing a cross-reactivity of <10% compared to the parent compounds). 
 
Figure 2. Inhibition of responses (%) obtained in three assays with a blank chicken serum 
spiked at the 100 ng ml−1 level with different sulfonamides and N4-acetyl-metabolites.
Chapter 5 
 119
  
 
 
Figure 3. Calibration curves in chicken serum obtained in the three assays with the five 
different sulfonamides registered for application in broilers in the Netherlands 
(sulfamethazine, sulfadiazine, sulfamethoxazole, sulfaquinoxaline and sulfachloropyridazine) 
and with some sulfonamides showing the highest and lowest sensitivity in the assays. 
 
In the three assays, all sulfonamides were detected however, with different 
sensitivities. The number of sulfonamides showing more than 50% inhibition (inh.) 
was 8 (Qflex), 9 (Mab 21C7) and 11 (mutant M.3.4).  
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Calibration curves were prepared in blank chicken serum for the five sulfonamides 
registered in the Netherlands for application in poultry (sulfamethazine (SMZ), 
sulfadiazine (SDZ), sulfamethoxazole (SMX), sulfaquinoxaline (SQX) and 
sulfachloropyridazine (SCP)) and for the sulfonamides showing the highest and 
lowest sensitivities in the assays (Fig. 3). 
The assay based on Mab 21C7 was most and least sensitive towards sulfamethazine 
and sulfadoxine (50% inh. at 14 and >1000 ng ml−1, respectively). The Qflex kit was 
most and least sensitive towards sulfapyridine and sulfatroxazole (50% inh. at 40 and 
>1000 ng ml−1, respectively). This is in agreement with the data presented in 
Application note 44 (Biacore AB, Uppsala, Sweden), describing the detection of 
sulfonamides in porcine muscle. In general, for the sulfonamides applied in this study, 
the results obtained are comparable with the results described in this application note 
except for sulfadiazine. For this sulfonamide the calculated cross-reactivity (compared 
to sulfamethazine) was 60% whilst 124% was described in the note. The cross-
reactivity was expressed as a percentage of the concentration at 50% inhibition (IC50) 
of sulfadiazine compared to sulfamethazine. Another difference was found in the 
LOD for sulfadiazine (16.9 ng g−1 for pork tissue) whilst in chicken serum this LOD 
was calculated as 62 ng ml−1. The difference in sample material (serum versus 
muscle) might cause such differences.  
 
Table 1. Average maximum responses obtained in the three assays with blank chicken serum 
samples (n=20) and the calculated limits of detection (LODs) using five different calibration 
curves in chicken serum (sulfamethazine (SMZ), sulfadiazine (SDZ), sulfamethoxazole (SMX), 
sulfaquinoxaline (SQX) and sulfachloropyridazine (SCP)).  
LOD IN CHICKEN SERUM (ng ml-1) 
ASSAY 
BLANK SERUM  
AVERAGE 
MAX. 
RESPONSE (RU) 
(n=20) 
SMZ SDZ SMX SQX SCP 
21C7 1180 ± 100 7 11 79 >1000 10 
Qflex kit 727 ± 26 44 62 25 45 19 
M.3.4 847 ± 40 82 5 5 44 4 
 
The mutant-based assay was most and least sensitive towards sulfachloropyridazine 
and sulfamethazine (50% inh. at 12 and 450 ng ml−1, respectively).  
The 20 blank chicken sera, obtained from the untreated broilers in the animal 
experiment, were analyzed with the three assays and the average responses obtained 
(minus three times the standard deviation) were used to calculate the LODs using the 
five calibration curves of the registered sulfonamides (Table 1). The lowest LOD for 
sulfamethazine was found in the Mab 21C7-based assay, which had a good sensitivity 
for sulfadiazine and sulfachoropyridazine as well. However, the LOD for 
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sulfamethoxazole and sulfaquinoxaline was much higher. The mutant M.3.4-based 
assay was found to be the most sensitive towards most of the sulfonamides and of the 
three assays tested, this assay showed the lowest LOD for the two sulfonamides 
(sulfamethoxazole and sulfadiazine) most frequently applied for poultry in the 
Netherlands. The highest LOD was found for sulfamethazine (82 ng ml−1) and this 
was also observed in a lanthanide fluoroimmunoassay (LFIA) using the same mutant 
[25] in which an LOD in chicken serum of 25 ng ml−1 was obtained. In this LFIA a 
sample preparation, to remove the proteins from chicken serum, had to be applied 
whilst the Biacore sample preparation consisted of a dilution step only. 
The Qflex Kit Sulfonamides detected the five sulfonamides within the narrowest 
measurements range and this is an advantage for the screening of total sulfonamide 
residues in chicken serum in the Netherlands.  
Samples from the batch of blank serum were spiked with sulfamethoxazole or 
sulfadiazine at the 50 ng ml−1 level and these samples were measured on 2 days with 1 
week in between and six times each day. The concentrations were calculated using 
calibration standards of the two sulfonamides added to the blank chicken serum. The 
LODs of the Qflex kit for sulfadiazine and of the Mab 21C7-based assay for 
sulfamethoxazole were higher than this level and were not analyzed. With the 
sulfadiazine-spiked samples the average concentration found with the Mab 21C7-
based assay was 52.0 ± 2.4 ng ml−1 and in the mutant-based assay 55.0 ± 2.6 ng ml−1. 
With the sulfamethoxazole-spiked samples, the average concentration found with the 
Qflex kit was 50.2 ± 6.9 ng ml−1 and with the mutant-based assay 55.7 ± 2.8 ng ml−1. 
 
 
 
Figure 4. Concentrations of sulfadiazine (ng ml−1) found with the mutant- and the Mab 21C7- 
based assays after analyzing the incurred serum samples. 
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Incurred serum samples 
Incurred serum samples were obtained from an animal experiment in which broilers 
were treated with sulfadiazine. As found with the mutant-based assay, the sera taken 
during the treatment contained high concentrations of sulfadiazine (>2700 ng ml−1). 
The sera taken 3, 6 and 10 days after the treatment contained concentrations between 
15 and 110 ng ml−1 and these results were compared with those obtained with the Mab 
21C7-based assay (Fig. 4). Although the Mab-21C7 based assay detects metabolites 
of sulfadiazine and the mutant M.3.4-based assay does not (Fig. 2), comparable 
concentrations were found with the two assays. This suggests a low (not detectable) 
concentration of sulfadiazine metabolites present in chicken serum. The depletion of 
another sulfonamide (sulfamethazine) in hens was studied [26] and the concentration 
of N4-acetyl-sulfamethazine in plasma was 6–8% only of the parent drug 
concentration. 
 
 
CONCLUSIONS 
 
For the application of the three multi-sulfonamide assays, three different small 
molecules were directly immobilized onto the sensor surface of a CM5 chip and this 
resulted in stable surfaces suitable for hundreds of cycles. The three assays were all 
found to be suitable for the multi-sulfonamide detection in chicken serum however, 
with different sensitivities within each assay for different sulfonamides. The mutant 
M.3.4 is a single chain variable fragment (scFv) consisting of the variable domains of 
the heavy and light chains of an antibody bound by a linker domain. The scFv has a 
molecular weight of 26-27 kDa and it is more than five times smaller than the IgG 
molecule (Mw =150 kDa). The mutant performed very well (high association and low 
dissociation) in the inhibition biosensor assay and was found to be the most sensitive 
towards most of the sulfonamides. The Qflex Kit Sulfonamides detected the five 
sulfonamides registered for application in poultry within the narrowest measurements 
range which is preferential for the multi-sulfonamide screening. Based on the 
comparison of results obtained with the incurred serum samples using the assay 
recognizing N4-acetyl metabolites (Mab 21C7) and the mutant M.3.4 assay (not 
sensitive towards these metabolites) it was concluded that only low concentrations of 
this metabolite for sulfadiazine occurred in chicken serum. Future experiments will be 
focused on the relation between concentrations of sulfonamides in chicken serum and 
tissue to establish predictive values for the application in control systems. 
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ABSTRACT 
 
A multi-sulfonamide biosensor immunoassay (BIA), based on a previously developed 
mutant antibody (A.3.5) in an optical biosensor (Biacore 3000), was applied to 
analyze serum and plasma samples obtained from the broilers treated with 
sulfamethoxazole and sulfadiazine. The assay was fast (5 min per sample), the sample 
preparation was easy (dilution in antibody-containing buffer only) and an equal 
sensitivity for the two sulfonamides was obtained with limits of detection in serum 
and plasma below 10 ng ml-1. The concentrations found with the BIA in serum and 
plasma of the treated broilers were comparable and higher than the concentrations 
found in tissue by LC-MS/MS. The average serum/tissue ratio’s for sulfamethoxazole 
were 6.2 (leg meat), 2.5 (liver) and 1.3 (skin+fat) and for sulfadiazine 8.7 (leg meat), 
3.1 (liver) and 2.2 (skin+fat). To predict the concentrations of the two sulfonamides 
below the maximum residue limit (MRL) of 100 ng g-1 in the tissue with the highest 
level (skin+fat), the proposed action level of the multi-sulfonamide BIA in serum is 
130 ng ml-1.  
A later developed mutant antibody (M.3.4), with a better sensitivity towards more 
sulfonamides, was applied during a survey. Serum samples (n=300) of broilers from 
30 different flocks were found negative. Concentrations between <5 and 152 ng ml-1 
(sulfamethoxazole equivalents) were found in serum samples of one flock (n=160) 
with an average of 25 ± 21 ng ml-1. The sulfonamide identified by LC-MS/MS in 
these samples was sulfamethoxazole. 
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INTRODUCTION 
 
One of the aims of the Dutch research project “Development of monitoring and 
surveillance systems in the poultry meat chain” is to evaluate the on-line detection of 
sulfonamide residues in slaughterhouses. In the Netherlands, at least nine different 
sulfonamides are approved for veterinary application. For the medication of poultry, 
five sulfonamides (sulfamethoxazole, sulfadiazine, sulfamethazine, sulfachloro-
pyridazine and sulfaquinoxaline) are approved of which the first two are most 
frequently applied. Unauthorized use of these drugs in animal breeding can lead to 
unwanted residues in food. To ascertain safe limits for human consumption, the 
European Union established a maximum residue limit (MRL) of 100 µg kg-1 for the 
total amount of sulfonamides in edible tissue [1]. 
For the detection of sulfonamides in slaughterhouses, body fluids (bile, urine and 
blood serum) can be employed as markers for residue presence in tissue [2-5]. These 
body fluids can normally be analyzed directly without extraction. Currently, the most 
rapid technology for performing an analysis is based on a commercially available 
surface plasmon resonance (SPR) biosensor (BiacoreTM). Applications were described 
for the determination of sulfamethazine residues in milk [6,7], the detection of 
sulfamethazine and sulfadiazine in pig bile [4,5] and for the multi-sulfonamide 
detection in chicken serum [8-10]. A monoclonal antibody 21C7 (Mab 21C7) raised 
against sulfamethazine [11] was identified as an antibody suitable for the biosensor 
detection of eight sulfonamides in chicken serum with LODs between 7 and 20  ng 
ml-1 [8]. However, the sensitivity of this assay for the detection of important 
sulfonamides, such as sulfamethoxazole and sulfaquinoxaline was not good enough. 
A mutant antibody (A.3.5) was selected after protein engineering [13] of a broad 
specificity sulfonamide-binding Mab (27G3) [12]. In a competitive time-resolved 
fluoroimmunoassay this mutant showed an improved sensitivity towards several 
sulfonamides compared with the wild-type Mab [13]. However, the sensitivity 
towards important sulfonamides such as sulfamethazine, sulfadimethoxine and 
sulfaquinoxaline was low. In order to improve the properties of the antibodies, 
mutants from the previous study were recombined and more mutations introduced 
[14]. In the time-resolved fluoroimmunoassay, the selected mutant from this study 
(M.3.4) showed an improved sensitivity for all 13 sulfonamides tested and even 
sulfamethazine, sulfadimethoxine and sulfaquinoxaline could be measured below the 
100 ng ml-1 level. This fluoroimmunoassay was successfully applied for the detection 
of sulfonamides in meat, milk and serum samples [15]. 
In an optical biosensor, the performances of the mutants (A.3.5 and M.3.4) were 
compared with the wild-type Mab with chicken serum as sample material [10];  
improved sensitivities for the mutants-based assays were observed for all 
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sulfonamides, and mutant M.3.4 was found to be the most sensitive towards the 17 
sulfonamides tested.  
In another study [9], the performance of the best mutant M.3.4 was compared with the 
multi-sulfonamide Mab 21C7 and with a recently launched multi-sulfonamide kit 
(Qflex®  Kit Sulfonamides) of Biacore (Uppsala, Sweden) [16]. The mutant M.3.4- 
based BIA was also selected as most sensitive towards most of the sulfonamides 
added to the chicken serum, and minor reactions with the N4-acetyl-metabolites were 
observed.  
The aims of the present study were (1) to evaluate the performance of the 
multi-sulfonamide mutant A.3.5-based BIA for the detection of sulfadiazine and 
sulfamethoxazole (most applied sulfonamides in the Netherlands) in the incurred 
samples (serum and plasma samples obtained from broilers treated with these 
sulfonamides (animal experiment performed in February 2003)), and to determine the 
concentrations of these sulfonamides in serum and plasma samples after different 
withdrawal times; (2) to determine the predictive levels of the biosensor assay in the 
serum for the levels of the two sulfonamides in edible tissue, by comparing the 
concentrations found in the serum with the concentrations detected by LC-MS/MS in 
edible tissue (leg meat, liver and skin plus fat); and (3) to evaluate the performance of 
a later developed and more sensitive mutant M.3.4-based BIA in a multi-channel 
combined assay for the detection of sulfonamides (one flow-channel) and three anti-
salmonella serotypes (three flow-channels), in which the sulfonamide assay 
conditions were adapted to the serological assay conditions, and to apply this assay 
during a survey (performed in 2004) in which serum samples from 31 different Dutch 
broiler farms were analyzed for the possible presence of sulfonamides. 
 
 
EXPERIMENTAL 
 
Materials 
The preparation of the sulfonamide derivative (N1[4-(carboxymethyl)-2-thiazolyl] 
sulfanilamide (TS)) was described previously [12]. Sulfamethoxazole, sulfadiazine 
and guanidine hydrochloride were obtained from Sigma-Aldrich Chemie BV 
(Zwijndrecht, the Netherlands). HBS-EP buffer (composition: 0.01 M HEPES pH 7.4, 
0.15 M NaCl, 3 mM EDTA and 0.005% Surfactant P20), CM5 sensor chips, the amine 
coupling kit (containing 0.1 M N-hydroxysuccinimide (NHS), 0.4 M N-ethyl-N'-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 1 M ethanolamine 
hydrochloride-NaOH (pH 8.5)) and 10 mM glycine-HCl buffer (pH 1.5) were 
supplied by Biacore AB (Uppsala, Sweden). The CM-dextran sodium salt was 
obtained from Fluka Chemie (Zwijndrecht, the Netherlands). Tween 20, Tween 80, 3-
[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS) and Triton X-
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100 were obtained from VWR International (Amsterdam, the Netherlands). 
Stomacher bags (BA6041) were obtained from Salm en Kipp b.v. (Breukelen, the 
Netherlands). The developments of the mutant antibodies A.3.5 and M.3.4 were 
described before [13,14].  
 
Equipment 
The Biacore 3000 biosensor was purchased from Biacore Benelux (Breda, the 
Netherlands) and the microtiter plate Varishaker-Incubator was obtained from 
Dynatech (Guernsey, UK). The Sigma-302k centrifuge and the Stomacher®400 were 
supplied by Salm en Kipp bv (Breukelen, the Netherlands).  
 
Biosensor immunoassays (BIAs) 
The coupling of the sulfonamide derivative TS to the CM5 sensor chip surface was 
described before [9]. 
 
Solutions applied in the BIAs 
Sample buffer I (used in the mutant A.3.5-based BIA) consisted of 20 mM sodium 
phosphate buffer containing 0.15 M sodium chloride and 0.3 g l-1 of CM-dextran 
sodium salt. Sample buffer II (used in the mutant M.3.4-based BIA) consisted of 
HBS-EP to which 5 g l-1 CM-dextran sodium salt, 0.3 M sodium chloride and 0.05% 
Tween 80 were added. Regeneration solution I (used in the mutant A.3.5-based BIA) 
was 0.1 M HCl. Regeneration solution II (used in the mutant M.3.4-based BIA) was 
prepared by mixing 10 ml of 18 M guanidine hydrochloride in detergent solution 
(0.3% of Tween 20, Tween 80, Triton X-100 and CHAPS) with 30 ml 10 mM 
glycine-HCl buffer (pH 1.5).   
 
Mutant A.3.5-based BIA for the analyses of serum and plasma samples. 
Prior to the analysis of the thawed chicken serum and plasma samples from the animal 
experiment, a 4 min centrifugation at 500 x g was applied. Of the supernatant, 20 µl 
was pipetted into a well of a microtiter plate. Mutant A.3.5 (approximately 0.6  mg  
ml-1) was diluted in sample buffer I (2000 times) and 100 µl of it was added to the 
well. After mixing for 2 min, 50 µl was injected at a flow rate of 20 µl min-1 with 
HBS-EP as the running buffer, and the response obtained 10 s prior to the injection of 
regeneration solution I (10 µl) was used for the calculations.  
For the calculation of concentrations of sulfamethoxazole and sulfadiazine in the 
serum and plasma, calibration graphs of the two sulfonamides were prepared in blank 
chicken serum and plasma using the following procedure. The sulfonamides were 
dissolved in methanol (1 mg ml-1) and stored at -20 ºC until used. Of each 
sulfonamide solution, a first intermediate standard solution with a concentration of 
270 µg ml-1 was prepared in HBS-EP buffer. The first intermediate standard solutions 
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(27 µg ml-1 sample) in mixed chicken serum or plasma samples (mixtures of materials 
coming from 20 blank broilers) were prepared by mixing 450 µl of the sample with 50 
µl of the standard solution with a concentration of 270 µg ml-1. Second intermediate 
standard solutions (2.7 µg ml-1) were prepared by a 10 times dilution in blank serum 
or plasma. From these intermediate standard solutions, calibrant solutions in the 
serum or plasma (270, 90, 30 and 10 ng ml-1 in serum or plasma) were prepared by 
dilution with the blank serum or plasma. The concentrations of the sulfonamides in 
the samples were directly calculated from the calibration curves (dilution factor =1). 
 
Mutant M.3.4-based BIA for the analyses of serum samples (surveillance). 
During the surveillance, a combined assay for the detection of sulfonamides (one 
flow-channel) and three anti-salmonella serotypes (three flow-channels) was applied 
in the four flow-channel biosensor and the biosensor conditions for the detection of 
sulfonamides (sample dilution, sample buffer, running buffer and regeneration 
conditions) were adapted to the serological assay conditions. 
Of the serum samples, 40 µl portions were pipetted into the wells of a microtiter plate 
and 60 µl of sample buffer II were added. The mutant (0.82 mg ml-1) was diluted in 
sample buffer II (450 times) and, in the Biacore, 50 µl of the diluted sample was 
added to 50 µl of diluted mutant. After mixing in the Biacore, 40 µl was injected at a 
flow rate of 20 µl min-1 with HBS-EP + 0.05% Tween 80 as running buffer, which 
was followed by the injection (10 s at 100 µl/min) of regeneration solution II. The 
response obtained 10 s prior to the injection of regeneration solution was used for the 
calculations. For the calculation of the concentrations of sulfamethoxazole and 
sulfadiazine in serum samples, calibration graphs of the two sulfonamides were 
prepared. Hereto, 40 µl portions of blank serum were pipetted into microtiter plate 
wells and 40 µl of standard solutions in sample buffer II (250; 125; 62.5; 25; 12.5; 4.3 
and 1.25 ng ml-1) and 20 µl of sample buffer II were added. In the Biacore, 50 µl of 
the diluted sample was mixed with 50 µl of the diluted mutant in sample buffer II, and 
the standards were analyzed as described above. The concentrations of the 
sulfonamides in the samples were directly calculated from the calibration curves 
(dilution factor =1).  
 
Sample materials 
 
Animal experiments 
The animal experiment with 4-weeks-old broilers was performed at the facilities of 
the Animal Sciences Group of Wageningen UR (ASG, Lelystad, the Netherlands) and 
started on 18-02-2003.  
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One group of broilers (10 males and 10 females) was not treated with sulfonamides 
and served as controls. These broilers were slaughtered before administration of the 
sulfonamides to the other groups.  
Another group of broilers (15 males and 15 females) received an oral treatment for 4 
days with Methoxasol-T (20 mg trimethoprim and 100 mg sulfamethoxazole per ml; 
Eurovet Animal Health BV, Bladel, the Netherlands). The dose was 2 ml L-1 of 
drinking water. The average daily water consumption of each broiler was determined 
to be 200 ml, resulting in a dose of approximately 40 mg of sulfamethoxazole per kg 
body weight. During the treatment, groups of six broilers (3 males and 3 females) 
were slaughtered at day 2 and 4, respectively, and after the treatment groups of six 
broilers each were slaughtered at day 6, 8 and 10 (2, 4 and 6 days after treatment). 
The prescribed withdrawal time for Methoxasol-T in broilers is 6 days. 
The third group of broilers (15 males and 15 females) received for 4 days an oral 
treatment with Trimethosulfmix 50% (80 mg trimethoprim and 420 mg sulfadiazine 
sodium per g; Eurovet Animal Health BV, Bladel, the Netherlands). The dose was 
0.45 g L-1 of drinking water. The average water consumption was determined to be 
200 ml per broiler resulting in a dose of approximately 38 mg of sulfadiazine per kg 
body weight. During the treatment, groups of six broilers (3 males and 3 females) 
were slaughtered at day 2 and 4, respectively, and after the treatment, groups of six 
broilers each were slaughtered at day 7, 10 and 14 (3, 6 and 10 days after treatment). 
The prescribed withdrawal time for Trimethosulfmix 50% in broilers is 12 days. 
At slaughter, blood samples (approximately 10 ml) were taken from each individual 
broiler. Half of the blood was used to obtain serum samples after a 24 h clotting. 
Plasma samples were prepared from the other half by transfer into heparinized tubes 
followed by a 10 min centrifugation at approximately 1500 x g.  Furthermore, from 
each broiler, liver, 40-50 g portions of breast meat and leg meat and about 10 g of 
skin+fat were sampled. The samples were ground and stored at -20°C. 
 
Survey 
Serum samples from 31 different flocks (10 samples per flock) originating from 31 
different Dutch broiler farms were taken at a slaughterhouse and were supplied by 
ASG in 100-200 µl quantities. From one flock, in which the presence of sulfonamides 
was detected during the survey, serum samples from another 150 broilers, slaughtered 
at the same day as the previous 10 broilers, were obtained. 
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LC-MS/MS analyses. 
 
Tissue samples 
The ground tissue samples (10 g each) were extracted with dichloromethane (25 ml) 
in a Stomacher® bag for 2 min. After filtration (folded filter of Schleicher & Schuell 
(Grade 595½, 150 mm diameter)) of the dichloromethane, the extraction was repeated 
twice, the filtrates were combined in an erlenmeyer flask and 25 ml of petroleum ether 
was added. This mixture was passed through a Sep-Pak® silica cartridge (Waters no. 
51900) and the erlenmeyer flask was washed with 5 ml of dichloromethane which was 
passed through the cartridge as well. The cartridge was dried for 15 min under a mild 
stream of nitrogen gas, and the sulfonamides were eluted with phosphate buffer (pH 
10) of which the first 4 ml was collected. After mixing (Vortex), the pH was measured 
and, if necessary, adjusted to a value between 6.5 and 7 by means of phosphoric acid 
(0.5 M) or sodium hydroxide (0.1 M) solutions. After the addition of ethyl acetate (2 
ml), mixing (Vortex) for 20 s and centrifugation (1 min at 2000 rpm), the upper layer 
was transferred into a test tube. The ethyl acetate extraction was repeated twice and 
the combined ethyl acetate fraction was evaporated at 30 °C under a stream of 
nitrogen gas. The residue was dissolved in 0.4 ml of 10 mM ammonium acetate (pH 
3.5) and after the injection of 100 µl, an acetonitrile-10 mM ammonium acetate eluent 
was used with a 15 min linear gradient from 0-90 vol.% acetonitrile, starting 5 min 
after injection, with a flow-rate of 400 µl/min. The applied LC-MS/MS conditions 
were described previously [17]. The limit of detection for sulfadiazine and 
sulfamethoxazole in tissue samples was approximately 1 ng g-1. 
 
Serum samples 
Two different mixed serum samples obtained from one positive flock of the 
surveillance study were analyzed by LC-MS/MS to identify the sulfonamide applied 
by the farmer. A comparable sample preparation (ultrafiltration) as described for the 
detection of sulfonamides in milk [17] was applied. In short, the serum sample (50 µl) 
was mixed with water (950 µl), and 20 µl of an internal standard solution (d7-
sulfadimidine [10 ng ml-1]) was added. Blank serum samples were fortified with the 
internal standard and, for quantification, with the sulfonamides of interest in the range 
of 0 - 1000 ng ml-1. After mixing, the sample was allowed to stand for 30 min at room 
temperature to allow equilibration.  The mixture was centrifuged for 15 min at room 
temperature at 3500 x g, 0.5 ml of the supernatant was transferred to a Microcon 0.5 
ml ultrafilter (molecular weight cut-off (MWCO) of 30 kDa (Millipore, Bedford, MA, 
USA)), centrifuged at 5000 x g for 30 min at room temperature, and 100 µl of the 
ultrafiltrate was injected into the LC-MS/MS system. The applied LC-MS/MS 
procedure was described previously [17]. The limits of detection for most 
sulfonamides in serum were 5 ng ml-1. 
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RESULTS AND DISCUSSION 
 
BIA for sulfadiazine and sulfamethoxazole in serum and plasma. 
A previously developed Mab 27G3 raised against the generic structure of 
sulfonamides [12] was modified by protein engineering [13], and in the BIA, the 
selected mutant A.3.5 showed an improved sensitivity towards several sulfonamides 
[10]. The sensitivities for sulfamethoxazole and sulfadiazine were improved 10 and 
50 times, respectively, and a similar sensitivity was obtained for both sulfonamides in 
the mutant-based assay. Compared with these two sulfonamides, this multi-
sulfonamide BIA showed a comparable or better sensitivity with at least eight other 
sulfonamides [10]. The increased and similar sensitivity for sulfadiazine and 
sulfamethoxazole (the most frequently applied sulfonamides in broilers in the 
Netherlands) was interesting for the analyses of the serum and plasma samples 
obtained from the animal experiment. The sample preparation consisted of the 
dilution of the serum or plasma (20 µl) with 100 µl of mutant A.3.5 containing sample 
buffer only.  After mixing, 50 µl was injected at a flow rate of 20 µl min-1 followed by 
a regeneration step with 0.1 M HCl  (0.5 min). The total time of analysis, including 
washing steps in the Biacore, was 5 min. A typical sensorgram (responses versus time) 
of one cycle of analysis obtained with a blank broiler serum is shown in Figure 1.  
 
 
Figure 1. Sensorgram obtained in the Biacore 3000 after the injection of 50 µl of diluted 
broiler serum (20 µl serum diluted with 100 µl of mutant A.3.5.) followed by a 20 µl injection 
of 0.1 M hydrochloric acid for the regeneration: (1) start sample injection (at this moment the 
relative response is set to 0); (2) bulk response; (3) binding of the mutant; (4) stop sample 
injection; (5) response used for calculation; (6) start injection regeneration solution; and (7) 
stop injection regeneration solution. 
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The response obtained 10 sec prior to the injection of regeneration solution was used 
during the calculations. For quantitative analyses, calibration graphs of both 
sulfonamides (see Figure 2) were prepared in blank broiler serum and plasma 
(mixtures of the 20 blank samples obtained from the animal experiment) using four 
calibrants with concentrations of 10, 30, 90 and 270 ng ml-1 (expressed as ng of the 
sulfonamide per ml of broiler serum).  
 
 
 
 
Figure 2. Calibration graphs of sulfadiazine (A) and sulfamethoxazole (B) in broiler serum 
and plasma in the mutant A.3.5-based BIA. Rel. responses were obtained after the injection of 
50 µl of a mixture of sample and antibody-containing buffer (20:100; v/v).  
 
In this assay, the mutant solution (approximately 0.6 mg ml-1) was diluted 2000 times 
to obtain high average maximum relative responses of 1640 ± 30 RU in blank broiler 
serum (n=20) and 1750 ± 30 RU in blank plasma (n=20). Using these values and the 
calibration graphs as presented in Figure 2, the LOD of both sulfonamides in serum 
and plasma (determined as the concentration corresponding to the average maximum 
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responses minus three times the standard deviation) were less than the lowest 
calibration standards in serum and plasma (<10 ng ml-1). 
As shown in Figure 2, the calibration graphs for both sulfonamides in serum showed a 
similar sensitivity (50 % inhibition at 50 ng ml-1). The sensitivities for sulfadiazine 
and sulfamethoxazole in plasma were somewhat less (50% inhibitions at 60 and 70 ng 
ml-1 for sulfadiazine and sulfamethoxazole, respectively).   
 
Concentrations in the sera and plasma samples from the animal experiment. 
The relative responses and calculated concentrations (using the calibration graphs of 
both sulfonamides in serum and plasma) obtained in the BIA with the sera and plasma 
samples from the animal experiments are presented in Table 1 (sulfamethoxazole) and 
Table 2 (sulfadiazine). Compared with the average relative responses obtained with 
the blank sera and plasma samples (20 each; day 0 of the experiment), all samples 
taken during treatment (days 2 and 4 of the animal experiment) and after treatment 
(days 6 to 14 of the experiments) showed lower responses due to the presence of the 
sulfonamides (inhibition of antibody binding).  
 
Table 1: Average relative response units (RU) and calculated concentrations (ng ml-1) 
obtained with the mutant A.3.5-based BIA in serum and plasma samples obtained from 
broilers treated with Methoxasol-T (sulfamethoxazole). 
Average Rel.  
Response (RU) 
Average concentration 
(ng ml-1) 
Day 
of 
exp. 
Day after 
treatment 
Number 
of 
broilers 
Serum Plasma Serum Plasma 
0  20 1640±30 1750±30 <10 <10 
2  6 100±80 80±70 >2700 a >2700 a 
4  6 80±40 70±60 >2700 a >2700 a 
6 2 6 620±300 710±340 97±54 115±62 
8 4 6 940±340 1120±370 48±39 56±47 
10 6 6 1050±320 1200±330 36±27 44±33 
aAnalysed after an extra 10 times sample dilution 
 
During the treatment at daily doses of 40 mg kg-1 bw (days 2 and 4), low responses 
were obtained due to the presence of high concentrations of the sulfonamides. Even 
after an extra 10 times dilution of these samples, the concentrations in serum and 
plasma were out of range in the calibration graphs (>2.7 µg ml-1).  This level is in 
accordance with Furusawa and Kishida [18] who fed laying hens for a longer period 
(7 days) with sulfadiazine and sulfamethoxazole at lower daily doses of 5.2 mg per kg 
bw and at the seventh day of the treatment, the average concentrations found in the 
plasma were 1.72 and 1.86 µg ml-1, respectively.  
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With the samples obtained from the broilers slaughtered after the treatments (2-10  
days after treatments) responses were obtained which fitted in the calibration graphs.  
Among the six broilers slaughtered at each day of the experiments, a high variation in 
concentration was observed which was due to the varying concentrations in the 
individual broilers and not due to the variation of the method of analysis (CVs < 5%).  
Good correlations between the concentrations in serum and plasma were found for 
both sulfonamides (R2= 0.996 and 0.993 for sulfamethoxazole and sulfadiazine, 
respectively), which means that both sample materials can be applied for screening. 
The prescribed Dutch withdrawal time for Methoxasol-T in broilers is 6 days, 
however, even after a 2 days withdrawal, the average concentration of 
sulfamethoxazole in serum and plasma (Table 1) decreased from >2700 ng ml-1 
(during treatment) to a level of approximately 100 ng ml-1. 
 
Table 2: Average relative response units (RU) and calculated concentrations (ng ml-1) 
obtained with the mutant A.3.5-based BIA in serum and plasma samples obtained 
from broilers treated with Trimethosulfmix (sulfadiazine). 
Average Rel. 
Response (RU) 
Average concentration 
(ng ml-1) 
Day 
of 
exp. 
Day after 
treatment 
Number 
of 
broilers 
Serum Plasma Serum Plasma 
0  20 1640±30 1750±30 <10 <10 
2  6 70±10 50±20 >2700a >2700 a 
4  6 50±10 40±10 >2700 a >2700 a 
7 3 6 690±170 890±250 75±29 75±32 
10 6 6 1020±360 1230±380 43±45 41±46 
14 10 6 850±250 1030±260 56±33 53±31 
aAnalysed after an extra 10 times sample dilution 
 
After a withdrawal time of 6 days, none of the serum and plasma samples contained 
concentrations higher than 100 ng ml-1. The prescribed Dutch withdrawal time for 
Trimethosulfmix in broilers is 12 days but after 3 days withdrawal period, the average 
concentration of sulfadiazine in serum and plasma (Table 2) had decreased from 
>2700 ng ml-1 (during treatment) to average levels of 75 ng ml-1.  
After a 10 days withdrawal period, the highest concentrations in serum and plasma 
(119 and 110 ng ml-1, respectively) were found in one of the broilers while the others 
contained concentrations < 100 ng ml-1.  The rapid elimination of sulfadiazine from 
plasma of orally treated broiler chickens (a mean half-life of 3.7 h) was previously 
described [19].  The elimination of sulfamethoxazole in plasma of pigs (after an oral 
single dose administration) was even more rapid (half-life of 2.5 h [20]).   
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Neither the concentrations of sulfamethoxazole nor those of sulfadiazine in the plasma 
and serum showed a significant decline during the (later stage of the) withdrawal 
period (from days 4 and 6 after the treatment, respectively (see Tables 1 and 2)). 
 
Concentrations in tissue as determined by LC-MS/MS. 
The MRL for the total amount of sulfonamides (parent compounds only) is 100 µg  
kg-1 in edible tissue. To establish a predictive level in broiler serum, the correlation 
with the parent compounds in the edible tissue had to be determined.  
 
Table 3: Concentrations of sulfamethoxazole in serum samples (ng ml-1, as determined with 
the BIA) and in tissue samples (ng g-1, as determined with LC-MS/MS) obtained 2, 4 and 6 
days after the treatment of broilers (n=18) with Methoxasol-T (sulfamethoxazole). 
LC-MS/MS 
Leg meat Liver Skin+fat 
Chicken  
no. 
Day after 
treatment 
BIA 
Serum 
ng ml-1 
ng  g-1 S/Ta ng  g-1 S/Ta ng  g-1 S/Ta 
6428 2 147 30 4.9 75 2.0 121 1.2 
6429 2 142 42 3.4 54 2.6 91 1.6 
6430 2 49 8 6.1 24 2.0 45 1.1 
6453 2 146 23 6.3 54 2.7 90 1.6 
6454 2 29 5 5.8 20 1.5 26 1.1 
6455 2 68 12 5.7 41 1.7 29 2.3 
Average  97±54 20±14 5.4±1.1 45±21 2.1±0.5 67±39 1.5±0.5
6431 4 17 3 5.7 8 2.1 37 0.5 
6432 4 116 19 6.1 45 2.6 56 2.1 
6433 4 70 8 8.8 28 2.5 43 1.6 
6456 4 18 2 9.0 8 2.2 12 1.5 
6457 4 28 6 4.7 14 2.0 42 0.7 
6458 4 41 6 6.8 15 2.7 37 1.1 
Average  48±39 7.3±6.1 6.8±1.7 20±14 2.4±0.3 38±14 1.2±0.6
6434 6 32 6 5.3 14 2.3 29 1.1 
6435 6 21 4 5.2 8 2.6 48 0.4 
6436 6 86 12 7.2 28 3.1 41 2.1 
6459 6 5 1 5.0 3 1.7 7 0.7 
6460 6 40 5 8.0 13 3.1 25 1.6 
6461 6 33 4 8.2 7 4.7 38 0.9 
Average  36±27 5.3±3.7 6.5±1.5 12±9 2.9±1.0 31±15 1.1±0.6
Overall average 60±47 11±11 6.2±1.5 25±20 2.5±0.7 45±29 1.3±0.6
a Serum/Tissue ratio 
 
Therefore, tissue samples (leg meat, liver and skin+fat) from the broilers with 
quantified concentrations of the sulfonamides in serum (originating from the 36 
broilers slaughtered 2 to 10 days after the treatment with the two sulfonamides) were 
analyzed by LC-MS/MS.  
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In the samples from the sulfamethoxazole experiment (18 broilers, see Table 3), the 
overall average concentration found by the BIA in serum during the withdrawal was 
60 ± 47 ng ml-1. The overall average concentrations of sulfamethoxazole found by 
LC-MS/MS in leg meat, liver and skin+fat were 11 ± 11, 25 ± 20 and 45 ± 29 ng g-1, 
respectively. All the tissue samples, except for one sample of skin+fat (2 days after 
the treatment), had concentrations less than the MRL of 100 ng g-1.   
 
Table 4: Concentrations of sulfadiazine in serum samples (ng ml-1, as determined with the 
BIA) and in tissue samples (ng g-1, as determined with LC-MS/MS) obtained 3, 6 and 10 days 
after the treatment of  broilers (n=18) with Trimethosulfmix (sulfadiazine). 
LC-MS/MS 
Leg meat Liver Skin+fat 
Chicken  
no. 
Day after 
treatment 
BIA 
Serum 
ng ml-1 
ng  g-1 S/Ta ng  g-1 S/Ta ng  g-1 S/Ta 
6478 3 57 7 8.1 21 2.7 36 1.6 
6479 3 114 13 8.8 31 3.7 37 3.1 
6480 3 105 8 13.1 26 4.0 32 3.3 
6503 3 47 4 11.8 17 2.8 52 0.9 
6504 3 74 9 8.2 23 3.2 43 1.7 
6505 3 50 4 12.5 16 3.1 39 1.3 
Average  75±29 7.5±3.4 10±2.3 22±6 3.3±0.5 40±7 2.0±1.0
6481 6 18 2 9.0 8 2.2 15 1.2 
6482 6 39 2 19.5 9 4.3 15 2.6 
6483 6 133 23 5.8 46 2.9 50 2.7 
6506 6 28 5 5.6 10 2.8 21 1.3 
6507 6 33 4 8.2 14 2.4 16 2.1 
6508 6 8 2 4.0 6 1.3 17 0.5 
Average  43±45 6.3±8.3 8.7±5.6 16±15 2.7±1.0 22±14 1.7±0.9
6484 10 44 4 11.0 11 4.0 14 3.1 
6485 10 63 12 5.2 18 3.5 16 3.9 
6486 10 119 18 6.6 34 3.5 41 2.9 
6509 10 41 7 5.9 13 3.2 12 3.4 
6510 10 40 6 6.7 13 3.1 20 2.0 
6511 10 29 5 5.8 13 2.2 15 1.9 
Average  56±33 8.7±5.4 6.9±2.1 17±9 3.2±0.6 20±11 2.9±0.8
Overall average 58±37 7.4±5.8 8.7±3.8 18±10 3.1±0.7 27±14 2.2±1.0
a Serum/Tissue ratio 
 
For leg meat and liver, all corresponding serum samples had higher concentrations of 
sulfamethoxazole and in the case of skin+fat, five samples had higher concentrations 
of sulfamethoxazole compared with the serum samples. For the sulfamethoxazole- 
containing samples, the differences between the daily average serum/tissue ratios 
were small with overall averages of 6.2 (leg meat), 2.5 (liver) and 1.3 (skin+fat). In 
the samples from the sulfadiazine experiment (18 broilers, see Table 4), the overall 
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average concentration found by the BIA in serum during the withdrawal was 58 ± 37 
ng ml-1. The overall average concentrations of sulfadiazine found by LC-MS/MS in 
leg meat, liver and skin+fat were 7 ± 6, 18 ± 10 and 27 ± 14 ng g-1, respectively. All 
tissue samples had concentrations below the MRL of 100 ng g-1 and, except for two 
skin+fat samples, all concentrations of sulfadiazine in serum were higher than the 
concentrations in the corresponding tissue samples.  
For the sulfadiazine containing samples, the differences between the daily average 
serum/tissue ratios were small with overall averages of 8.7 (leg meat), 3.1 (liver) and 
2.2 (skin+fat). 
Plotting the individual concentrations of sulfamethoxazole and sulfadiazine in serum 
found with the BIA (X) versus the tissue concentrations found with LC-MS/MS (Y) 
resulted in correlation data as presented in Table 5. The highest correlations were 
obtained between the serum and the liver samples and the lowest between the serum 
and skin+fat samples. 
 
Table 5: Correlation data (Y = aX +b) obtained by plotting the concentrations found in 
broiler serum (n = 108) with the BIA (X) against the concentrations found in tissue with LC-
MS/MS (Y) using the samples obtained from the broilers after the treatment with 
sulfamethoxazole and sulfadiazine (n = 18 for each tissue and sulfonamide). 
Sulfonamide Tissue a b R2 
Sulfamethoxazole Leg meat 0.2140 -1.98 0.8538 
Sulfamethoxazole Liver 0.4099 +0.69 0.9113 
Sulfamethoxazole Skin+Fat 0.5278 +13.52 0.7594 
Sulfadiazine Leg meat 0.1400 -0.68 0.7887 
Sulfadiazine Liver 0.2714 +2.57 0.9152 
Sulfadiazine Skin+Fat 0.2523 +12.72 0.4560 
 
We were surprised that during the total withdrawal periods, the concentrations of both 
sulfonamides found in serum samples were higher than the concentrations in tissue. 
However, Furusawa and Kishida [18] also found higher concentrations of 
sulfonamides in plasma compared to the levels in tissue. During the treatment of 
laying hens with sulfamethoxazole and sulfadiazine, the ratio (%) of the sulfonamides 
in the tissue to that in the plasma were reported as 40 % (liver) and 28 % (muscle) for 
sulfamethoxazole and 20% (liver) and 15% (muscle) for sulfadiazine. In an 
experiment with calves treated with sulfadiazine [21], the concentrations in kidney, 
liver and muscle, determined 1, 3 and 7 days after the last dose, respectively, were 
also generally lower than the corresponding plasma concentrations, although the 
tissue-to-plasma concentration ratio increased for each tissue over the 7 days period. 
This increase was not observed in our study. 
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Survey in chicken sera. 
Broiler sera (n=310) were obtained from 31 different flocks of 31 different Dutch 
farms (10 sera from each farm). These samples were analyzed with the mutant M.3.4-
based BIA which proved to be more sensitive towards different sulfonamides 
compared with mutant A.3.5 [10]. The 50% inhibition values for sulfamethoxazole 
and sulfadiazine in serum were 20 ng ml-1 and this is 2.5 times more sensitive 
compared with the mutant A.3.5-based BIA. Although a two times higher amount of 
mutant was injected, the average maximum response obtained with blank sera (approx. 
750 RU) was lower compared with the A.3.5-based BIA (1640 RU). This is caused by 
the relative high amounts of NaCl (0.3 M versus 0.15 M in the A.3.5-based BIA) and 
CM-dextran (0.5% versus 0.03% in the A.3.5-based BIA) in the sample buffer of the 
mutant M.3.4-based BIA (adapted to the serological assay conditions).  
The samples (n=300) from 30 farms were found negative (<5 ng ml-1 
(sulfamethoxazole equivalents)) and the 10 serum samples obtained from one farm 
contained levels varying from 10 to 72 ng ml-1 with an average of 26 ± 20 ng ml-1 
(sulfamethoxazole equivalents). Another 150 serum samples, taken from that flock at 
the same time, were analysed and measured concentrations ranged from <5 to 152 ng 
ml-1 with an average of 25 ± 21 ng ml-1 (sulfamethoxazole equivalents). Of these 
samples, 4 were found negative (<5 ng ml-1) and in 3 samples the concentrations were 
>100 ng ml-1.  
Two different combined serum samples from that flock were prepared (each by 
mixing approximately 50 µl portions of 13 different serum samples with a relative 
high concentration (sulfamethoxazole equivalents)). In the BIA, the concentrations 
found in these combined samples were 26 ± 0.7 and 42 ± 4 ng ml-1 (sulfamethoxazole 
equivalents). The samples were also analysed by LC-MS/MS according to a 
previously described and fully validated procedure for the analysis of milk samples 
[17] and sulfamethoxazole was identified and quantified (33 and 49 ng ml-1).  
 
 
CONCLUSIONS 
 
The mutant antibody-based multi-sulfonamide BIAs proved to be robust and fast (5 
min per sample) for the detection of sulfamethoxazole and sulfadiazine in serum and 
plasma of untreated and treated broilers. The sample preparation procedure was easy 
and consisted of a dilution of the sera and plasma samples with antibody containing 
buffer only. The assays showed equal sensitivities for the two sulfonamides in serum 
or plasma with LODs of <10 ng ml-1 (mutant A.3.5-based BIA) and <5 ng ml-1 
(mutant M.3.4-based BIA). The concentrations found with the BIA in serum and 
plasma of the treated broilers were comparable and generally higher than the 
concentrations found in tissue by LC-MS/MS, which made these body fluids suitable 
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for screening. The decline in sulfonamide residues at the beginning of the withdrawal 
was very rapid and variability in the residue levels between animals was quite large. 
The overall average serum/tissue ratios for sulfamethoxazole were 6.2 (leg meat), 2.5 
(liver) and 1.3 (skin+fat) and for sulfadiazine 8.7 (leg meat), 3.1 (liver) and 2.2 
(skin+fat). The proposed action level of the multi-sulfonamide BIA in serum, to 
predict concentrations of the two sulfonamides below the MRL of 100 ng g-1 in the 
tissue containing the highest level (skin+fat), is 130 ng ml-1. In the serum samples 
from the animal experiments, taken 2 to 10 days after the treatment, only 4 of the 36 
samples (11 %) contained concentrations higher than the proposed action level and of 
the corresponding edible tissues only one sample contained a level higher than the 
MRL (121 ng g-1 in skin+fat) while the concentrations in the others ranged between 
50 and 91 ng g-1.  
The mutant antibody (M.3.4), with the best sensitivity towards most sulfonamides, 
was applied in the BIA during a survey and in the 10 serum samples from one flock 
(out of 31 different flocks), concentrations between 10 and 72 ng ml-1 
(sulfamethoxazole equivalents and later identified by LC-MS/MS as 
sulfamethoxazole) were found.  A high variation in concentrations (<5 to 152 ng ml-1, 
with only one sample above the proposed action level) was observed after the 
analyses of another 150 serum samples of that flock sampled at the same time. High 
variations were also observed in the serum samples obtained on the same days in the 
animal experiments (Tables 3 and 4). Such a high variation in concentration is 
probably due to differences in water consumption and intestinal absorption of the 
sulfonamide by the broilers. This implies that control of broiler flocks on the possible 
presence of sulfonamides should always be based on sampling of at least 10 animals.  
Another point of concern with the multi-sulfonamide assays is the differences in 
sensitivity towards different sulfonamides. Although the assays showed an equal 
sensitivity towards sulfamethoxazole and sulfadiazine, the mutant M.3.4-based assay 
showed a higher sensitivity towards at least six other sulfonamides (including the for 
poultry approved sulfachloropyridazine) and a lower sensitivity towards two other 
approved sulfonamides (sulfaquinoxaline and sulfamethazine) [9]. Based on one 
action level in the serum, the application of such a multi-sulfonamide screening assay 
will result in a higher number of false-negative and -positive results and confirmation 
by LC-MS/MS is mandatory.  
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Chapter 7 
 
 
 
 
 
Direct versus competitive biosensor 
immunoassays for the detection of 
aminoglycoside residues in milk 
 
 
 
 
 
Composed from the following two publications: 
 
• A direct (non-competitive) immunoassay for gentamicin residues with an optical 
biosensor.  
Willem Haasnoot1 and Ron Verheijen1, published as short communication in Food 
and Agricultural Immunology (2001) 13, 131-134.  
 
• Direct versus competitive biosensor immunoassays for the detection of (dihydro)-
streptomycin residues in milk.  
Willem Haasnoot1, Elma E.M.G. Loomans2, Geert Cazemier1, Richard Dietrich3, 
Ron Verheijen1, Aldert A. Bergwerff4, Rainer W. Stephany4 in Food and 
Agricultural Immunology (2002) 14, 15-27. 
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AE  Wageningen, the Netherlands; 2Agrotechnological Research Institute (ATO), P.O. Box 
17, 6700 AA Wageningen, the Netherlands; 3Institute for Hygiene and Technology of Food 
of Animal Origin, Veterinary Faculty, University of Munich, Veterinärstrasse 13, 80539 
Munich, Germany; 4Utrecht University, Faculty of Veterinary Medicine, Department of 
the Science of Food of Animal Origin, P.O. Box 80.175, 3508 TD Utrecht, the Netherlands 
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ABSTRACT 
 
Using sensor chip (CM5) immobilized anti-gentamicin monoclonal antibodies (Mabs) 
in an optical biosensor (Biacore 3000) resulted in the first single antibody-based and 
label free non-competitive immunoassay for the direct detection of residues of a low 
molecular weight compound in a food product. Calibration curves for gentamicin 
(Mw. 466 Da) in buffer and milk showed 50% binding at 20 and 35 ng ml–1, 
respectively, which is well below the maximum residue limit of 100 ng ml–1. 
For the detection of streptomycin (STREP; mw. 581 Da) and dihydrostreptomycin 
(DHS; Mw. 583 Da), a Mab against DHS (4G8) was developed and its performance 
compared with a previously developed Mab against STREP (4E2). Direct biosensor 
immunoassays (BIAs) for the detection of DHS and STREP were developed and 
compared with competitive inhibition BIAs, using a STREP–protein conjugate 
immobilized on the chip. The sensitivities of the direct and competitive BIAs for both 
drugs in buffer were comparable (10–20 ng ml–1 at 50% binding or inhibition). With 
milk, interferences, probably due to the nonspecific binding of proteins to the sensor 
chips, were observed in both BIAs. These interferences could be largely reduced 
using ultra filtration (UF) as sample pre-treatment. Another option was the use of a 
reference flow channel to correct for nonspecific binding. Using this option with five 
times diluted milk, Mab 4G8 was found to be suited for the direct BIA of both drugs 
with a limit of detection (LOD) of 20 ng ml–1 and both Mabs could be applied in the 
competitive BIA format with similar LODs. 
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INTRODUCTION 
 
Gentamicin and the closely related compounds streptomycin (STREP) and 
dihydrostreptomycin (DHS) are antibiotics belonging to the group of aminoglycosides. 
They are used in veterinary medicine for treatment of Gram-negative infections. The 
use in lactating cows may lead to the presence of residues of these antibiotics in milk. 
With regard to consumer protection, the European Union (EU) has established 
maximum residue limits (MRL) of 100 μg kg–1 for gentamicin and 200 μg kg–1 for 
STREP and DHS in milk (EU regulation no. 1140/96).  
For the detection of aminoglycosides, three techniques are mainly applied: the 
microbial inhibition screening tests (IDF Bulletin, 1991; Nouws et al., 1991; Nouws 
et al., 1995), immunoassays or receptor assays (IDF Bulletin, 1991; Dietrich et al., 
1993; Schnappinger et al., 1993; Haasnoot et al., 1999; Verheijen et al., 2000) and 
HPLC (Essers, 1984; Gambardella et al., 1985; Albracht & de Wit, 1987; Gerhardt et 
al., 1994; Guggisberg & Koch, 1995a; Guggisberg & Koch, 1995b). HPLC might be 
the most suitable technique for the confirmation of positive screening results. For a 
large scale first screening, microbiological methods are preferred because of their 
convenience, low costs and broad-spectrum characteristics. However, with such 
methods it takes at least 6 h before the results are known (Nouws et al., 1995). More 
rapid methods for the detection of these antibiotics are microtiter plate ELISAs with 
results being available within 2 h (Haasnoot et al., 1999). However, such ELISAs are 
specific and normally performed in a laboratory. The fastest and easiest assay 
described so far is the one-step strip test in which the results can be obtained within 
10–15 min (Verheijen et al., 2000). This test was developed for on-site screening of 
raw milk samples for the presence of DHS and STREP on a farm. However, this test 
is qualitative only and not suitable for large scale screening.  
For a few years, rapid and automated surface plasmon resonance (SPR)-based 
biosensor immunoassays (BIAs) are described for the detection of sulfamethazine 
(Sternesjö et al., 1995), enrofloxacin and ciprofloxacin (Mellgren & Sternesjö, 1998) 
in bovine milk and for sulfamethazine and sulfadiazine residues in pig bile (Elliott et 
al., 1999; Crooks et al., 1998). The small size of these low molecular weight 
compounds (LMWC), with molecular weights (Mw) of 466 (gentamicin), 581 (DHS) 
and 583 Da (STREP), prevents a simultaneous exposure of more than one antibody 
binding site (epitope) or receptor binding site. Therefore, for the detection of these 
compounds, the competitive inhibition immunoassay format is mandatory and the 
LMWC were covalently immobilized to a carboxy-methylated dextran modified gold 
film. Polyclonal antibodies (Pabs) against the LMWC were added to the sample and 
the immobilized surface was used to determine the amount of free antibodies. The 
major advantage of SPR-based biosensor assays is the label free detection. Other 
described advantages are the lack of a sample preparation, their fully automated 
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operation, the short time of analysis (5–20 min) and the high specificity. The newest 
biosensor model, Biacore 3000 (Biacore AB, Uppsala, Sweden), was designed to 
measure LMWC directly. This was confirmed during an investigation of interactions 
between immobilized thrombin and its inhibitors in solution (Karlsson et al., 2000).  
The objective of the present study was to demonstrate that a direct immunoassay for 
LMWC could work at a level below the maximum residue limit (MRL) in a food 
product. The aminoglycosides gentamicin, DHS and STREP with Mw between 466 
and 583 Da) were chosen as the target analytes and milk as the model matrix. For the 
direct detection of gentamicin, a commercially available monoclonal antibody (Mab) 
was used. For the detection of DHS and STREP, a Mab against DHS was developed 
and its performance in the Biacore 3000 was compared with a Mab previously 
developed against STREP. With these Mabs, direct and competitive BIAs were 
developed and their performances with regard to the detection of DHS and STREP in 
buffer and milk were compared. The influence of several parameters (origin of 
antibodies, flow rate, coating concentration, sample volume and especially matrix 
effects from milk) on the performance of the assays are described. 
 
 
MATERIALS AND METHODS 
 
Instruments and Reagents 
The Biacore 3000 biosensor system, sensor chips (CM5), HBS-EP buffer and the 
Amine Coupling Kit (containing 0.1 M N-hydroxysuccinimide (NHS), 0.4 M N-ethyl- 
N’-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 1 M 
ethanolamine hydrochloride-NaOH (pH 8.5)) were supplied by Biacore AB (Uppsala, 
Sweden). A Sigma model 2K15 centrifuge was obtained from Salm and Kipp BV 
(Breukelen, the Netherlands). The FPLC system and HiTrap Protein G columns (1 ml) 
were supplied by Amersham Pharmacia Biotech AB (Uppsala, Sweden). Specol was 
obtained from the Institute for Animal Science and Health (ID-Lelystad, Lelystad, the 
Netherlands). Dulbecco modified Eagle’s medium (DMEM) was obtained from Bio 
Wittaker (Verviers, Belgium). Hybridocult and Hybridokine were purchased from 
Immuno Quality Products (Groningen, the Netherlands) and Fetal Clone I (FCI) came 
from HyClone (Logan, UT, USA). Hypoxanthine–thymidine (HT), aminopterine (A) 
and chlortetracycline were obtained from Life Technologies (Breda, the Netherlands). 
Gentamicin sulfate, neomycin sulfate, spectinomycin, tobramycin, kanamycin, 
amikacin, streptomycin sulfate (STREP) and dihydrostreptomycin sesquisulfate 
(DHS), succinic anhydride, N-hydroxysuccinimide (NHS), N-ethyl-N’-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC), ethanolamine 
hydrochloride, triethylamine, sodium sulfate, N,N-dimethylformamide (DMF), 
dichloromethane, ethyl acetate, 2-(N-morpholino)ethanesulfonic acid (MES), 
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tris(hydroxymethyl)aminomethane (Tris), glycin hydrochloride, L-glutamine, L-
glucose, sodium carbonate, glutaraldehyde, sodium borohydride, goat anti-mouse 
immunoglobulins-alkaline phosphatase (GAM-AP), keyhole limpet hemocyanin 
(KLH), bovine serum albumin (BSA), ovalbumin (OVA) and polyethyleneglycol 
(PEG; Hybri-Max) were purchased from Sigma-Aldrich Chemie BV (Zwijndrecht, 
the Netherlands). Mouse anti-gentamicin Mab (Clone 905.1; 0.5 ml with a 
concentration of 1.9 mg ml-1) was obtained from HybriDomus (Rhoon, the 
Netherlands) and affinity purified rabbit IgG (10 mg ml-1) from Lampire (Piersville, 
PA, USA). The BCA protein assay was supplied by Pierce (Rockford, IL, USA). Flat 
bottom microtiter ELISA (EIA/RIA high binding plates, 96 wells), tissue culture 
plates and culture flasks came from Costar (Schiphol-Rijk, the Netherlands). 
Ultrafree-0.5 centrifugal filter devices (Biomax-10, –30 and –100) were obtained 
from Millipore (Bedford, USA).  
 
Preparation of Immunogen and Coating Conjugates 
 
Activated carbodiimid coupling method (acc method)  
DHS was coupled to pre-activated KLH or BSA through the activated carbodiimid 
coupling method (acc method). Preactivation of the proteins was performed with 
succinic anhydride in order to introduce additional coupling sites and to reduce the 
chance of creating inter-protein cross-links. Subsequently, the conjugation reaction 
between the protein carboxyl groups and the aminogroups of DHS was performed 
using the water soluble carbodiimide reagent EDC.  
In order to produce NHS–succinate, necessary for the pre-activation of the proteins, 
NHS (5 g) and succinic anhydride (4.35 g) were dissolved in dichloromethane (30 ml). 
Triethylamine (7.2 ml) was added and the reaction mixture was stirred for 3 h at room 
temperature. Ethyl acetate (50 ml) was added and the mixture was transferred to a 
separator funnel. The organic phase was washed twice with 25 ml ice-cold 1 M HCl, 
dried over sodium sulfate and concentrated in a rotary evaporator. An amount of 1 g 
off-white solid was obtained that was used without further purification.  
The protein (2 mg in 1 ml PBS at pH 7) was transferred to an eppendorf vial. NHS–
succinate was dissolved in DMF (10 mg ml–1), and 60 μl was added to the protein 
solution. The reaction mixture was vortexed, left at room temperature for 45 min and 
another 60 μl of the NHS–succinate solution was added. The reaction mixture was 
vortexed, left for 45 min at room temperature, transferred to a Biomax concentrator 
(cut-off 30000 Da) and concentrated by centrifugation for 30 min at 3000 x g and at 
4°C. A volume of 1 ml 5 mM MES buffer at pH 5 was added to the retentate and the 
solution was centrifuged for 30 min at 3000 x g at 4°C. This step was repeated twice 
to ensure complete buffer exchange. The protein solution was taken up in 1 ml 5 mM 
MES buffer. A portion of 200 μl of 10 mg ml–1 DHS in 5 mM MES buffer was added 
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to the protein solution followed by 200 μl of a 10 mg ml–1 EDC solution in 5 mM 
MES buffer, which was prepared just before use. The reaction mixture was vortexed, 
kept at room temperature for 2 h, transferred to a Biomax concentrator and 
concentrated by centrifugation for 30 min at 3000 x g at 4°C. A volume of 1 ml of 
PBS at pH 7 was added and the solution was centrifuged again. This step was 
repeated twice to ensure complete buffer exchange. The protein solution was diluted 
with PBS to give a 1 mg ml–1 solution.  
 
Glutaraldehyde coupling method (GDA)  
The glutaraldehyde (GDA) coupling method was performed at two pH values (7.3 and 
8.5) because of observed differences in solubility at these pH values. KLH or BSA (2 
mg ml–1) was dissolved in a mixture of 0.1 M sodium carbonate and 0.15 M NaCl (pH 
7.3 or 8.5) and subsequently DHS was added to the protein carrier solution to obtain a 
concentration of 2 mg ml–1. After adding 1% (m/v; final concentration) freshly 
prepared glutaraldehyde, the reaction mixture was vortexed and kept for 3 h at 4 °C 
under gentle agitation. Sodium borohydride was then added to a final concentration of 
10 mg ml–1 and the solution was incubated for 1 h at 4°C. Finally, the conjugate was 
purified by gelfiltration or dialysis to remove excess reagents.  
 
STREP–OVAL conjugate  
The STREP–OVAL conjugate was prepared according to a similar procedure as 
previously described for the preparation of STREP–BSA (Verheijen et al., 2000).  
 
Immunization of Mice 
Two female Balb/cByHlco mice (99049/99050) of 9 weeks old were immunized  
(subcutaneously) with 75 μg KLH–DHS in 200 μl PBS/Specol (1:1; v/v). The 
immunogen consisted of a cocktail of three KLH–DHS conjugates prepared by three 
different coupling methods; glutaraldehyde pH 7.3 (GDA7.3), glutaraldehyde pH 8.5 
(GDA8.5) and the activated carbodiimid coupling (acc). One month before and 14 
days after immunization, blood was taken by orbital punction to determine the 
specific antibody titer in ELISA. Mice were boostered (subcutaneously) twice, at 
various intervals, with 25 μg conjugate in 200 μl PBS/Specol (1:1; v/v). One week 
after each booster, the serum was analyzed with regard to the presence of specific 
antibodies by indirect ELISA, using microtiter plates coated with BSA–DHS 
conjugates. Competitive ELISAs were used to assess the ability to recognize free 
DHS. 
 
Production of Mabs 
Four days after the final booster (intraveneously), the spleen of one mouse (99049) 
was used to produce Mabs by the hybridoma technology (Köhler & Milstein, 1975). 
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Spleen cells were fused with myeloma cells (NS-20, American Type Culture 
Collection, Rockville, USA) at a ratio 2:1, using PEG 1500 precipitation. Cells were 
suspended in HAT selection medium [culture medium (DMEM supplemented with 
8% FCI + 1% hybridocult + 1% tetracycline) + 1% HT (hypoxanthine/ thymidine) + 
1% A (aminopterin)] and plated in 96-well tissue culture plates at 150000 cells per 
well. After one week, the medium was changed to HT medium (culture medium + 1% 
HT) and seven days thereafter to normal culture medium. In this period, hybridoma 
culture supernatants were screened by ELISA for antibody activity on specific binding 
to the homologous coating conjugate (1–5 μg ml–1) and displacement capacity in the 
presence of the free hapten (1 μg per well). Positive cultures were further cloned by 
limiting dilutions (5, 1 and 0.2 cells per well) in ‘limiting dilution’ medium (DMEM + 
8% FCI + 2.5% Hybridokine). When positive again, larger quantities of Mabs were 
obtained by growth from larger-well plates to tissue culture flasks (up to 20 ml). 
Isotyping was performed using a multi-analyte one-step lateral flow assay in 
combination with anti-mouse isotype antibodies conjugated to carbon particles 
(developed at ATO).  
To culture supernatant (50 ml of Mab 4G8, see Results and Discussion), 50 ml of 
saturated ammonium sulfate were added slowly. After centrifugation, the supernatant 
was removed and the residue was dissolved in 1 ml of PBS and dialyzed against PBS. 
The dialyzed product was transferred to a protein G column and, after washing with 
PBS, the bound IgG was eluted with 2.5 ml of 0.1 M glycine. HCl (pH 2.5). The pH 
of the eluted fraction was immediately neutralized by the addition of 0.5 ml of 1 M 
Tris-HCl buffer (pH 9.5). The final volume was 3 ml with a protein concentration of 
0.53 mg ml–1 (as determined by the Pierce protein assay, according to the instructions 
of the manufacturer, with BSA as standard protein). 
 
Anti-STREP Mab  
The development of the Mab against STREP (4E2) was described before (Dietrich et 
al., 1993; Schnappinger et al., 1993). The antibody (IgG1) was affinity-purified from 
hybridoma culture supernatant on protein A Sepharose to a concentration of 0.52 mg 
ml–1 in PBS. The cross-reactivity with DHS was 86% (Dietrich et al., 1993). 
 
ELISAs 
Microtiter plates were coated (overnight at 4 °C or 1 h at 37 °C) with 100 μl of a 
BSA–DHS conjugate at different coating concentrations (maximum concentration of 
1 μg per well) in carbonate/ bicarbonate coating buffer (0.05 M; pH 9.6). The plates 
were washed three times with PBS-Tween (0.05% Tween 20; pH 7.2) and blocked 
(incubation of 2 h at 37 °C with 200 μl of BSA or casein (2% in PBS, pH 7.2). After 
washing, 100 μl serum or culture supernatants (different dilutions in dilution buffer 
(PBS + 0.1% BSA or casein)) were added to the wells and the plate was incubated for 
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1 h at 37°C. After washing, 100 μl GAM-AP (1:1000 in dilution buffer) was added to 
the wells and the plate was incubated for 1 h at 37°C. After washing, color was 
developed by adding 200 μl of the substrate solution (1 mg 4-nitrophenylphosphate 
disodium salt per ml of 0.05 M carbonate/bicarbonate buffer containing 100 ng 1–1 
MgCl2·H2O, pH 9.6). The optical density of each well was measured with a plate 
reader at 405 nm after various time intervals. 
For the competition with free DHS, 50 μl of the diluted antibodies were mixed with 
50 μl of a 20 μg ml–1 DHS solution in PBS. The plates were further treated as 
described above. 
 
BIAs 
Proteins (Mabs or STREP–OVAL) were immobilized on the sensor surface of a CM5 
sensor chip by using the amine coupling kit and the Surface Preparation Wizard, as 
present in the Biacore 3000 control software. The biosensor surface was activated by 
injection of 35 μl of a mixture of EDC and NHS (1:1; v/v) in one of the four flow 
channels (Fcs) at a flow rate of 5 μl min–1. Then the proteins, diluted in coupling 
buffer, were injected and attached via primary amine groups to the carboxy-
methylated dextran surface. After coupling, active groups were blocked with 1 M 
ethanolamine. 
 
Direct BIAs.  
The Mab-containing solutions were diluted to an end concentration of 0.1 mg ml–1 in 
coupling buffer (10 mM-sodium acetate, pH 4.5). In order to obtain measurable 
responses from binding gentamicin, DHS and or STREP, the amount of antibodies on 
the sensor surface should be as high as possible and a level of 15000 RU was aimed at 
in the Surface Preparation Wizard. Immobilized total rabbit IgG was used in the 
reference Fc (Fcl). Standard solutions of gentamicin, STREP or DHS were injected 
(20, 50 or 100 μl) at different flow rates (20 or 50 μl min–1) and antibody-bound 
gentamicin was regenerated by the injection of 5 μl of a 20 mM sodium hydroxide 
solution and bound STREP or DHS were regenerated by the injection of 5 μl 5 mM 
hydrochloric acid solution. The response measured 10 s prior to the start of the 
regeneration was used for calculations. 
Defatted milk samples were five-fold diluted in HBS-EP buffer and portions of 20 μl 
were injected at a flow rate of 20 μl min–1 (direct method A) or 0.5 ml diluted milk 
was pipetted into the centrifugal filter device (Biomax-10). After centrifugation for 30 
min at 12000 x g, volumes of 20 μl or 50 μl of the filtrate were injected at a flow rate 
of 20 μl min–1 (direct method B). The total run times between samples for the 20 and 
50 μl injections were 3 and 5 min, respectively. 
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Competitive BIAs.  
The STREP–OVAL conjugate-containing solution was diluted in coupling buffer (10 
mM sodium acetate, pH 5.0) to a final concentration of 25 μg ml–1. Different 
immobilization levels and reference Fcs were applied (see Results and Discussions). 
In the final method, STREP–OVAL was immobilized in Fc2 (1000 RU) and OVAL 
was immobilized in Fc1 (950 RU), which served as a reference Fc. A volume of 80 μl 
in HBS–EP buffer diluted antibodies was added to 20 μl defatted milk sample, mixed 
and 50 μl was injected at a flow rate of 20 μl min–1. The regeneration was performed 
with 10 μl 50 mM hydrochloric acid. The response measured 10 s prior to the start of 
the regeneration was used for calculations. The total run time was 5 min. 
 
Milk Samples 
A pasteurized skimmed milk powder was supplied by NIZO Food Research (Ede, The 
Netherlands). To reconstitute milk, 9 ml water was added to 1 g of powder. Blank 
milk samples (n = 17) from five different cows and taken at different milking 
moments were obtained from the Research Institute for Animal Husbandry (Lelystad, 
the Netherlands). The samples were previously found negative (< 1 ng ml–1) with 
regard to the presence of DHS and STREP by LC-MS and were stored at –20 °C 
before analysis. Prior to the use of thawed milk, samples were centrifuged for 5 min at 
1000 x g and the defatted milk sample was pipetted from below the layer of fat.  
 
 
RESULTS AND DISCUSSIONS 
 
Mab Production 
DHS was coupled to the carrier protein (KLH) through three different coupling 
methods; glutaraldehyde pH 7.3 (GDA7.3), glutaraldehyde pH 8.5 (GDA8.5) and the 
activated carbodiimid coupling (acc). A cocktail of these conjugates was used to 
immunize two BALB/c mice. After the second booster, both mice (99049 and 99050) 
showed good titers and, in the competitive indirect ELISA, sera of day 35 showed 
70% and 40% inhibition, respectively, caused by the addition of 1 μg DHS to the 
BSA–DHS (acc) coated wells. Spleen cells from mouse 99049 were used for PEG-
fusion and the resulting hybridomas were cultured in a total of 1152 wells of 96-well 
microtiter plates. An indirect ELISA, using microtiter plates coated with a cocktail of 
BSA–DHS conjugates, was used to screen the supernatants from each well showing 
cell-growth for antibodies against DHS. A total of 15 wells contained specific 
antibody producing hybridomas. These positive hybridoma cells were transferred into 
1 ml bottles and tested once more in a competitive ELISA for their ability to 
recognize unconjugated (free) DHS. Only one cell line (62–4G8) showed a high titer 
and competition with DHS with all DHS conjugates. This cell line was brought into 
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limiting dilution (LD). Four stable cell lines (62–4G8-C10/D10/E8/G3) produced 
anti-DHS antibodies, of which the binding to DHS coated plates was inhibited by 1 μg 
ml–1 DHS. The supernatants of the first LDs of 62–4G8-G3 and 62–4G8-E8 contained 
Mabs (IgG1 with a kappa light chain). A second LD for 62–4G8-C10 and -D10 was 
performed to guarantee their monoclonal origin.  
In a competitive ELISA with BSA–DHS (acc or GDA8.5) coated plates, the culture 
supernatant of 62–4G8-E8 (further abbreviated as 4G8) showed the highest sensitivity 
with IC50 values of approximately 100 and 50 ng ml–1 for DHS in raw milk and buffer, 
respectively. This Mab (4G8) and the previously developed Mab against STREP 
(4E2), after concentration from culture supernatant by affinity chromatography, were 
used in the BIAs.  
 
Direct BIAs 
 
Gentamicin.  
Using the immobilization wizard of the Biacore 3000 control software, the coupling 
of antibodies in Fc1 and Fc2 resulted in final responses of 9940 and 10 000 RU, 
respectively. During the measurements, Fc1 served as the reference channel and the 
obtained response was subtracted from that in Fc2. Standard solutions of gentamicin 
were injected (20 μl) at a flow rate of 20 μl min–1. This resulted in sensorgrams as 
shown in Figure 1. 
 
Figure 1. Sensorgrams obtained with standard solutions of gentamicin (0-125 ng ml-1). 
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Gentamicin-bound antibodies were regenerated by the injection of 5 μl of a 20 mM 
sodium hydroxide solution. The total run time (sample injection and regeneration) per 
sample was 5 min. As shown in Figure 1, the immobilized antibodies were saturated 
with gentamicin at a concentration of 125 ng ml–1 (2.5 ng per injection) and lower 
concentrations resulted in reduced responses during and after injection. The detection 
limit in buffer (three times background response) was 2 ng ml–1 (40 pg per injection). 
The response differences, measured 20 s before the regeneration started (100 s after 
injection, see Figure 1), obtained from the different standard solutions in buffer and in 
milk were plotted against the concentration of gentamicin (see Figure 2). This resulted 
in a calibration curve in buffer with 50% binding at 20 ng ml–1.  
The calibration curve in milk (reconstructed from skimmed milk powder) showed a 
50% binding at 35 ng ml–1 (see Figure 2) and a detection limit of 10 ng ml–1 which is 
well below the MRL of 100 ng ml–1. 
 
 
 
Figure 2. Calibration curves of the direct gentamicin immunoassay in buffer and milk.  
 
 
STREP and DHS. 
In the direct assays for DHS and STREP we were aiming for an immobilization level 
of 15000 response units (RU) in the Surface Preparation Wizard and final responses 
of 14000 RU (Mab 4E2 in flow channel 2 (Fc2)) and 12800 RU (Mab 4G8 in Fc4) 
were obtained (biosensor chip A). Total rabbit IgG was immobilized in Fc1 and Fc3 
(9000 RU) which served as reference Fcs. After 20 μl injections of standard solutions 
(0–1000 ng ml–1) of STREP (581 Da) in the four serially connected Fcs, maximum 
responses of 105 RU in Fc2 and 90 RU in Fc4 were found (see Figure 3). 
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Figure 3. Sensorgrams showing the binding of STREP to the immobilized Mabs in the direct 
BIAs: (a) Mab 4E2 in Fc2 and (b) Mab 4G8 in Fc4. Several standard solutions of STREP in 
HBS-EP buffer (0–1000 ng ml–1) were injected (20 μl) using a flow rate of 20 μl min–1. (i) 
injection start; (s) stop injection; (r) response (RU) used for calibration curves. 
 
The immobilized antibodies were saturated with STREP after 20 μl injections of 
standard solutions with a concentration of 50 ng ml–1 (1 ng absolute) or higher at a 
flow rate of 20 μl min–1. Lower concentrations of STREP resulted in reduced signals 
(see Figure 3). These results were comparable with the results obtained with the direct 
BIA for gentamicin. The antibodies were regenerated by the injection of 5 μl 5 mM 
HCl at a flow rate of 20 μl min–1. The responses, measured 10 s before the start of the 
regeneration (40 s after the injection stop, see Figure 3), obtained for the different 
concentrations of STREP and DHS in buffer were plotted against their corresponding 
concentrations (see Figure 4). With both Mabs, STREP injections resulted in higher 
responses than DHS injections. Due to the differences in dissociation (see Figure 3), 
the responses obtained with STREP and DHS binding to Mab 4E2 (Fc2) were higher 
than those obtained with Mab 4G8 (Fc4). 
The concentration corresponding with 50% binding of STREP and DHS to the two 
Mabs was 11 ± 1 ng ml–1. The measurement ranges for both aminoglycosides were 
narrow, from 5 (10% binding) to 30 ng ml–1 (90% binding). Increasing the injection 
volumes from 20 to 50 and 100 μl resulted in increased sensitivities (from 11 to 6 and 
3 ng ml–1 at 50% binding, respectively). Increasing the flow rate from 20 to 50 μl 
min–1 resulted in reduced maximum signals, due to a less efficient binding. Solutions 
of 1000 ng ml–1 of other aminoglycosides (spectinomycin, tobramycin, kanamycin, 
amikacin, gentamicin and neomycin) were injected and neither BIA responsed, 
demonstrating the specificity of both Mabs with regard to DHS and STREP. 
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Figure 4. Calibration curves of STREP and DHS obtained in the direct BIAs with both Mabs 
(4E2 and 4G8). Injection volumes were 20 μl at a flow rate of 20 μl min–1. 
 
 
DHS and STREP in milk. 
The calibration curves of DHS (binding to Mab 4G8 in Fc4) in buffer and 
reconstituted milk from skimmed milk powder were compared (see Figure 5). Due to 
matrix effects, the calibration curve for DHS in milk showed less sensitivity (22 ng 
ml–1 at 50% binding) compared with the curve in buffer (12 ng ml–1 at 50% binding). 
However, with an LOD (determined as three times the average response of the blank 
milk) of 10 ng ml–1, the assay was still useful for the detection far below the MRL of 
200 ng ml–1. These results were similar to the results obtained with the direct BIA for 
gentamicin using the same milk sample. By diluting the milk sample with buffer (five 
times), the difference between the curves in buffer and milk was reduced, supporting 
the suggestion of matrix interference.  
The 17 different blank milk samples were diluted five times in HBS–EP buffer and 20 
μl of each sample was injected (20 μl min–1) in the four serially connected Fcs. 
Average background responses of 42 ± 16, 118 ± 64, 49 ± 16 and 41 ± 9 RU were 
obtained in Fc1, Fc2, Fc3 and Fc4, respectively. The average background response in 
Fc2 (Mab 4E2) was very high compared with those obtained in the other Fcs and also 
compared with the maximum responses obtained after binding of STREP or DHS 
(approximately 100 RU) and Mab 4E2 was considered to be not suitable for a direct 
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BIA in milk without a sample preparation. The best results were obtained with Mab 
4G8 (Fc4) and when corrected for the responses obtained in the reference Fc (Fc3), an 
acceptable average background was obtained (–8 ± 8 RU). 
 
 
Figure 5. Comparison of calibration curves of DHS (20 μl injections at 20 μl min–1) in the 
direct BIA (Mab 4G8) in buffer and undiluted milk (reconstituted milk powder). 
 
Using this Mab, the detection limit in milk (using five times diluted samples) was 20 
ng ml–1.  
The observed background responses were caused by matrix effects (probably protein–
protein interactions), which could be reduced effectively by means of an ultra 
filtration (UF) device with a cut-off of 10 kDa. Unlike the reconstituted skimmed milk 
powder, the 17 different milk samples could not be used undiluted in the UF device 
because of blocking of the membrane. Using such devices with five times diluted milk, 
the filtrates were clear and, after 20 μl injections of the filtrates of the 17 blank milk 
samples, average background responses of 0.4 ± 0.6, 3.6 ± 2.0, 0.0 ± 2.0 and 3.5 ± 1.4 
were obtained in Fc1, Fc2, Fc3 and Fc4, respectively. A calibration curve of STREP 
in milk (0–1000 ng ml–1), injected after UF, was almost comparable to the curve in 
buffer (50% binding at 40 and 50 ng ml–1 in buffer and milk, respectively, in five 
times diluted standards and samples). Using UF as sample preparation, both Mabs 
could be applied for the detection of DHS and STREP at the 20 ng ml–1 level. 
However, a direct BIA without sample preparation is easier to perform and this could 
be achieved with Mab 4G8 only. 
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Competitive BIAs 
 
Most BIAs for the detection of LMWC use the competitive inhibition assay format in 
which the LMWC is directly immobilized onto the sensor surface. In these 
immobilization procedures, a high concentration of the LMWC (2 mg ml–1) was used 
(Sternesjö et al., 1995). In order to avoid contamination of the biosensor system with 
the LMWC, causing interferences with following sample analysis, these 
immobilizations were performed outside the biosensor system in which the whole 
sensor surface was coated with the same LMWC. Having a biosensor system in which 
four different Fcs could be used for different BIAs, immobilizations in the individual 
Fcs were preferred. Another disadvantage of the direct coupling of the LMWC to the 
sensor surface was that for each type of LMWC a new immobilization procedure on 
the chip had to be developed. For these reasons, a drug–protein conjugate (STREP–
OVAL) was chosen for the immobilization. The immobilization of proteins on the 
CM5 sensor chip by amine coupling is a standard procedure in which low 
concentrations of protein are used (25–100 μg ml–1). This enables the direct coupling 
in the different Fcs and gives the possibility to vary and control the coating 
concentration. 
To examine the influence of coating concentration on the BIA performance, two 
different amounts of STREP–OVAL were bound to the sensor surface of a new 
biosensor chip (chip B). In Fc4, we aimed for a high amount (10000 RU) bound to the 
sensor surface and obtained, after the injection of 63 μl of a 25 μg ml–1 solution, a 
final response of 5900 RU. In Fc2, a 10 times lower concentration of STREP–OVAL 
was aimed at (600 RU) and, after injection of 13 μl of the 25 μg ml–1 solution, a final 
response of 620 RU was obtained. Bound antibodies could be released from the 
surface by injection of 5 μl of 50 mM HCl. For the preparation of calibration curves 
of STREP and DHS with the two Mabs in the two Fcs, 50 μl of standard solutions 
were mixed (just prior to the injection, no incubation) with 50 μl of diluted Mabs. The 
final dilution of Mab 4E2 used in combination with Fc2 was 800 times (4.3 nM) and 
2000 times (1.7 nM) in combination with Fc4, which resulted in maximum responses 
of 240 RU in both Fcs. The calibration curves for STREP showed 50% inhibitions of 
10 and 9 ng ml–1 in Fc2 and Fc4, respectively, which means that the effect of the Fc 
capacity on the sensitivity of the calibration curves is minimal. Final dilutions of Mab 
4E2 of 400 times (8.6 nM) and 4000 times (0.86 nM) in Fc4 resulted in 50% 
inhibition at 30 and 8 ng ml–1, respectively, which means that the sensitivity of the 
assay decreased with higher concentrations of the Mab.  
The calibration curves for STREP and DHS obtained with both Mabs (each fd 2000 
times; 1.7 nM) in Fc4 are shown in Figure 6. 
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Figure 6. Calibration curves of STREP and DHS obtained in the competitive BIAs in Fc4 of 
chip B using Mabs 4E2 and 4G8 at final dilution of 2000 times (1.7 nM). Standard solutions 
(50 μl) were mixed with diluted antibodies (50 μl) and 50 μl was injected at a flow rate of 20 
μl min–1. 
 
With Mab 4E2, the 50% inhibitions for STREP and DHS were 9 and 12 ng ml–1, 
respectively, which means a cross-reactivity for DHS of 75%, which is comparable 
with the cross-reactivity (86%) obtained in the ELISA (Dietrich et al., 1993). The 
50% inhibition values obtained with Mab 4G8 were 12 and 20 ng ml–1 for STREP and 
DHS, respectively, which means that this Mab, although raised against DHS, had a 
better sensitivity towards STREP. 
 
Competitive BIAs in milk 
The blank milk samples (n = 17), with and without the addition of STREP, were 
analyzed. After injection of milk, increased responses due to matrix effects were 
observed. This nonspecific binding could easily be detected by injecting milk without 
the addition of antibodies. The nonspecific binding was highest in Fc4 (STREP–
OVAL 5900 RU) where, with undiluted milk, responses were recorded up to 500 RU. 
Dilution of the milk samples reduced the nonspecific binding only slightly. To study 
this nonspecific binding in more detail, a new biosensor chip (chip C) was prepared 
with immobilized OVAL (950 RU) in Fc1 and STREP–OVAL (1000 RU) in Fc2. Fc3 
was activated with NHS/EDC and directly blocked with ethanolamine (EA; blank 
reference Fc) and Fc4 was not treated at all. Chip C was first used to measure the 
nonspecific binding from the 17 blank milk samples (five times diluted) in the four 
Fcs.  
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Table 1. Nonspecific binding in the four Fcs (without Mab) and specific binding in Fc2 (with 
Mab 4E2) of biosensor chip C using the competitive BIA with 17 blank milk samples with and 
without the addition of STREP (0, 10, 20, 50, 100, 200 and 400 ng ml–1). The milk samples 
were diluted five times prior to injection. 
RESPONSE (RU) Addition 
of STREP 
(ng ml–1) 
 
Addition 
of 
Antibo-
dies 
n 
 Fc1 
OVAL 
 
Fc2 
STREP
–OVAL 
Fc3 
Blocked 
with EA
Fc4 
No 
coating  
Fc2–
Fc1 
 
0 No 17 67 ± 33a 53 ± 25a 60 ± 34a 75 ± 26a –15 ± 7 
0 Yes 17 66 ± 32a 286 ± 30b 59 ± 34a 70 ± 25a 220 ± 10c 
10 Yes 17 62 ± 33a 249 ± 37b 56 ± 33a 63 ± 25a 187 ± 12c 
20 Yes 17 62 ± 31a 233 ± 35b 56 ± 32a 63 ± 24a 171 ± 9c 
50 Yes 17 63 ± 33a 139 ± 29b 58 ± 36a 67 ± 26a 76 ± 7c 
100 Yes 17 62 ± 33a 106 ± 28b 56 ± 34a 66 ± 26a 44 ± 7c 
200 Yes 17 69 ± 38a 84 ± 30b 64 ± 40a 74 ± 31a 15 ± 9c 
400 Yes 17 72 ± 37a 74 ± 31b 68 ± 39a 78 ± 30a 1 ± 8c 
a Nonspecific binding. 
b Total response (nonspecific binding + specific binding of Mab 4E2 to OVAL—STREP). 
c Corrected response (specific binding of Mab 4E2). 
 
As shown in Table 1 (no addition of antibodies), nonspecific binding was observed in 
all Fcs. Compared with Fc2 (STREP–OVAL), in general, the nonspecific binding in 
the other Fcs was higher. This proved that the low level of immobilized STREP–
OVAL did not contribute to this nonspecific binding. With most samples, the 
nonspecific binding was highest in Fc4. This should be due to the binding of proteins 
to the negative charged carboxymethylated dextran surface. Activating this surface 
with EDC/NHS and blocking with ethanolamine, as in Fc3, resulted in less 
nonspecific binding. Compared with Fc2, the nonspecific binding in Fc1 was slightly 
higher with all samples. This might be due to the serial connection of the four Fcs 
through which samples were first introduced in Fc1. Fc1 may therefore have filtered 
some interfering compounds.  
Mixing the milk samples with Mab 4E2 (in a final dilution of 500) gave a total 
response in Fc2 of 286 ± 30 RU (see Table 1). By subtracting the responses obtained 
in Fc1 (reference Fc) from Fc2, the corrected responses varied less (220 ± 10 RU). 
The addition of antibodies did not result in an increase of nonspecific binding in Fc1, 
Fc3 and Fc4. The 17 blank milk samples were also analyzed after the addition of 
increasing concentrations of STREP, which resulted in decreasing responses in Fc2 
(see Table 1). Especially at low concentrations of added STREP, the variation in the 
corrected responses (Fc2-Fc1) was less than the variation in the responses obtained in 
Fc2, which reduced the detection limit to 20 ng ml–1, which is 10 times below the 
MRL. 
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CONCLUSIONS  
 
In our opinion, this study presents the first non-competitive single antibody-based and 
label free immunoassay for the direct detection of low molecular weight compounds 
in a food matrix at relevant levels (well below the MRL). In these direct BIAs, 
antibodies are the only reagents needed. However, in order to obtain sufficient high 
responses (approximately 100 RU) for a binding LMWC, highly pure antibodies and 
high immobilization levels are required. These high immobilization levels result in 
background responses probably due to nonspecific binding of milk components to the 
immobilized antibodies. This nonspecific binding can be reduced considerably by 
removing the high molecular weight components from milk by means of UF. One of 
the Mabs (4G8) showed less background responses in the direct BIA and a limit of 
detection (LOD) of 20 ng ml–1 was obtained without the sample pretreatment by UF.  
In general, the competitive BIA format is more flexible. Here, different amounts of 
antibodies can be used and high responses can be obtained. Drug–protein conjugates 
can be used as ligands immobilized on the sensor chip surface. If the ligand 
concentration is low (<1000 RU), the background response, due to nonspecific 
binding of milk components, is comparable with the nonspecific binding to the 
dextran coating on the CM5 chip. The use of drug–protein conjugates as ligands, 
instead of a direct immobilization of the drug, has the advantages that immobilizations 
can be performed directly into the biosensor, without a risk of contamination of the 
system, and that the immobilization level can be adjusted. This provides the 
possibility to create multi-analyte BIAs by means of immobilizing different drug–
protein conjugates in the different Fcs. The use of a reference Fc allows to subtract the 
background responses, obtained as a result of matrix interferences, from the 
measurements in both the direct and competitive BIAs, which results in lower LODs. 
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ABSTRACT 
 
The application of an optical biosensor (Biacore 3000), with four flow channels (Fcs), 
in combination with a mixture of four specific antibodies resulted in a competitive 
inhibition biosensor immunoassay (BIA) for the simultaneous detection of the five 
relevant aminoglycosides in reconstituted skimmed milk. Four aminoglycosides 
(gentamicin, neomycin, kanamycin and a streptomycin derivative) were immobilized 
onto the sensor surface of a biosensor chip (CM5) in the four Fcs of the biosensor 
system by amine coupling. In the Biacore, milk (reconstituted from skimmed milk 
powder) was 10 times diluted with a mixture of the four specific antibodies and 
injected through the four serially connected Fcs (1 min at a flow rate of 20 μl min−1). 
The responses measured just prior to the injection (20 μl at a flow rate of 20 μl min−1) 
of the regeneration solution (0.2 M NaOH + 20% acetonitrile) were indicative for the 
presence or absence of the aminoglycosides in reconstituted milk. The limits of 
detection were between 15 and 60 ng ml−1, which was far below the maximum residue 
limits (MRLs) (varying from 100 to 500 ng ml−1) and the total run time between 
samples was 7 min. 
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INTRODUCTION 
 
Aminoglycosides are broad-spectrum antibiotics most commonly used in veterinary 
drug medicine in the treatment of infections caused by aerobic Gram-negative bacteria, 
such as mastitis [1]. The presence of residues of these drugs in food is considered a 
high risk to the consumer and maximum residue limits (MRLs) have been established. 
In the European Union (EU), the MRLs for gentamicin (Genta), kanamycin (Kana), 
streptomycin (Strep), dihydrostreptomycin (DHS) and neomycin (Neo) in milk are 
100, 150, 200, 200 and 500 ng ml−1, respectively.  
For the detection of aminoglycosides, three techniques are mainly applied: microbial 
inhibition screening tests [2–4], immunoassays or receptor assays [2,5–8] and liquid 
chromatography (LC) [9–14]. LC might be the most suitable technique for the 
confirmation of positive screening results. For a large-scale screening, first 
microbiological methods are preferred because of their convenience, low cost and 
broad-spectrum characteristics. However, with such methods it takes at least 6 h 
before the results are known [4]. More rapid methods for the detection of these 
antibiotics are microtiter plate enzyme-linked immunosorbent assays (ELISAs) with 
results being available within 2 h [7]. However, such ELISAs are specific only for one 
or two of the aminoglycosides and are normally performed in a laboratory. The fastest 
and easiest assay described so far is the one-step strip test in which the results can be 
obtained within 10–15 min [8]. This test was developed for on-site screening of raw 
milk samples for the presence of DHS and Strep on a farm. However, this test is 
specific for DHS and Strep only, and is not suitable for large-scale screening.  
Rapid and automated surface plasmon resonance (SPR)-based biosensor 
immunoassays (BIAs) have been proposed for the detection of sulfamethazine [15], 
enrofloxacin and ciprofloxacin [16] and Strep [17] in bovine milk. For the detection 
of these low molecular weight compounds, the competitive inhibition immunoassay 
format was used in which the drugs were covalently immobilized on to 
carboxymethylated dextran-modified gold film on the biosensor chip. Applications for 
the direct detection of Genta [18] and Strep and DHS [19] were also described. In 
these unique direct assays, monoclonal antibodies were immobilized onto the 
biosensor chip and the binding of the aminoglycosides was measured directly. 
Although these direct assays were applied in milk, the competitive inhibition format 
was found to be more flexible and robust [19]. 
The assays described above are specific for one or two of the aminoglycosides. To 
detect the five relevant aminoglycosides in milk simultaneously, the four flow channel 
biosensor (Biacore 3000) was applied in the present study. Genta, Neo, Kana and a 
Strep derivative were immobilized onto the surface of a biosensor chip (CM5) in the 
four Fcs of the biosensor system and a mixture of selected specific antibodies was 
used in the competitive inhibition format in which the four Fcs were serially 
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connected. The combined assay was constructed, with regard to sensitivity, to allow 
the determination of the five aminoglycosides below and at the regulatory MRL levels. 
To avoid the instability of milk during the several experiments performed with the 
different assays over a longer period, reconstituted milk from skimmed milk powder 
was used as a model matrix in this study. 
 
 
EXPERIMENTAL 
 
Materials 
Gentamicin sulphate, neomycin trisulphate, kanamycin disulphate, streptomycin 
sulphate and dihydrostreptomycin sesquisulphate were purchased from Sigma–
Aldrich Chemie B.V. (Zwijndrecht, the Netherlands). The Qflex Kit Streptomycin 
(containing streptomycin binding protein (SBP), streptomycin derivative, 
streptomycin calibration stock solution, HBS-EP buffer (composition: 0.01 M HEPES 
pH 7.4, 0.15 M NaCl, 3 mM EDTA and 0.005% surfactant P20), a CM5 sensor chip 
and kit accessories), the Qflex Kit Streptomycin handbook, 10 mM sodium acetate 
(pH 4.5) and the amine coupling kit (containing 0.1 M N-hydroxysuccinimide (NHS), 
0.4 M N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1 
M ethanolamine hydrochloride-NaOH (pH 8.5)) were supplied by Biacore AB 
(Uppsala, Sweden). The anti-gentamicin polyclonal antiserum (422 batch 8.2) was 
raised in a rabbit; the performance of this antiserum in an ELISA has been described 
before [7]. The development of the anti-dihydrostreptomycin monoclonal antibody 
(4G8) was also described before [19]. An affinity purified culture supernatant with a 
final IgG1 concentration of 0.53 mg ml−1 was used as the stock solution. The anti-
neomycin (CR2389R) and anti-kanamycin (CR2383S) polyclonal antisera were 
supplied by Cortex Biochem Inc. (San Leandro, CA). The purified monoclonal 
antibody and the polyclonal antisera were stored at −20 ◦C. 
 
Equipment  
The Biacore Q biosensor system was loaned from NIZO Food Research (Ede, the 
Netherlands). The Biacore 3000 biosensor system was supplied by Biacore AB 
(Uppsala, Sweden).  
 
Preparation of the biosensor chip 
The immobilization of the aminoglycosides onto the biosensor chip surface and into 
the four flow channels (Fcs) was performed in the Surface Prep unit of the Biacore Q 
and was guided by the immobilization wizard. The Surface Prep unit is a sensor chip 
holder that fits directly onto the auto sampler rack base of the Biacore Q. Fcs are 
formed on the sensor chip by docking a plastic block (the flow cell carrier) onto the 
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chip. Solutions were injected directly into the Fcs with the autosampler needle and 
effluents from the flow channels were collected in a small waste beaker.  
The immobilization of the Strep derivative in Fc4 of the sensor chip (CM5) was 
performed according to the instructions prescribed in the Qflex Kit Streptomycin 
handbook. Prior to immobilization, the sensor chip surface in Fc4 was activated by 
injecting a mixture of 0.4 M EDC and 0.1 M NHS (1:1; v/v) at a flow rate of 10 μl 
min−1 and with a contact time of 7 min. After washing with 0.1 M sodium hydroxide, 
the Step derivative (10 times diluted in 10 mM sodium acetate (pH 4.5)) was injected 
through Fc4 for 7 min at a flow rate of 5 μl min−1. To deactivate the remaining active 
sites, 1 M ethanolamine was injected for 3 min at a flow rate of 10 μl min−1. An extra 
wash step with water was used to remove any adsorbed chemicals at the end of the 
immobilization procedure.  
Genta, Neo and Kana were immobilized into Fc1, Fc2 and Fc3, respectively. Here, the 
sensor chip surfaces in the Fcs were activated with the mixture of EDC and NHS for 
40 min at a flow rate of 2 μl min−1. After washing with water, solutions of the 
aminoglycosides (3 mg ml−1 in borate buffer (pH 8.5)) were injected over the surface 
for 60 min at a flow rate of 2 μl min−1. The sensor surfaces were deactivated and 
washed as described above for the immobilization of the Strep derivative.  
 
Biosensor immunoassays (BIAs) 
The Biacore Q was used for the immobilization of the four aminoglycosides onto the 
surface of the biosensor chip into the four Fcs. A major disadvantage of this biosensor 
system is that the four different Fcs can only be used separately. For that reason, the 
chip with the immobilized aminoglycosides was docked into the Biacore 3000 system 
in which the four Fcs can be used individually or serially connected. The running 
buffer was HBS-EP at a flow rate of 20 μl min−1. For all the assays, the standard 
solutions in buffer or milk and the milk samples (reconstituted from skimmed milk 
powders) were pipetted (100 μl) into the wells of a microtiter plate. Using the Biacore 
3000 control software, 10 μl of the standards or samples was mixed with 90 μl of the 
antibody solution in the microtiter plate. Of this mixture, 20 μl was injected at a flow 
rate of 20 μl min−1. After this injection, the surface was regenerated by injection of 0.2 
M sodium hydroxide containing 20% acetonitrile (20 μl at 20 μl min−1). The 
responses measured 10 s prior to the injection of the regeneration solution were used 
for the calculations in the Biacore Evaluation software. The total run time between 
samples was 7 min. 
 
Milk powder samples 
Ten skimmed milk powders obtained from the General Inspection Service (Kerkrade, 
the Netherlands) in the year 2001 and taken from 10 different suppliers were used 
during the experiments. The average fat, protein and lactose content of these milk 
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powders were 0.8 ± 0.4, 36.0 ± 0.9 and 47 ± 2 %, respectively. To reconstitute milk, 
90 ml of water were added to 10 g of the milk powders and after stirring for 30 min at 
room temperature on a magnetic stirrer, the milk samples were ready to use. The 
reconstituted milk samples were stored at 4–6 ◦C for a maximum of 5 days. 
 
 
RESULTS AND DISCUSSION 
 
Biosensor chip 
The primary amine-containing aminoglycosides were immobilized onto the NHS-
activated biosensor chip surface by amine coupling. Of the aminoglycosides used is 
this study, Strep and DHS have only two primary amine groups, Genta has three or 
four, Kana has four or five (dependent of the component) and Neo has six amine 
groups. For the immobilization of Strep, the derivative as supplied in the Qflex 
Streptomycin Kit and the procedure described in the handbook (see Experimental 
section) were used. For the immobilization of the other three aminoglycosides in the 
other Fcs, a coupling buffer of pH 8.5 was used because the attachment of primary 
amine-containing ligands to the NHS-activated surface required an uncharged primary 
amine function [20]. Long contact times during the NHS activation (40 min) and 
during the immobilization (60 min) of the aminoglycosides were applied to ensure 
that enough of the aminoglycosides were bound to the surface. Directly after the 
immobilizations, the base responses, measured in the Biacore 3000 with HBS-EP as 
running buffer, were 22150 RU in Fc1 (Genta), 22600 RU in Fc2 (Neo), 23125 RU in 
Fc3 (Kana) and 21340 in Fc4 (Strep derivative). After 250 cycles, the base responses 
in the first three Fcs were at the same level as directly after the immobilization, while 
the base response in Fc4 decreased to 20600 RU and stayed at that level during the 
next 250 cycles. 
 
Biosensor immunoassays 
 
Streptomycin assay  
The performance of the SBP from the Qflex kit was compared with a previously 
developed monoclonal antibody against DHS (Mab 4G8 [19]) in combination with 
Fc4 of the coated biosensor chip docked into the Biacore 3000. According to the 
Qflex Kit Streptomycin handbook for milk assay, calibration graphs for milk were 
prepared using four calibrants (500, 250, 125 and 62.5 ng ml−1), the SBP (five times 
diluted in HBS-EP) and 20 μl injections at a flow rate of 40 μl min−1. The calibrants 
were 10 times diluted with the SBP solution using the Biacore 3000 control software. 
The regeneration solution (0.2 M sodium hydroxide + 20% acetonitrile) was injected 
for 1 min at a flow rate of 40 μl min−1. Under these conditions, calibration graphs for 
reconstituted milk and buffer were compared. The average maximum responses 
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obtained with buffer and milk (n = 10) were 1030 ± 10 and 878 ± 32 RU, respectively, 
and the 50 % inhibition values were calculated as 120 and 340 ng ml−1, respectively. 
This clearly demonstrated the negative influence of milk on the performance of the 
assay. The 10 blank milk samples were also analysed after the addition of Strep at the 
MRL level (200 ng ml−1). This resulted in an average response of 546 ± 65 RU, which 
means that the inhibition of the maximum response due to the presence of Strep at the 
MRL level was only 38 %.  
Using a 40 times dilution of the stock solution of the anti-DHS Mab, comparable 
maximum responses and sensitivities in buffer and milk were obtained as with the 
SBP. The regeneration conditions as used with the SBP worked well with this Mab 
also. To obtain a better sensitivity, the flow rate of the assay was lowered to 20 μl 
min−1 and the Mab stock solution was diluted 100 times. The calibration graphs 
obtained under these conditions in buffer and milk showed 50 % inhibition values of 
60 and 140 ng ml−1, respectively (see Fig. 1A), which is sensitive enough to control 
milk samples at the MRL level. 
 
 
Figure 1. BIA calibration graphs for buffer (dotted lines) and reconstituted milk (solid lines) 
obtained in the individual Fcs: (A) Strep in Fc4; (B) Kana in Fc3; (C) Neo in Fc2; and (D) 
Genta in Fc1. The arrows indicate the MRLs in milk. 
 
 
Single biosensor immunoassay for the detection of five aminoglycosides 
172 
Kanamycin assay  
The commercially available anti-Kana Pab was used in a 25000 times dilution in 
combination with Fc3, and the regeneration procedure as described above worked 
well with this combination. The calibration graphs obtained for buffer and 
reconstituted milk are shown in Fig. 1B. The 50 % inhibition values in buffer and 
milk were 20 and 40 ng ml−1, respectively, which is sufficient to control milk  samples 
at the MRL level of 150 ng ml−1. 
 
Neomycin assay  
The commercially available anti-Neo Pab was used at 400 times dilution in 
combination with Fc2 and with the regeneration conditions as described above. The 
calibration graphs obtained for buffer and reconstituted milk are shown in Fig. 1C. 
The 50 % inhibition values for buffer and milk were 70 and 150 ng ml−1, respectively, 
which is sufficient to control milk samples at the MRL level of 500 ng ml−1.  
 
Gentamicin assay  
The previously developed Pab against gentamicin [7] was used at 1000 times dilution 
in combination with Fc1 and with the regeneration conditions described above. The 
calibration graphs obtained for buffer and reconstituted milk are shown in Fig. 1D. 
The 50% inhibition values for buffer and milk were 40 and 70 ng ml−1, respectively, 
which is sufficient to control milk samples at the MRL level of 100 ng ml−1.  
 
Mixed antibody assay in buffer  
 
Table 1. BIA in buffer. Responses (average of triplicate analyses) obtained in the four Fcs 
with the mixed antibodies (without and with the addition of the aminoglycosides at MRL 
levels) and with the individual antibodies (percentage of inhibition in parenthesis). 
Response in RU (% of inhibition) Antibody Added 
aminogl. 
(ng ml-1) 
Genta 
Fc1 
Neo 
Fc2 
Kana 
Fc3 
Strep 
Fc4 
Mixed antibodies – 445 ± 8 323 ± 5 623 ± 13 336 ± 8 
Anti-Genta – 418 ± 3 4 ± 2 3 ± 2 0 ± 2 
Anti-Neo – 15 ± 0 310 ±0 63 ± 1 0 ± 0 
Anti-Kana – 2 ± 0 1 ± 0 551 ± 2 0 ± 0 
Anti-DHS – 0 ± 0 0 ± 0 0 ± 0 331 ± 0 
Mixed antibodies Genta (100) 70 ± 1 (84) 268 ± 2 (17) 578 ± 1 (7) 297 ± 3 (12) 
Mixed antibodies Neo (500) 424 ± 1 (5) 42 ± 1 (87) 554 ± 2 (11) 304 ± 1 (10) 
Mixed antibodies Kana (150) 422 ± 1 (5) 270 ± 3 (16) 72 ± 1 (88) 279 ± 25 (17) 
Mixed antibodies Strep (200) 432 ± 1 (3) 315 ± 1 (2) 607 ± 1 (3) 46 ± 1 (86) 
Mixed antibodies DHS (200) 431 ± 1 (3) 316 ± 1 (2) 608 ± 0 (3) 53 ± 0 (84) 
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A mixture of the four antibodies was prepared. Anti-Genta, anti-Neo, anti-Kana and 
anti-DHS were used at dilutions of 1000, 400, 25000 and 100 times, respectively. The 
four Fcs were serially connected and the maximum responses obtained in the four Fcs, 
with buffer as sample, are presented in Table 1. The individual antibodies were 
injected through the four Fcs also and the responses due to the interactions in the four 
Fcs are shown in Table 1. The anti-Genta, anti-Kana and anti-DHS gave specific 
responses in the corresponding Fcs (immobilized with Genta, Kana and Strep, 
respectively). The anti-Neo reacted also in Fc3 and slightly in Fc1. Standard solutions 
of the five aminoglycosides at MRL levels were analyzed with the mixed antibodies. 
As shown in Table 1, the maximum responses in the corresponding Fcs were strongly 
inhibited (from 84 to 88%). The addition of Strep and DHS resulted in a significant 
inhibition in Fc4 only. The addition of the other three aminoglycosides had an 
inhibiting effect in the non-corresponding Fcs also, which means that the specific 
antibody–antigen interactions were influenced by the other aminoglycosides. 
 
Mixed antibody assay in reconstituted milk  
At first, the 10 reconstituted milk samples were injected without the antibody mixture 
(1:10 diluted with buffer) to investigate the nonspecific binding (NSB) of milk 
components to the aminoglycosides-coated Fcs. As shown in Fig. 2, the lowest NSB 
was found in Fc4 and the highest in Fc3. However, compared with the maximum 
responses obtained after the injection of the mixed antibodies in blank milk, these 
NSBs were low (see Fig. 2).  
 
 
Figure 2. Average relative responses obtained by the mixed antibody assay with reconstituted 
milk samples (n = 10) in the four Fcs. The milk samples were analyzed without the antibody 
mixture (nonspecific binding (NSB)) and with the antibody mixture without (blank) and with 
the addition of the five aminoglycosides at MRL levels. 
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The addition of Genta at the MRL level (100 ng ml−1) resulted in an average 
inhibition in Fc1 of 69 % and the inhibitions in the other Fcs were low (3–8 %). Using 
a calibration graph for Genta in milk (25, 50, 100 and 200 ng ml−1), the limit of 
detection (LOD is equal to the concentration corresponding with the average response 
of blank milk samples minus three times the standard deviation) was calculated as 20 
ng ml−1. 
The addition of Neo at the MRL level (500 ng ml−1) resulted in an average inhibition 
in Fc2 of 75 % and the inhibition in the other Fcs were between 3 and 12 %. Using the 
calibration graph for Neo in milk (125, 250, 500 and 1000 ng ml−1), the LOD was 
calculated as 40 ng ml−1.  
The addition of Kana at the MRL level (150 ng ml−1) resulted in an average inhibition 
in Fc3 of 75 % and the inhibitions in the other Fcs were between 0 and 12 %. Using 
the calibration graph for Kana in milk (37.5, 75, 150 and 300 ng ml−1), the LOD was 
calculated as 15 ng ml−1.  
The addition of Step and DHS at the MRL level (200 ng ml−1) resulted in average 
inhibitions in Fc4 of 64 and 57 %, respectively, and the inhibitions in the other Fcs 
were between 0 and 5 %. Using calibration graphs for Strep and DHS in milk (50, 100, 
200 and 400 ng ml−1), the LODs were calculated as 30 and 60 ng ml−1. The greater 
sensitivity of the anti-DHS Mab for Strep was reported before [19]. 
 
Table 2. Calculated concentrations (average of triplicate analyses) of the aminoglycosides in 
spiked reconstituted milk samples (at the levels: 0.25 MRL, 0.5 MRL, MRL and 2 MRL) using 
the four calibrants with mixed aminoglycosides (at the levels: 0.07 MRL, 0.22 MRL, 0.67 
MRL and 2 MRL). 
Calculated concentration (ng ml−1) 
(percentage recovery) 
 
Aminoglycoside MRL 
0.25 MRL* 0.5 MRL* MRL* 2 MRL* 
Genta 100 17 ± 3 (68) 38 ± 9 (76) 77 ± 1 (77) 136 ± 5 (68) 
Neo 500 90 ± 2 (72) 190 ± 5 (76) 434 ± 7 (89) 979 ± 6 (98) 
Kana 150 25 ± 2 (67) 50 ± 4 (67) 77 ± 4 (51) 93 ± 1 (31) 
Strep 200 52 ± 11 (104) 89 ± 3 (89) 176 ± 2 (88) 356 ± 1 (89) 
DHS 200 50 ± 5 (100) 79 ± 1 (79) 139 ± 1 (70) 272 ± 11 (68) 
* Level of spiking 
 
Mixed calibration standards in the mixed antibody assay in reconstituted milk.  
To investigate the possibility of using the combined assay as a quantitative assay and 
to reduce the amount of calibration standards, mixtures of four aminoglycosides 
(Strep, Neo, Kana and Strep) were prepared in reconstituted milk at different levels 
(0.07 MRL, 0.22 MRL, 0.67 MRL and 2 MRL). These mixed calibration standards 
were used with the mixed antibodies (1:10; v/v) and analyzed as described in the 
experimental section. The four calibration graphs obtained with the responses in the 
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four Fcs were used to calculate the concentrations of the aminoglycosides in blank 
and spiked milk samples. The concentrations calculated in the 10 blank milk samples 
were all below the lowest calibrations standards <0.07 × MRL. As shown in Table 2, 
in general, due to the influence of the different aminoglycosides in the mixed 
calibration standards on the calibration graphs in the four Fcs, the calculated 
concentrations of the spiked milk samples with the individual aminoglycosides were 
underestimated. Especially the higher concentrations of Kana were highly 
underestimated. At the higher concentrations, the calibration graph for Kana is quite 
flat (see Fig. 1B) and a small change in relative response has a great impact on the 
calculated concentrations.  
 
 
CONCLUSIONS 
 
The combined BIA used a mixture of four specific antibodies and four 
aminoglycosides immobilized onto the biosensor chip surface into the four serially 
connected Fcs of the Biacore 3000. This combined assay was found to be a qualitative 
assay for the detection of the five relevant aminoglycosides in reconstituted milk 
below their MRL levels and within 7 min. In this qualitative assay, five calibrants are 
recommended (blank milk sample and blank milk spiked with Genta, Neo, Kana and 
Strep at the MRL levels).  
Due to the significant interaction of the anti-Neo in other Fcs and some of the 
aminoglycosides into the different BIAs, the quantification in the combined assay 
resulted in underestimated concentrations (especially for Kana). For the more accurate 
quantification of the aminoglycosides in reconstituted milk, the individual BIAs, 
using the separate Fcs, should be applied.  
Three of the Fcs (coated with Genta, Neo and Kana) were used for around 250 cycles 
(within 3 weeks) and no significant decreases in the assay performances were noticed 
in these Fcs. After 500 cycles in Fc4 (coated with the Strep derivative), the initial 
maximum response of the binding Mab was strongly reduced (by ca. 50 %). The 
instability of this coating should be improved to use this assay for high throughput 
screening or for a longer period.  
Additional experiments have to be performed to prove that the combined assay is 
suitable for the detection of the aminoglycosides in whole milk samples and to 
investigate possible interferences from fat and somatic cell count. 
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ABSTRACT 
Flumequine (Flu) is one of the fluoroquinolones most frequently applied for the 
treatment of broilers in the Netherlands. For the detection of residues of Flu in blood 
serum of broilers, a biosensor immunoassay (BIA) was developed which was fast (7.5 
min per sample) and specific (no cross-reactivity with other (fluoro)quinolones). This 
inhibition assay was based on a rabbit polyclonal anti-Flu serum and a CM5 biosensor 
chip coated with Flu which could be detected in the range of 15 to 800 ng ml-1.  
For the detection of Flu in muscle, an easy extraction procedure in buffer was selected 
and the measuring range was from 24 to 4000 ng g-1. Average recoveries of 66 till 
75% were found with muscle samples spiked at 0.5, 1 and 2 times the maximum 
residue limit (MRL in muscle = 400 ng g-1) and the decision limit (CCα) and the 
detection capability (CCβ) were determined as 500 and 600 ng g-1, respectively.  
Incurred muscle samples were analyzed by the BIA and by LC-MS/MS and a good 
correlation was found (R2 = 0.998). Serum and muscle samples from with Flu treated 
broilers were analyzed and the concentrations found in serum were always higher than 
those found in muscle (average serum/muscle ratio was 3.5) and this proved the 
applicability of the BIA in serum as predictor of the Flu concentration in muscle. 
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INTRODUCTION 
“The development of chain oriented monitoring and surveillance in the poultry chain" 
was the title of a Dutch research project in which biosensor options for the on-site and 
simultaneous detection of pathogens and drug residues in broiler slaughterhouses 
were evaluated. Automated optical biosensors of the company Biacore AB were 
chosen and, to perform combined assays, the Biacore 3000, with four serially 
connectable flow channels (Fcs), was selected. Blood serum of broilers was chosen as 
the matrix for the detection of antibodies against pathogens (i.e. Salmonella) and drug 
residues with sulfonamides as the first model compounds. For the biosensor detection 
of sulfonamides in broiler serum, different approaches, ranging from specific to multi-
sulfonamide assays, were followed [1]. In the finally selected multi-sulfonamide 
biosensor immunoassay (BIA), a mutant antibody (M.3.4) was used in combination 
with a sulfonamide-derivative coated on the surface of the biosensor chip in one of the 
flow channels (Fcs) [2]. The sample preparation consisted of a dilution in buffer only 
and with this BIA, all 17 sulfonamides tested, including the five sulfonamides 
registered for application in broilers, could be detected in broiler serum with limits of 
detection between 4 and 82 ng ml-1. For the application in a combined assay with the 
detection of anti-salmonella, the biosensor conditions (sample dilution, sample buffer, 
running buffer and regeneration conditions) were adapted to the serological assay 
conditions (using lipopolysaccharides (LPS)-coated chips [3]). The adapted BIA was 
successfully applied during the analysis of samples from an animal experiment and 
during a survey in which 310 broiler serum samples of 31 different flocks were tested 
for anti-salmonella and sulfonamides [4]. 
However, other antibiotics can be used and for instance the quinolones are frequently 
applied veterinary drugs of which flumequine (Flu) is the most applied in broilers in 
the Netherlands. To establish safe limits for human consumption, the European Union 
(EU) established maximum residue limits (MRL) for Flu in chicken edible tissues of 
1000, 800, 400 and 250 ng g-1 in kidney, liver, muscle and skin + fat, respectively [5].  
For the development of a BIA, antibodies are necessary and different approaches for 
raising antibodies against (fluoro)quinolones were described previously [6-13]. 
Polyclonal [6,7] and monoclonal antibodies [8] were developed against sarafloxacin 
and cross-reactivities (CR’s) were observed with structurally related quinolones 
including difloxacin, enrofloxacin, norfloxacin, trovafloxacin and nalidixic acid. 
Monoclonal antibodies against enrofloxacin were highly specific [9] whilst polyclonal 
antibodies against enrofloxacin [10] showed CR with ciprofloxacin and antibodies 
against ciprofloxacin showed CR with enrofloxacin and norfloxacin [11]. An ELISA 
with polyclonal antibodies raised against norfloxacin, linked to ovalbumin via the 
secondary amine group as found in the piperazine moiety of norfloxacin, was able to 
detect nine different (fluoro)quinolones [12]. However, the CR towards Flu was 6% 
only. In the same study, highly specific ELISA’s were obtained with polyclonal 
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antibodies against ciprofloxacin, enrofloxacin, Flu and nalidixic acid. The Flu ELISA 
in milk showed 50% inhibition at 29 µg kg-1 and that is three to four times more 
sensitive than obtained with highly specific chicken egg yolk antibodies against Flu 
[13]. As shown in Figure 1, Flu has a deviating structure compared to the other 
quinolones. This explains the high specificity of the antisera against Flu.  
 
Figure 1. Molecular structures of the (fluoro)quinolones. 
 
In the present study, because of the availability, antisera against Flu were raised in 
rabbits using two immunogens (Flu-bovine serum albumin (BSA) and Flu-keyhole 
limpet hemocyanin (KLH)). The antisera were tested in an ELISA and in the Biacore 
using a CM5 biosensor chip coated with Flu in which a previously described two-step 
immobilization procedure [10], with ethylene diamine as spacer, was applied. For the 
Chapter 9 
 183  
detection of Flu in broiler sera, the easy sample preparation (dilution in anti-Flu 
containing buffer only) was adapted to the conditions previously described for the 
detection of anti-salmonella and sulfonamides [4]. Maximum residue limits (MRLs) 
for serum are not prescribed and the MRL in muscle of 400 ng g-1 was chosen as the 
minimum required performance limit (MRPL) in serum and, under these conditions, 
the decision limit (CCα) and the detection capability (CCβ) for Flu in serum were 
determined. The BIA was further applied during a survey with 310 broiler serum 
samples obtained from 31 different farms and sera from treated and untreated broilers 
were analyzed. For the application of the BIA in muscle, a simple extraction 
procedure was used, and CCα  and CCβ were determined using blank muscle samples 
analyzed with and without the addition of Flu at the MRL level. The BIA results were 
compared with LC-MS/MS results using incurred samples. Serum and muscle 
samples obtained from broilers treated with Flu were analyzed and the ratio of Flu in 
both materials was determined to evaluate the applicability of serum levels as 
predictor for Flu levels in muscle. 
 
  
MATERIALS AND METHODS 
 
Materials 
Piromidic acid was supplied by ICN Biochemicals (Ohio, USA) and marbofloxacin 
by Laboratoire Pharmaceutique Veterinaire (Lure Cedex, France). Enrofloxacin, 
ciprofloxacin and CM-dextran sodium salt were obtained from Fluka Chemie 
(Zwijndrecht, the Netherlands) and difloxacin from Abbott Laboratories (North 
Chicago, Illinois, USA). Isobutyl chloroformate, Tween-20, Tween-80, N,N-
dimethylformamid (DMF), tributylamine (TBA), dimethylsulfoxide (DMSO), 
ethylene diamine (EDA) and acetonitrile were obtained from VWR International 
(Amsterdam, the Netherlands). EIA grade horseradish peroxidase (HRP) was from 
Roche Diagnostics (Mannheim, Germany). HBS-EP buffer (containing 0.01 M 
HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA and 0.005% Surfactant P20), CM5 
biosensor chips and the amine coupling kit (containing 0.1 M N-hydroxysuccinimide 
(NHS), 0.4 M N-ethyl-N’-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC) and 1 M ethanolamine hydrochloride-NaOH (pH 8.5)) were supplied by 
Biacore AB (Uppsala, Sweden). Goat anti-rabbit IgG was obtained from Caltag 
Laboratories (Burlingame, CA). COSTAR® ELISA microtiter plates were obtained 
from Corning Incorporated (Corning, NY 14831, USA). Solutions of 
tetramethylbenzidine (TMB) peroxidase substrate and peroxidase were obtained from 
Kirkegaard and Perry Labs (Gaithersburg, MD, USA). Flumequine (Flu), ofloxacin, 
enoxacin, cinoxacin, oxolinic acid, norfloxacin, naldixic acid, lomefloxacin, bovine 
serum albumin (BSA), keyhole limpet haemocyanin (KLH), NHS, EDC, antifoam Y-
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30 emulsion and all other reagents were supplied by Sigma-Aldrich Chemie BV 
(Zwijndrecht, the Netherlands) unless stated otherwise. 
 
Equipment 
The Biacore 3000 and the Biacore Q were purchased from Biacore AB (Uppsala, 
Sweden). Both instruments have four flow channels (Fcs) and are fully automated 
with a capacity of 192 samples (two microtiter plates). The Biacore Q is dedicated to 
the qualitative or quantitative determination of analytes in food related products and 
can be used in combination with specially developed Qflex® Kits. A disadvantage of 
the Biacore Q is that only one of the four Fcs can be used at the same time. In the 
Biacore 3000, the four Fcs can be serially connected and simultaneously detected. 
During the development of the Flu BIA, one Fc was used only (a reference Fc was not 
applied) and therefore, both instruments were used, when available, during this study. 
The Ultra Microplate Reader (Model ELX 808) of Bio-Tek Instruments was supplied 
by Beun de Ronde (Abcoude, the Netherlands).  
 
Preparation of the immunogens 
For the coupling of Flu to BSA and KLH, the mixed anhydride procedure was 
followed. Here, by means of isobutyl chloroformate, the carboxyl group of Flu is 
converted to an acid anhydride what reacts with the amino groups of the proteins. Flu 
(5 mg) was dissolved in DMF (1 ml) and cooled to 4 ºC. TBA (5 µl) was added and 
after 10 min at 4 ºC, isobutyl chloroformate (5 µl) was added and stirred for 20 min at 
4 ºC. A portion (0.25 ml) of this solution of activated Flu was added to a cooled 
solution of the proteins (10 mg BSA or KLH dissolved in 3 ml 0.1 M Na2CO3) and, 
after stirring for 3.5 h at 4 ºC, the solution was dialyzed at 4 ºC against PBS for 3 
days. The molar ratios of Flu/proteins were determined by measuring the ultraviolet 
spectra of Flu, the proteins, and the conjugates and, using the absorbances at 250 nm, 
were calculated as 7.2 and 6.5 for BSA and KLH, respectively. The Flu-protein 
conjugate solutions were diluted in PBS until concentrations of 1 mg ml-1. 
 
Preparation of the HRP-conjugates 
The Flu-HRP conjugate was prepared according to the activated succinimide ester 
procedure in which the carboxyl group of Flu is converted to a reactive succinimide 
ester by adding a mixture of EDC and NHS. The ester reacts spontaneously with 
primary amine groups of the HRP. Flu (6.3 mg) was dissolved in a mixture of DMF (1 
ml) and PBS (0.2 ml) and to 1 ml of this solution, 0.5 ml of EDC (32 mg EDC in 1.4 
ml of PBS), 0.5 ml of NHS (30 mg in 2.9 ml of PBS) and 1 ml of DMF were added. 
After 1 h of mixing at RT, 0.5 ml of this solution was added to a solution of HRP (5 
mg dissolved in 1 ml of PBS). After overnight mixing at RT, the product was dialyzed 
at 4 ºC for four days against PBS and stored at -20 ºC until used. 
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Preparation of the antisera  
For the preparation of polyclonal antisera, immunizations were performed at the 
Laboratory of Hormonology (Marloie, Belgium). Two rabbits (New Zealand White 
SPF) were immunized with the two Flu-protein conjugates (Flu-BSA in rabbit MH41 
and Flu-KLH in rabbit MH42). Intradermal multisite injections were performed 
according to the laboratory protocol: first injection at day 0, second injection at day 
14, third injection at day 28, and thereafter one injection every 4 weeks. The first 
injection consisted of 1 ml of the protein solution (0.5 mg protein in 0.5 ml PBS 
mixed (1:1; v/v) with Freund's complete adjuvant). In all subsequent injections, the 
complete adjuvant was replaced by Freund's incomplete adjuvant. The first bleeding 
was performed at day 0 before the first injection (pre-immune serum) and the second 
bleeding at day 38. The following bleedings were performed every 10 days after each 
injection. Due to a misunderstanding, the final bleeding was performed 4 months after 
the last injection. After collection, the blood samples were placed in vacutainer tubes 
at room temperature for 24 h. After that, the blood was centrifuged and the collected 
serum was stored at -80 °C until further use. From each of the two rabbits, small 
amounts (3 ml) of pre-immune serum and the first bleeding were obtained followed 
by five large bleedings (ca. 24 ml of serum each) and a final bleeding (72 ml of serum 
each). The sera obtained from the final bleedings (fbs) were used in the final BIA. 
 
ELISA 
Microtiter plates were coated overnight with 100 µl aliquots of goat anti-rabbit IgG [5 
µg ml-1 in 50 mM sodium carbonate (pH 9.6)] at 4 °C. After coating, the plates were 
washed three times with washing buffer (PBS (pH 7.2) to which 0.05 % Tween-20 
and 0.004 % antifoam were added) with a microplate washer. Aliquots of 50 µl of 
diluted standard or sample or buffer (during titer evaluations) were added to the wells, 
followed by 25 µl of appropriately diluted Flu-HRP in PBS and finally 25 µl of in 
PBS diluted anti-Flu. The plate was incubated for 1 h at 4 °C and after washing (three 
times with washing buffer), the bound peroxidase was assessed by adding 100 µl 
aliquots of a tetramethylbenzidine (TMB) peroxidase substrate system. After 
incubation in the dark for 20-30 min at RT, the reaction was stopped by adding 100 µl 
aliquots of 1 M phosphoric acid and the colored product of the peroxidase reaction 
was measured at 450 nm in the microplate reader. 
Stock solutions of the quinolone standards (1 mg ml-1) were prepared in methanol 
which contained 2 mM NaOH.   
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Preparation of the biosensor chip 
For the immobilization of Flu via its carboxyl group to the carboxylated sensor 
surface of the CM5 biosensor chip, a previously described two-steps procedure 
applied for enrofloxacin was followed [10].  
First, the chip surface was bench top activated with 50 µl of a mixture of 0.4 M EDC 
and 0.1 M NHS (1:1; v/v) during 15 min at RT. The chip surface was washed with 
water and dried under a stream of nitrogen gas. To the chip, 50 µl of 0.1 M EDA (pH 
of 8.5) was added and after 15 min incubation at RT, the chip was washed with water 
and dried under a stream of nitrogen gas.  
Then, Flu was esterified with NHS in the presence of EDC. Flu (3-4 mg) was 
dissolved in 0.3 ml DMSO and 1.2 ml of sodium carbonate buffer (1.59 g Na2CO3 + 
2.93 NaHCO3 in 1 L water, adjusted to pH 9.6) was added. Of this solution, 100 µl 
was mixed with 100 µl 0.4 M EDC and 100 µl 0.1 M NHS and after an incubation of 
1 h at RT, this mixture (50 µl) was added to the activated chip. After an incubation of 
1 h at RT, the chip was washed with water, dried under a stream of nitrogen and 
docked into the Biacore 3000. 
 
Biosensor Immunoassay (BIA) 
After the immobilization of Flu to the chip surface of the CM5 chip, the chip was 
docked into the Biacore 3000 or the Q. HBS-EP with 0.05% Tween-80 was used as 
the running buffer with a flow rate of 20 µl min-1 and an injection volume of 40 µl 
was applied. For the regeneration, 10 µl of 0.2 M HCl was injected, followed by 20 µl 
of 0.2 M NaOH + 20% acetonitrile, both at a flow rate of 20 µl min-1. A complete 
cycle between two sample injections took 7.5 min. 
 
Samples and preparation 
 
Samples 
Broiler serum samples (n=310) from 31 different flocks of 31 different Dutch farms 
(10 sera from each farm) used during the survey and serum and muscle samples from 
100 broiler chickens (75 blank and 25 treated with Flu) were obtained from the 
Animal Sciences Group (ASG; Lelystad, the Netherlands). The 25 incurred samples 
were obtained via an animal experiment performed at the ASG in which 3-week-old 
Ross 308 broilers (n=25) were treated with Flu (Flumequine 50% water-soluble 
powder of Dopharma (Raamsdonksveer, the Netherlands)) through the drinking water 
for five consecutive days with an intended dose of 30 mg kg-1 total body weight. To 
obtain incurred samples with high concentrations of Flu, animals were slaughtered 
directly after the treatment with Flu.  
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Sample preparation for broiler serum samples 
Chicken serum (20 µl) was pipetted into a 96 well microtiter plate and 40 µl of 
sample buffer (HBS-EP to which 5 g l-1 CM-dextran sodium salt, 0.3 M sodium 
chloride and 0.05% Tween 80 were added) and 40 µl of diluted antiserum (final 
bleeding of MH41 which was diluted 25 times in sample buffer) were added. For the 
calculations of concentrations of Flu in serum, a calibration graph was prepared by 
adding 40 µl of standard solutions of Flu in sample buffer to the 20 µl of a blank 
sample and 40 µl of diluted antiserum. The standard solutions added were 400; 200; 
100; 50; 25; 12.5; 6.25 and 3.125 ng ml-1, which resulted in final concentrations of 
160; 80; 40; 20; 10; 5; 2.5 and 1.25 ng ml-1 in the well and 800; 400; 200; 100; 50; 25; 
12.5 and 6.25 ng ml-1 of broiler serum.  
 
Sample preparation for muscle samples 
Broiler muscle was grinded and 1 g was extracted with 5 ml of sample buffer during a 
10 min head over head mixing. After centrifugation (3500 rpm during 10 min), 20 µl 
of the extract was pipetted into a well of a 96 wells microtiter plate and 40 µl of 
diluted antiserum (25 times diluted in sample buffer) and 40 µl of buffer were added. 
For the calculations of concentrations of Flu in muscle, a calibration graph was 
prepared by adding 40 µl of standard solutions of Flu in sample buffer to the 20 µl of 
a blank muscle extract and 40 µl of diluted antiserum. The standard solutions added 
were 400; 200; 100; 50; 25; 12.5; 6.25 and 3.125 ng ml-1, which resulted in final 
concentrations of 160; 80; 40; 20; 10; 5; 2.5 and 1.25 ng ml-1 in the well and 4000; 
2000; 1000; 500; 250; 125; 62.5 and 31.2 ng g-1 of broiler muscle.  
 
 
RESULTS AND DISCUSSION 
 
Evaluation of Flu antisera in the ELISA 
The sera obtained from the different bleedings of the two rabbits (MH41 and MH42) 
were compared for optimum dilution in the ELISA (final dilution (fd) resulting in an 
absorbance op 1.0). All bleedings, except for the final bleeding (fb), were taken at 4 
weeks intervals and 10 days after the booster injections. The fbs were, due to a 
misunderstanding, taken 4 months after the last booster injection. The highest titers 
(1/100000) were obtained with the large bleedings taken before the fbs. The titers of 
the fbs were two (MH41) and five times (MH42) lower.  
The dilutions of the antisera (fbs) and HRP dilutions, as well as sensitivity towards 
Flu and specificity were comparable using antiserum MH 41 (against Flu-BSA) and 
MH 42 (against Flu-KLH). The antisera and the Flu-HRP were used in final dilutions 
(fd) of 6000 and 100000 times, respectively. A calibration curve of Flu in buffer 
(PBS) showed a 50% inhibition at 5 ng ml-1. This is a comparable sensitivity as 
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obtained with the last large bleedings and as obtained in a direct competitive ELISA 
[12] with polyclonal antibodies raised in sheep (50% inhibition at 30 ng g-1 of kidney 
using a 10% kidney homogenate) and 100 times more sensitive than obtained in assay 
buffer in an indirect competitive ELISA [13] using polyclonal antibodies against Flu 
extracted from chicken eggs (IgY). The specificity was tested with standard solutions 
of different (fluoro)quinolones and no cross-reactivity (<0.1%) was found with 
enrofloxacin, oxolinic acid, lomefloxacin, ofloxacin, enoxacin, norfloxacin, 
cinoxacin, naldixic acid, piromidic acid, difloxacin, marbofloxacin and ciprofloxacin. 
This specificity was also described with the other polyclonal antisera against Flu [12-
13] and is explainable by the deviating structure of Flu (Figure 1). 
 
BIA 
 
Preparation and testing of the biosensor chip 
The total surface (0.5 cm2) of the CM5 chip was bench top coated with Flu and, after 
washing with three 5 µl injections of 50 mM NaOH, the average absolute response 
measured in the four Fcs was 21900 ± 380 RU which was approximately 1600 RU 
higher compared with a blank untreated chip surface.   
 
Figure 2:  Typical sensorgram showing a complete cycle involving an injection of a  zero 
standard solution followed by the double regeneration procedure (0.5 min injection with 0.2 
M HCl followed by a 1 min injection with 0.2 M NaOH + 20% acetonitrile).  
 
Of the two rabbits (MH 41 and 42), the three last bleedings (bleeding 4, 5 and fb) 
were tested in the Biacore. Just as with the ELISA, the bleedings 4 and 5 could be 
used more diluted than the fbs (fds of 1000-2000 versus 400 for the fb). Injecting (2 
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min at a flow rate of 25 µl min-1) the fbs of MH 41 and 42 in a fd of 400 times 
resulted in maximum responses of 700-800 RU. In the final protocol, the antiserum 
(fb of MH41) was even less diluted (fd = 62.5 times) to obtain a robust assay with 
high maximum relative responses (>2000 RU, see Figures 2 and 3). Compared with 
the ELISA, the BIA under these conditions, consumes about 100 times more of the 
antiserum. The higher consumption of antibodies in a BIA compared to an ELISA 
(about 10 times) was described previously for a sulfonamide assay [14] and the higher 
consumption of antibodies is, in general, considered as a disadvantage of such fast 
assays. For the removal of the bound antibodies and re-use of the chip, different 
reagents were tested and the best results were obtained by the injection of 0.2 M HCl 
(0.5 min) followed by a 1 min injection of 0.2 M NaOH + 20% acetonitrile. As shown 
in Figure 2, the second regeneration step (Reg.2) had much more effect than the first 
regeneration step (Reg.1). However, both regeneration steps were necessary for a 
stable baseline during a series of injections of standards and samples.     
A calibration curve of Flu in sample buffer showed 50% inhibition at 2.5 ng ml-1 
(Figure 3) and, compared with the ELISA, this is two times more sensitive.  
 
BIA in broiler serum   
Prior to the injection into the Biacore, broiler serum was diluted in sample buffer. For 
the possible future combination with the other assays in broiler serum (e.g. anti-
salmonella and sulfonamides), a previously applied sample buffer, with additives to 
reduce non-specific binding (CM-dextran sodium salt, a high concentration of sodium 
chloride and Tween 80), was used.  
 
Figure 3. Calibration graphs of Flu in sample buffer, broiler serum and muscle. 
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Just as with the sulfonamide assay, broiler sera were five times diluted in this sample 
buffer. To evaluate the performance of the BIA in broiler serum, calibration curves of 
Flu were prepared in blank broiler serum. In the final format, a two-fold serial dilution 
series was prepared starting from 800 ng ml-1 of broiler serum. As shown in Figure 3, 
compared with the calibration curve of Flu in buffer, the presence of chicken serum 
had an effect on the calibration curve (shift to the right) which only partly could be 
explained by the dilution step (factor of 5). Because of this matrix effect, 
quantification of Flu in serum should be performed with the help of calibration curves 
in broiler serum. Using such calibration curves, the limit of detection (LOD = the 
concentration at the average relative response minus 3 times the standard deviation 
(S.D.)) of 15 ng ml-1 of broiler serum was determined after analysing 21 blank broiler 
serum samples. This resulted in a measuring range of 15 - 800 ng ml-1 of broiler 
serum.  
 
Survey  
Broiler sera (n=310) were obtained from 31 different flocks of 31 different Dutch 
farms (10 sera from each farm). Except for one sample (containing 130 ng ml-1), all 
samples obtained from the 31 farms were found negative (< LOD of 15 ng ml-1). 
Another 116 serum samples from the same flock of which the positive sample came 
from and which were taken at the same time, were analyzed and in 77 samples, the 
concentrations were found below the LOD and in the other 39 samples, the 
concentrations varied from 15 to 50 ng ml-1.  
 
BIA in broiler muscle   
For the detection of Flu in muscle, an easy sample preparation procedure was 
selected. The homogenized muscle sample was extracted with buffer (1 g + 5 ml) and 
further diluted (five times) in an anti-Flu containing buffer of which an aliquot was 
injected into the Biacore. In Figure 3, a calibration graph, obtained with fortified 
muscle extract, with a 50% inhibition at about 200 ng g-1 is shown. Blank muscle 
samples obtained from 21 different broilers were analyzed and the average 
background concentration found was 6 ± 6 ng g-1, resulting in an LOD of 24 ng g-1 
(average + 3 times S.D.). The same samples (n=21) were spiked with Flu at 200, 400 
and 800 ng g-1 and analyzed spread over 3 days by one technician and the average 
concentrations found were 150 ± 30, 265 ± 61, and 527 ± 135 ng g-1, respectively and 
the average recoveries ranged from 68 till 75%.  
Considering the BIA for muscle as a quantitative screening method and using the data 
obtained with the samples fortified at the MRL (400 ng g-1), the decision limit (CCα) 
and the detection capability (CCβ) were calculated according to the validation 
procedures prescribed in the European Commission Decision 2002/657 [15] as 500 ng 
g-1 (MRL plus 1.64 times the corresponding S.D. (1.64 x 61 ng g-1)) and 600 ng g-1 
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(CCα + 1.64 x 61 ng g-1), respectively. For a screening assay, only CCβ, which is the 
concentration at which the method is able to detect permitted limit concentrations 
with a statistical certainty of 1-β, is mandatory [15]. 
By mixing the proper amounts of incurred and control materials, muscle samples of 
broilers were prepared with concentrations of Flu of approximately 0.5, 1 and 2 times 
the MRL (400 ng g-1). The preparation of these materials and the results obtained by 
LC-MS/MS analyses, averages of 10 randomly selected and in duplicate analysed 
samples (see Table 1), were presented during the 5th International Symposium on 
Hormone and Veterinary Drug Residue Analysis (May 16-19, 2006, Antwerp, 
Belgium) [17]. In Table 1, the results obtained with the LC-MS/MS method 
(considered as reference method in which data are corrected for recovery by the 
application of a calibration curve in the matrix) are compared with the BIA results 
(average of four analyses each in which data were not corrected for recovery) and, 
although the average concentrations found by the BIA were 20% lower (at one and 
two times MRL) than found by LC-MS/MS (explainable by the 66-75 % recovery in 
the BIA), a high correlation (R2 = 0.9982) was found.  
 
Table 1: Average concentrations of Flu as found by the BIA (n=4) and by LC-MS/MS (n=10) 
in incurred muscle samples.  
RESULTS (ng g-1)  
Incurred samples MRL* BIA LC-MS/MS 
0.5 81 ± 16 82 ± 6 
1 248 ± 6 312 ± 12 
2 447 ± 48 562 ± 23 
* Mixed muscle samples from treated and untreated broilers aiming for levels of 0.5, 1 and 2 
times MRL. 
 
Animal experiment  
Using the normal sample preparation (five times diluted sera), the serum samples 
from the treated broilers (n=22) were analyzed and in 85% of the samples 
concentrations outside the range of the calibration curve (>800 ng ml-1) were found. 
The sera were diluted an extra 10 times with blank broiler serum and the 
concentrations found (corrected for the dilution) varied from 500 to 2400 ng ml-1 with 
an average of 1740 ± 550 ng ml-1. The concentrations in the corresponding muscle 
samples, as measured with the BIA, varied from 85 to 645 ng g-1, with an average of 
495 ± 132 ng g-1. The data obtained in serum and muscle samples were not corrected 
for recoveries. As shown in Figure 4, all serum samples had higher concentrations of 
Flu than the corresponding muscle samples with an average serum/muscle ratio of 3.5. 
However, the correlation (y=2.9314x + 292) between the concentrations of Flu found 
in the individual sera (y-axe) and muscle samples was rather low (R2= 0.50). This was 
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probably caused by the fact that all samples were obtained at the same time directly 
after treatment and by possible differences in intestinal absorption of Flu by the 
individual broilers.  
From literature, the serum/tissue ratio of Flu is unknown. For two other quinolones 
(danofloxacin and enrofloxacin) in orally treated broiler chickens, steady state tissue 
concentrations markedly exceeded plasma concentrations [16]. The average 
concentrations in muscle were 2.1 and 2.5 times higher compared to levels in plasma 
(showing averages of 120 (for danofloxacin) and 520 ng ml-1 (for enrofloxacin)). 
Previously, high serum/muscle ratios in broilers were reported [4] for 
sulfamethoxazole (6.2) and sulfadiazine (8.7). 
 
 
Figure 4. Correlation between Flu concentrations in broiler serum and muscle, as determined 
with the BIA, showing the variation of the serum versus muscle concentrations around the 
average serum/muscle ratio of 3.5 (y=3.5x) and showing that this ratio was above 1 (y=x) for 
all broilers.  
 
Flu in serum as predictor of Flu levels in muscle 
MRLs for Flu are established for the edible parts of broilers only. However, according 
to the project aim, an action limit in serum should be established to guarantee Flu 
levels in muscle below the MRL of 400 ng g-1. Because all sera from the animal 
experiment contained higher concentrations than the corresponding muscle samples, 
the MRL in muscle of 400 ng g-1 was chosen as the minimum required performance 
limit (MRPL) in broiler serum. From 21 different blank broiler serum samples spiked 
at MRPL level, the decision limit CCα in broiler serum was calculated as 460 ng ml-1 
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(MRPL plus 1.64 times the corresponding S.D.) and the detection capability CCβ was 
calculated as 520 ng ml-1 (CCα + 1.64 times the corresponding S.D.). 
In broiler serum samples from the animal experiment (n=22), the concentration of Flu 
ranged from 500 till 2400 ng ml-1 of which 21 samples were non-compliant (>CCβ) 
and one sample was compliant with a concentration just below CCβ (506 ng ml-1). 
The Flu concentration in the corresponding muscle sample was 85 ng g-1 (no false 
compliant result). Three of the 21 muscle samples of which the corresponding sera 
samples were non-compliant (>CCβ) contained Flu concentrations below the MRL of 
400 ng g-1, which results in a percentage of false non-compliant results of 14. 
 
 
CONCLUSIONS 
 
The polyclonal antiserum-based BIA for Flu in broiler serum and muscle is a 
quantitative screening assay and it proved to be robust (thousands of cycles per chip), 
specific (no cross-reactivity with other quinolones), fast (7.5  min per sample) and, 
due to the simplicity of the sample preparation procedures, easy to apply and with 
suitable measurements ranges (15 to 800 ng ml-1 for serum and 24 to 4000 ng g-1 for 
muscle) which can simply be adapted by changing the sample (extract) volumes.  
Concentrations of Flu in sera of treated broilers (obtained directly after treatment) 
were higher than the concentrations found in the corresponding muscle (with an 
average ratio of 3.5). The MRL in muscle was chosen as the MRPL in serum and the 
CCβ in serum, calculated as 520 ng ml-1, was proposed as action level. In the future, 
such an action level should be confirmed by analyzing serum and muscle samples in 
which different withdrawal times are applied.  
Although the conditions of the Flu BIA were adapted to previously prescribed 
conditions for the assays for sulfonamides and anti-salmonella, a combined assay still 
has to be tested. Such a combined assay should also include an assay which detects 
other allowed quinolones (danofloxacin, difloxacin, enrofloxacin and ciprofloxacin). 
Such a group-specific antiserum for (fluoro)quinolones was developed and  applied in 
an SPR biosensor assay for the determination of fluoroquinolone residues in egg, 
chicken muscle and fish [18]. The application of the combination of both biosensor 
assays was described in a dual SPR biosensor immunoassay-directed identification of 
fluoroquinolones in chicken muscle by liquid chromatography electrospray 
quadrupole time-of-flight mass spectrometry [19]. The application of the combined 
assay in broiler serum is ongoing. 
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CONCLUSIONS 
 
Searching for an assay which could detect most of the relevant sulfonamides, the 
approach in which antibodies were raised against the generic structure of the 
sulfonamides was partly successful. Monoclonal antibodies (Mabs) were obtained 
which recognized different sulfonamides, however, they were less sensitive for other 
sulfonamides. The use of mutated recombinant antibodies (Rabs), after the 
modification of the single chain variable fragment (scFv) molecules of the wild-type 
Mab 27G3, resulted in improved immunoassays. The applications of two genetically 
modifications (mutants A.3.5 and M.3.4) and the wild-type Mab 27G3 were evaluated 
in the biosensor using a CM5 sensor chip coated with the sulfonamide-derivative (TS, 
see Chapter 5) and chicken serum as sample material (Haasnoot et al., 2005a). The 
improvements in inhibition, due to the presence of different sulfonamides added to 
chicken serum at the 100 ng ml-1 level, are shown in Figure 1 for the three antibodies.  
 
 
Figure 1. Inhibition (%) of the maximum responses, obtained with a BIA, due to the presence 
of different sulfonamides (100 ng ml-1) added to a blank chicken serum using the wild-type 
Mab 27G3 and mutants A.3.5 and  M.3.4. Chicken serum (20 μl) was diluted with 100 μl of 
the antibody-containing buffer of which 50 μl was injected at a flow rate of 20 μl/min 
(Haasnoot et al., 2005a). 
 
With the wild-type Mab 27G3 and mutants A.3.5 and M.3.4, the number of 
sulfonamides showing significant inhibitions of the response (>20%) were 7, 12 and 
17, respectively. The performance of the best mutant was compared in a biosensor 
immunoassay (BIA) format with other multi-sulfonamide antibodies and it was found 
to be the most sensitive towards most of the sulfonamides. 
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In comparison to Pabs and Mabs, the with the phage display technique obtained Rabs 
can be developed faster, in a more automatic process and with reduced or no 
consumption of laboratory animals (Brichta et al., 2005) and the Rab technology 
should be considered as a promising tool for future antibody development. However, 
in my experience, it took four years (the full Ph.D.-period of Dr. Korpimäki 
(University of Turku, Finland)) to develop and improve the anti-sulfonamide Rabs, 
which might be the reason why the number of available Rabs is still limited. The Rab-
based BIAs were successfully applied to the detection of sulfonamides in serum and 
levels were higher and correlated well with levels in tissue as measured with LC-
MS/MS (Haasnoot et al., 2005b).  
Such a biosensor was also used for the detection of serum antibodies against 
Salmonella in chicken blood, in which recombinant DNA antigens were immobilized 
on the chip surface, and the results obtained suggested that this approach could be 
used for detecting past or present infections with a range of pathogens in animals 
(Jongerius-Gortemaker et al. (2002)). A comparable fast assay (testing in minutes) 
was developed for the detection of antibodies directed to Salmonella sero-groups B 
and D in porcine blood sera in a routine setting (Achterberg, et al., 2005) and was 
marketed (GE Healthcare) in combination with high-throughput equipment (8-channel 
Biacore Q100) with a capacity of up to eight samples in four to five minutes and a 96-
well plate within one hour. Of one of the sulfonamide assays (using mutant M.3.4), 
the conditions were successfully adapted to the serological assay conditions (higher 
salt  and carboxymethylated-dextran (CM-dextran) concentrations) by which the 
antibody concentration had to be increased as well (Haasnoot et al., 2005b). Under 
these conditions, the assay still worked perfectly well and this indicated the possibility 
for the simultaneous detection of anti-pathogens and residues of animals drugs which 
is an interesting combination for future research to broaden the application area in 
food safety control systems.  
The successful combination of immunoassays was already demonstrated in this thesis 
with the simultaneous detection of five aminoglycosides in milk in which four 
different assays were combined and with the flumequine BIA which was successfully 
coupled to a multi-fluoroquinolones BIA ( Marchesini et al., 2007a). 
In conclusion, serum and milk are suitable sample materials for the biosensor 
detection of antibiotics in the food chain. Such assays are fast, robust, automated, easy 
to handle, and require simple sample preparations (dilutions in antibody-containing 
buffer). However, the applied four-channel biosensor systems are expensive, too 
limited in multiplexing and antibodies are too specific for the simultaneous detection 
of antibiotics from different groups and the systems are therefore less suitable for 
control agencies and food industries to provide an increased and more efficient 
control on food contaminants (such as antibiotics) in the food chain. Cheaper 
alternatives and more extended multiplex systems need to be explored in which the 
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knowledge obtained and unique reagents prepared in the present research will likely 
be of great value and are used at present to study the application of some of the other 
promising systems described hereafter in the future perspectives. 
 
FUTURE PERSPECTIVES 
 
Biosensors 
The application of a low-cost SPR-based prototype biosensor system (SpreetaTM) has 
been described previously (Marchesini et al., 2007b) in which the sensitivities with 
inhibition assays for endocrine disruptors were comparable to those obtained with a 
Biacore 3000. However, this system was less robust and built with a single flow-
channel only. Alternative eight-channel SPR sensor instruments were developed and 
used for the detection of low molecular weight endocrine-disrupting compounds 
(Dostálek et al., 2007) and an environmental contaminant in a miniaturized and 
portable format (Kim et al., 2007), which are interesting approaches for future 
research. Beyond that, an SPR system with the possibility for the simultaneous 
detection of 20 spots in 4 flow-channels (Biacore A100) is available (GE Healthcare). 
The SPR imaging (iSPR) technology takes multiplex SPR analysis a step further.  
 
 
 
Figure 2. a) Schematic diagram of SPR imaging. b) Calculated SPR reflectance curve for a 
pure gold surface, a reactant dot and adsorbed analyte molecules on a reactant dot. c) The 
contrast of the SPR image is based on the different reflectance rA>rR>rAU. (Steiner, G., 2004). 
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With iSPR (Figure 2), broad-beam monochromatic polarized light from a laser diode 
(at a specific wavelength) illuminates the whole functionalized area of the biosensor 
chip surface. The high resolution CCD video camera provides real-time difference 
images across the array format with up to hundreds of active spots and it captures all 
of the local changes at the surface of the biochip. There are several commercial iSPR 
instruments available, e.g. Biacore Flexchip (GE Healthcare), SPRi-PlexTM 
(Genoptics Bio interactions), ProteOnTM XPR 36 (Bio-Rad laboratories), 
SPRimager®II ARRAY system (GWC Technologies) and IBIS iSPR (IBIS 
Technologies B.V.). The instruments differ in optics, fluidics, sample handling and 
surface preparation. Rebe Raz et al. (2008) applied the IBIS iSPR and developed an 
inhibition immunoassay for gentamicin and neomycin which displayed a sensitivity at 
the low ng ml-1 level which is comparable with assays performed in the Biacore 3000. 
By combining more immunoassays on one sensor chip, such instruments will be 
highly relevant for multi-analyte screening of various food contaminants.  
Another interesting automated multiplex biochip array technology (Evidence®) is 
marketed by Randox (www.randox.com) in which 25 immunoassays can be measured 
simultaneously using chemiluminescent signals and spots are measured with a CCD 
camera. They supply arrays for growth-promoters and antimicrobials but a major 
disadvantage is that it is a closed system which is not suitable for assay development. 
The different immunoanalytical microarray systems based on fluorescence, 
chemiluminescence, electrochemical, and label-free microarray readout systems have 
recently been reviewed by Seidel & Niessner (2008) and they also included an 
interesting and commercially available suspension microarray on a flow cytometer. 
 
Flow cytometry 
This promising and evolving suspension microarray is the Multi Analyte Profiling 
(xMAP®) technology (Luminex, 2007), which is an open system suitable for assay 
development. This technology uses small carboxylated polystyrene microspheres (5.6 
μm beads), which are internally dyed with a red and an infrared fluorophore. By 
varying the ratio of the two fluorophores, up to 100 different color-coded bead sets 
can be distinguished, and each bead set can be coupled to a different biological probe. 
In combination with flow cytometry, it is possible to simultaneously measure up to 
100 different biomolecular interactions in a single well. The carboxylated bead 
surface allows simple chemical coupling of capture reagents such as antibodies or 
drug-protein conjugates. This technology was already applied for the detection of 
sulfonamides in milk (Keizer de, et al., 2008) and in blood serum, meat drip and eggs 
(Bienenmann-Ploum, et al., 2008) using the Rab M.3.4 and for the simultaneous 
detection of aminoglycosides and sulfonamides in milk and blood serum (Haasnoot, et 
al., 2008). These experiments demonstrate that this technology is suitable for 
multiplexing of antibiotic assays in food materials and it is a serious option for future 
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multiplex applications. A five-fold increase in multiplexing capabilities can be 
obtained with the FlexMAP 3DTM platform of Luminex, using a third fluorophor, 
which offers 500-plex capability and runs three times faster compared with the 
Luminex100 or -200 systems. More relevant to food diagnostics is the development of 
the new Luminex multiplex platform called MagPixTM which is a low-cost, compact, 
rugged, diagnostic and environmental testing xMAP analyzer which moves away 
from a flow cytometry-based system to an instrument based on their already existing 
magnetic bead array (MagPlexTM) analyzed on a magnet in a 2D readout with 
inexpensive Light Emitting Diodes (LEDs) and a CCD imager. It is expected to be 
launched in 2010 and this development will make future multiplexing faster, cheaper 
and more robust and applicable in the food chain.  
 
Nanoparticles 
The former described particles used in flow cytometry are on a microscale and 
nanoparticle research is currently an area of intense scientific investigations, due to a 
wide variety of potential applications in biomedical, optical, and electronic fields. 
Nanoparticles (NPs) are defined as particles having one or more dimensions in the 
sub-100 nanometer range (BSI, 2005). In analytical biochemistry, they are used as 
biosensor response enhancers (Guo and Dong, 2009) and as labels in clinical and food 
diagnostics due to their unique characteristics as the high surface-to-volume ratio and 
the size-dependent optical or magnetical properties.  
Gold NPs (25 nm) were used by Mitchell and Lowe (2009) as response enhancers (by 
increased mass and gold plasmon coupling effect) in an SPR BIA for the detection of 
steroids. The biosensor chips were coupled with the steroids via oligoethylene linkers 
and the responses obtained with the anti-steroid primary antibodies were about 13-
fold enhanced with a secondary antibody labeled with the gold NPs. Due to this 
enhancement, the primary antibody concentration could be reduced which resulted in 
a 12.5-fold increase in sensitivity. Yuan et al. (2008) reported about the use of larger 
gold NPs (40 nm) for signal enhancement on a mixed self-assembled monolayer 
(mSAM) sensor surface which resulted in 21.5 fold increase in signal and, due to a 
large reduction in antibody concentration, in a 30 times more sensitive assay for 
chloramphenicol.  
The use of gold NPs and other new nanodiagnostic tools (e.g. quantum dots (QDs)) 
for diagnostic applications promise increased sensitivity, multiplexing capabilities, 
and reduced costs (Azzazy et al., 2006). The nanometer sized colloidal gold particles 
are frequently used as labels in lateral flow tests (Wang et al. (2007)) because of their 
ability to adhere proteins (e.g. antibodies) and their intense red color which is due to 
localized SPR (LSPR) a common phenomenon for nanometer-sized metallic 
structures (Hutter and Fendler, 2004). Localized surface plasmons (LSPs) are charge 
density oscillations confined to metallic NPs. Excitation of LSPs by an electric field 
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(light) at an incident wavelength where resonance occurs results in strong light 
scattering, in the appearance of intense surface plasmon (SP) absorption bands, and an 
enhancement of the local electromagnetic fields. The frequency (i.e. absorption 
maxima or color) and intensity of the SP absorption bands are characteristic of the 
type of material (gold, silver or platinum), and highly sensitive to the size, size 
distribution, and shape of the nanostructures, as well as to the environments which 
surround them. The fact that the color of metallic NPs depends markedly on the 
refractive index of the surrounding medium has been exploited for sensing 
applications. LSPR sensing is based on a simple optical extinction measurement, is 
not temperature sensitive, and requires only common laboratory equipment. 
Molecular interaction analysis of gold NPs on a solid transparent substrate (glass), to 
avoid the possibility of aggregation, have been reported by several groups. Such an 
LSPR-based immunosensor was developed for the detection of casein in milk (Hiep et 
al., 2007) in which anti-casein antibodies were immobilized to gold-capped silica NPs 
on a glass slide substrate and the binding of casein could be monitored by the peak 
absorbance intensity increments at around 520 nm using a UV-Vis spectrophotometer. 
Kreuzer et al. (2008) developed an LSPR-based biosensor for the detection of 
stanozolol using gold colloids (100 nm), coated with a stanozolol-protein conjugate, 
chemically sized on an activated glass substrate. Binding of anti-stanozolol antibodies 
was observed by a shift of the resonance wavelength (with a maximum of 13 nm) and 
the detection limit of the system was calculated as 2.4 nM or 0.7 ng ml-1.  Gold-silica 
core nanoshells, spherical silica core surrounded by a gold shell of a few nanometers 
in thickness, with different core/shell ratios result in different optical resonances and 
can be used for multiplexing (Prodan, et al., 2003). Advantages of the LSPR devices 
were described as the simplicity of the optical configuration, easy fabrication, the 
great potential for miniaturization, simple handling, low-cost, short assay times, and 
high sensitivity.  
Advances in nanomaterials have produced a new class of fluorescent labels which is 
more suitable for multiplex detection by conjugating semiconductor nanocrystals, also 
known as quantum dots (QDs), with biorecognition molecules (Chan et al., 2002). 
These QDs (2-8 nm) are atom clusters comprising a core, shell, and coating. The core 
is made up of a few hundred to a few thousand atoms of a semiconductor material 
often composed of atoms from group II-VI (e.g. CdSe, CdTe, CdS, and ZnSe) or 
group III-V elements (e.g. InP and InAs) in the periodic table. A semiconductor shell 
(typically zinc sulfide) surrounds and stabilizes the core, improving both the optical 
and physical properties of the material. An amphiphilic polymer coating then encases 
the core and shell, providing a water-soluble surface that can be modified. For some 
of these QDs, this amphiphilic inner coating is covalently modified with a 
functionalized polyethylene glycol (PEG) outer coating to reduce nonspecific binding. 
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By varying the size and composition of QDs, the emission wavelength can be tuned 
and the broad absorption spectra, useful for the simultaneous excitation of different-
sized QDs, and narrow symmetric emission spectra make QDs very well suited to 
optical multiplexing (Algar et al., 2009). More multicolor optical coding for 
biological assays has been achieved by embedding different-sized QDs into polymeric 
microbeads at precisely controlled ratios (Han et al., 2001). Other advantages of QDs 
are excellent brightness, negligible photobleaching, fairly high quantum yields, and 
photostability. These extraordinary fluorescence properties can be attributed to the 
unique fluorescence mechanism of semiconductor materials which fluoresce through 
the formation of excitons, or Coulomb-correlated electron-hole pairs, upon absorption 
of a photon of light. Compared with the excited state of a fluorophore, this exciton 
typically exhibits a much longer lifetime (up to about 200 nanoseconds). For 
diagnostic multiplex applications, a set of seven amine-, or carboxyl-derivatized or 
streptavidin-labeled Qdot® nanocristals with a broad excitation and narrow symmetric 
emission properties (maxima at: 525, 565, 585, 605, 655, 705 and 800 nm) is 
commercially available (www.invitrogen.com). 
Highly monodisperse (1.57 ± 0.21 nm), ball-shaped and alkyl-functionalized silicon 
NPs (Si NPs) have been synthesized on a gram scale (Rosso-Vasic et al., 2008). Next 
to the size-dependent optical properties, the kind of surface influenced the 
photoluminescent properties as well. This phenomenon was the basis for a Dutch 
project (Functionalized silicon nanoparticles in multiplex diagnostics platforms 
(Nanoplex); http://www.onderzoekinformatie.nl/en/oi/nod/onderzoek/OND1334082/) 
[2008-2012] which will set a new test format by directly measuring multiplex 
biointeractions in solution (omitting flow cytometry) using (changes in) the different 
emission addresses of the Si NPs, both defining the type of biointeraction and the 
intensity.   
Although QDs have proven to be suitable labels in bioanalysis, their application in 
quantitative immunoassays is still limited. Ding et al (2006) developed a competitive 
fluorescence-linked immunosorbent assay (cFLISA) in a microtiter plate for the 
detection of sulfamethazine in chicken muscle tissue extracts using a commercially 
available QD (QD 655 (Quantum Dot Corp, Hayward, CA, USA) as the fluorescent 
label coupled to the secondary antibody. The same QD was used for the detection of 
enrofloxacin in chicken muscle tissue (Chen et al., 2009) and the high emission 
amplitude of the QD (655 nm) led to significant improvements in the signal to noise 
ratios of the final detected signals. Nichkova et al (2007) described the application of 
two commercially available QDs as labels in an immunoassay microarray for the 
simultaneous microscopic detection of two biomarkers of exposure to two major 
classes of compounds: pyrethroid insecticides and triazine herbicides. Goldman et al. 
(2004) prepared bioinorganic conjugates of highly luminescent nanocrystals (CdSe-
ZnS core-shell QDs) and antibodies to develop a four-plex immunoassay in a 
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microtiter plate for the simultaneous detection of four toxins (cholera toxin, ricin, 
shiga-like toxin 1 and staphylococcal enterotoxin B) in a single well using QDs with 
emission maximums of 510, 555, 590 and 610 nm.  
 
Artificial “antibodies” 
The most critical and time-consuming reagent in an immunoassay is the antibody and 
artificial “antibodies” such as molecularly imprinted polymers (MIPs) and aptamers 
are described as potential alternatives. These alternatives can be prepared in vitro, 
avoiding the need for animals, and against non-immunogenic and toxic targets. 
MIPs have been demonstrated to be a promising class of synthetic receptors 
that can be tailored to meet specific end-use recognition requirements. MIP 
technology is a general strategy of synthesis that allows preparation of polymeric 
materials with “memory” of a particular molecule (analyte). Most modern imprinting 
is performed through a process called non-covalent imprinting in which a template 
molecule interacts with a functional monomer to form a pre-polymerization complex 
in the presence of a solvent. The solvent is known as the porogen because of its role in 
pore forming during polymerization. A cross-linking monomer is added to the pre-
polymerization complex to form a scaffold around the binding site during polymer 
synthesis. The template is removed from the polymer and the result is a highly cross-
linked polymer with exposed imprinted cavities capable of analyte binding. The 
serious problem of interferences in analysis by bleeding of residual template (analyte) 
was successfully solved by the use of analogs as templates (Urraca et al., 2006). For 
antibiotics, HPLC, as for sulfadimethoxine (Hung et al., 2008), and molecularly 
imprinted solid-phase extraction (MISPE), as for fluoroquinolones (Turiel et al., 
2007), are the analytical techniques where MIPS have found most applications 
(Fernández-González et al., 2006). They are usually synthesized in bulk, ground, 
sieved, sedimented to remove fine particles and packed in columns. MIP-based SPE 
columns for the selective pre-concentration of the antibiotics chloramphenicol and 
fluoroquinolones (with high recoveries for sarafloxacin, norfloxacin, enrofloxacin, 
ciprofloxacin, lomefloxacin and ofloxacin) are commercially available via the 
company MIP Technologies (http://www.miptechnologies.com). While the selectivity, 
high capacity, robustness, low costs, and easy handling and synthesis of MIPs make 
them an ideal choice for the development of sensing devices, their use for antibiotic 
sensing is an unexplored field that deserves further research. In residue analysis, MIPs 
are most frequently described for mycotoxin detection (Urraca et al., 2006 and Appell 
et al., 2008). Yu and Lai (2005) described an SPR sensor (Spreeta) chip surface which 
was covered with a thin molecularly imprinted polypyrrole (MIPPy) film by 
electrochemical polymerization. The same procedure was followed be Choi et al 
(2009) for the preparation of a MIPPy film with zearalenone on bare gold biosensor 
chips. These chips were successfully applied for the direct detection of ochratoxin A 
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in wheat and wine extracts and zearalenone in corn extracts, which are interesting 
examples for future research with MIPs in the optical biosensors described in this 
thesis. 
Aptamers are oligonucleotides (DNA or RNA) with the ability to bind to non-
nucleic acid target molecules such as peptides, proteins and antibiotics with high 
affinity and specificity. They are isolated from combinatorial libraries of synthetic 
single-stranded nucleic acids of 1014-1015 DNA or RNA molecules containing a 
random region flanked on both sides with fixed primer sequences for amplification. 
This isolation by exponential enrichment, via an in vitro iterative process of 
adsorption, recovery and reamplification is known as systematic evolution of ligands 
by exponential enrichment (SELEX). The enriched library is cloned and sequenced, 
and individual sequences are chosen for their best affinity and specificity. The final 
selected aptamer(s) can now be produced in sizeable quantities by chemical syntheses. 
The high affinity of aptamers for their targets is given by their capability of folding 
upon binding their target molecule. They can incorporate small molecules into their 
nucleic acid structure or integrate into the structure of larger molecules such as 
proteins. Thanks to their unique characteristics and chemical structure, aptamers offer 
themselves as ideal candidates for use in analytical devices and techniques. The 
mainly clinical applications are reviewed (Tombelli et al., 2005; Hamula et al., 2006 
and Mairal et al., 2008). Aptamers have been selected for binding to several 
antibiotics (tetracyclines, aminoglycosides, chloramphenicol and viomycin (Lorenz 
and Schroeder, 2006) however they were used to study the mode of interaction of 
these antibiotics with RNA and not in a screening assay. Stead et al. (2008) described 
the first aptamer-based and food control-related screening assay for the detection of 
malachite green in salmon tissue extracts. The assay uses an RNA-based aptamer with 
an affinity for malachite green of which the complex showed a circa 2000 times 
increase in fluorescence signal and this detection principle was used for the 
spectrofluorimetric detection. They described a rapid complex formation (within 10 
min) and the complex was found to be stable for circa 18 hours. It should be 
mentioned that malachite green was known to bind to RNA and DNA at forehand 
since it has been used as an interacting dye for many years. A further broadening of 
aptamers into an area as food control will have to address the new challenge of 
complex matrices. However, just as with antibodies, MIPs and aptamers are relatively 
target specific. 
 
Bio-effect related assays 
For the broader detection of compounds or bio-effect related detections, the 
application of whole cells or other biomolecules (transport proteins or receptors) 
might be more interesting for future applications in food diagnostics. For the detection 
of tetracyclines in poultry tissue, such a whole-cell-based bioassay in a 96-well 
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microtiter plate format, based on a genetically engineered luminescent bacterial strain 
containing the regulation unit of tetracycline resistance factor, has been applied 
(Virolainen et al., 2008). This assay is better suited for high-throughput analysis and 
has the potential to displace growth inhibition assays. However, such bioassays are 
not yet described for other antibiotics although the use of the multidrug-binding 
repressor protein (QacR) from Staphylococcus aureus (Schumacher et al., 2001) 
might be an interesting approach for the future development of a multi-drug biosensor. 
Currently, cellular biosensors, based on various microbial species containing reporters 
which are specifically induced via selected promoters, are more widely used in 
pharmaceutical drug discovery and in environmental biology (Urban et al., 2007) and 
for monitoring environmental chemical contaminants (Patel, 2006) and this will also 
influence the development of new bioassays for the detection of antibiotics in food.  
Whole cell-based assays need incubation times of a few hours and by the use of their 
functional ingredients (e.g. receptors) in multiplex diagnostic platforms, faster 
functional binding assays can be developed. Such fast receptor-based lateral flow tests 
are already commercially available for the detection of beta-lactams in combination 
with tetracyclines (e.g. Twin sensorTM of Unisensor (Angleur, Belgium)). The 
combination of a receptor assay for β-lactams antibiotics with antibody-based assays 
for groups of sulfonamides and fluoroquinolones in an ELISA format has also been 
described as an interesting option for multi-analyte detection (Adrian et al., 2008).  
 
According to an EU definition (2002/657/EC), screening methods are used to detect 
the presence of a substance or class of substances at the level of interest with the 
capability for a high sample throughput. They are used to sift large numbers of 
samples for potential non-compliant results and they are specifically designed to avoid 
false compliant results. Of the technologies described above, only two of the flow 
cytometers have high-throughput capacities (see Table 1). In my opinion, different 
potential end-users (e.g. farmers, inspectors, food industries, or control laboratories), 
require different strategies for screening (from low- to high-throughput, handheld to 
automated on-line devices and from single analyte to multiplex systems) and the 
suitability of the different technologies for the different end-users are presented in 
Table 1. The dip sticks or lateral flow tests are most suitable for farmers and 
inspectors, because of the lack of investment in equipment, easy format and 
performance and speed (minutes per sample), but they are most limited in multiplex 
capacity and qualitative results (compliant or suspected non-compliant) are obtained. 
All other suggested technologies are quantitative when calibrations curves are used 
for the calculations of concentrations. Multiplex capacities of more than 100 (like the 
FlexMap 3D and iSPR) are not very useful and realistic in food control. Future 
multiplexing will probably consist of combinations of 5 to 25 assays and most 
technologies are capable of handling that. The nanoparticle-based assays are limited 
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in multiplex capacity (<10) but some (e.g. LSPR) require less investment in 
equipment compared with the other technologies of which the cost-prices of the flow 
cytometers are estimated as <25 and 50 k€ for the MagPix and Luminex 200, 
respectively. 
 
Table 1. The possible multiplex capacity (MC (the estimated theoretically maximum number 
of assays in the multiplex format)), sample throughput (TP (high (H), medium (M) or low 
(L))), costs of investment in equipment (Inv. (high (H) >100 k€, medium (M) 25-50k€, low (L) 
<25 k€, or no costs (N)))), application format (AF (handheld (H), automated with on-site 
possibility (A), or not automated (N))) and end-users of the multiplex technologies described 
in the future perspectives. 
End-user  
Technology 
 
MC 
 
TP 
 
Inv. 
 
AF Farmer/ 
Inspector
Food 
industry 
Control 
labs 
Biosensors 
-  Multichannel 
-  iSPR 
-  Evidence 
 
20 
>100 
25 
 
M 
M 
M 
 
H 
H 
H 
 
A 
A 
A 
 
- 
- 
- 
 
+ 
+ 
+ 
 
+ 
+ 
+ 
Flow cytometry 
- Luminex 200 
- FlexMAP 3D 
- MagPix 
 
100 
500 
50 
 
H 
H 
M 
 
M 
H 
M 
 
A 
A 
A 
 
- 
- 
- 
 
+ 
- 
+ 
 
+ 
+ 
+ 
Nanoparticles 
- LSPR 
- QDs 
 
<10 
<10 
 
M 
M 
 
L 
M 
 
N 
N 
 
- 
- 
 
+ 
+ 
 
+ 
+ 
Dip sticks 4 L N H + + - 
- not or less suitable, + suitable  
 
The developments described above bring great promise for future custom-made and 
cost-effective screening assays in the different areas of the control of the food chain. 
The knowledge obtained from the research described in this thesis about the use of 
biosensors, chip surface coupling chemistries, assay formats, assay and regeneration 
conditions for the different antibiotic assays and for one in combination with the 
detection of anti-salmonella, sample behavior, antibiotic concentrations in serum, 
plasma and the different tissues, etc., and the unique reagents (Pabs, Mabs and Rabs 
and antibiotic-derivatives and conjugates) prepared within this research are of great 
value and are used at present to study the application of the other promising multiplex 
systems based on iSPR and flow cytometry. 
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The food chain is threatened by various hazards and the presence of residues of 
antibiotics, used during cattle-breeding, is one of the serious risks for consumers. In 
food analysis for antibiotics, screening technologies are powerful tools that provide a 
rapid screen of large numbers of samples when conventional analytical methods are 
too cumbersome. Due to their simplicity and high-throughput capacity, immunoassays 
are applicable for screening in the food chain. However, in general, they are very 
specific, and only suitable for the detection of one or two antibiotics, which seriously 
limits their application. New antibodies and assay formats with multiplex capacity 
might give new possibilities for control agencies and food industries for increased and 
more efficient controls on food contaminants.  
Surface Plasmon Resonance (SPR)-based optical biosensors with four serially 
connectable flow channels have been launched with claims as being suitable for fast 
(in minutes) four-plex assays, providing easy (label-free) detection and fully 
automated operation and the option for the direct detection of small molecules (as 
antibiotics). 
The aim of the research described in this thesis was to evaluate the application of 
these new optical biosensors as possible control instruments in the food chain with 
multiplex immunoassays for antibiotics as a model. To reduce the number of tests, the 
development and application of group-specific antibodies (with sulfonamides as 
model compounds) was explored together with their improved performances after 
protein engineering. Their application in biosensor immunoassays was investigated, 
together with the possibility to predict sulfonamide levels in tissue from levels in 
blood serum and the combined application with serological assays for anti-pathogens. 
The other antibiotics (aminoglycosides and flumequine) were used as models to 
explore different biosensor immunoassay formats and to study the interference of 
immunoassays in a multiplex format and the foreseen matrix interferences from 
protein-rich products as milk, meat extract and blood serum. The overall result should 
be an answer to the question: “Can biosensors fulfill the needs of control agencies and 
food industries to provide an increased and more efficient control on food 
contaminants (such as antibiotics) in the food chain?” 
In the introduction (Chapter 1), the background of antibiotics, their analysis, the 
applied biosensors and the different types of antibodies are described. Part I presents 
the development of multi-sulfonamide antibodies by the development of polyclonal 
(Pabs) and monoclonal antibodies (Mabs) against the generic ring structure of 
sulfonamides (Chapter 2). Hereto, a sulfathiazole derivative (abbreviated as TS) was 
synthesized and linked to carrier proteins in such a way that the aromatic amino group, 
common to all sulfonamides, was distal to the proteins. Mice were immunized with 
the TS-protein conjugates, and four different Mabs were obtained after the fusion of 
spleen cells of one of the mice with myeloma cells and the screening of the produced 
hybridomas supernatants. With an optimized ELISA protocol, the best of these Mabs 
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(Mab 27G3) showed 50% inhibition with eight structurally different sulfonamides at 
concentrations less than 100 ng ml-1 or 5 ng/well. Although this was a uniquely broad 
specificity with a never seen sensitivity, the sensitivity towards the different 
sulfonamides varied too much to call it a generic sulfonamide ELISA. In Chapter 3, 
the preparation of  Pabs against eight different sulfonamides is described. Here, the 
aromatic amino group, common to all sulfonamides, was used for linking to carrier 
proteins and, in ELISA’s, these antibodies showed high sensitivities and specificities. 
Their performances were compared with multi-sulfonamide Pabs raised against the 
generic structure of sulfonamides by the immunization with two sulfonamide 
derivatives (abbreviated as TS and PS) coupled to carrier proteins in such a way that 
the common structure was distal to the proteins. These Pabs recognized several 
structurally different sulfonamides. ELISA’s with the anti-TS Mabs (from Chapter 2) 
were found to be much more sensitive towards different sulfonamides as compared 
with another Mab described in literature. However, the sensitivity towards some 
important sulfonamides, such as sulfamethazine (= sulfadimidine), was low. 
Part II describes the development of multi-sulfonamide biosensor immunoassays 
(BIAs) based on broad-specificity Mabs and recombinant antibodies (Rabs) derived 
from one of them. In Chapter 4, the development of BIAs in chicken serum is 
described and different antibodies (one Mab and two Pabs), all raised against similar 
sulfamethazine-carrier protein conjugates, were used. Compared with the specific 
Pabs, the Mab 21C7-based BIA resulted in a better sensitivity for sulfamethazine 
detection and it was found suitable for the detection of 8 sulfonamides in 10 times 
diluted chicken serum with limit of detection (LODs) between 7 and 20 ng ml-1. In 
Chapter 5, the performance of this unique Mab was compared with another multi-
sulfonamide Mab supplied in a commercial kit (Qflex Kit Sulfonamides) and with a 
mutant antibody (M.3.4), which was derived previously from the anti-TS Mab. Each 
of these antibodies showed interactions with all 17 sulfonamides tested and one (Mab 
21C7) was sensitive for the N4-acetyl metabolites also. The mutant M.3.4-based assay 
was found to be the most sensitive towards most of the sulfonamides, whereas the 
Qflex Kit Sulfonamides detected the five sulfonamides registered for application in 
poultry in the Netherlands within the narrowest measurement range. In Chapter 6, the 
application of mutant antibodies (A.3.5 and M.3.4) in BIAs for the detection of 
sulfamethoxazole and sulfadiazine (most applied sulfonamides in broilers in the 
Netherlands) in serum and plasma samples from treated broilers is described. The 
assays were fast (5 min per sample), the sample preparation was easy (dilution in 
antibody-containing buffer only) and an equal sensitivity for the two sulfonamides 
was obtained with LODs in serum and plasma below 10 ng ml-1 (for the A.3.5-based 
BIA). The concentrations found with the BIA in serum and plasma of the treated 
broilers were comparable and higher than the concentrations found in tissue by LC-
MS/MS. To predict the concentrations of the two sulfonamides below the maximum 
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residue limit (MRL) of 100 ng g-1 in the tissue with the highest level (skin+fat), the 
proposed action level of the multi-sulfonamide BIA in serum is 130 ng ml-1.  
The latest mutant antibody (M.3.4), with a better sensitivity towards more 
sulfonamides, was applied during a survey in which sera of 1 out of 31 different 
flocks were found positive with low concentrations (25 ± 21 ng ml-1) of 
sulfamethoxazole. This BIA was performed under the conditions applied in the 
serological assay for the detection of three anti-salmonella serotypes which broadens 
the future application area. 
In Part III, the development of BIAs for aminoglycosides is described, starting with 
the direct assay, using antibody-coated biosensor chips, for gentamicin and 
(dihydro)streptomycin (Chapter 7). These BIAs even worked in milk far below the 
MRLs. In that chapter, the direct assay format for (dihydro)streptomycin was 
compared with the inhibition assay format using a streptomycin (STREP)-protein 
conjugate immobilized on the chip surface, and the sensitivities in buffer were 
comparable for both drugs in both formats. With milk, interferences, probably due to 
the nonspecific binding of milk proteins to the protein-coated sensor chips, were 
observed in both BIAs. These interferences could be reduced by the application of 
ultrafiltration as sample pretreatment or by the use of a reference flow channel. In 
Chapter 8, the development of a single BIA for the simultaneous detection of five 
aminoglycosides in reconstituted skimmed milk is described. Four aminoglycosides 
(gentamicin, neomycin, kanamycin and a streptomycin derivative) were directly 
(without coupling to proteins) immobilized onto the sensor surface in the four flow 
channels that were serially connected, and these flow channels were used in 
combination with a mixture of four specific antibodies. Milk samples were diluted ten 
times in the antibodies-containing buffer and the LODs in reconstituted milk were 
between 15 and 60 ng ml-1, which was far below the MRLs (varying from 100 to 1500 
ng ml-1).  
In Chapter 9 the development of a specific flumequine BIA is described. Such an 
assay was useful because flumequine is one of the fluoroquinolones most frequently 
applied for the treatment of broilers in the Netherlands and - at that time – could not 
be detected at the desired level with a multi-fluoroquinolone BIA. This assay was 
validated as a quantitative assay for the performance in broiler muscle. Applying an 
easy extraction procedure with buffer, the measuring range was from 4 to 4000 ng g-1 
(MRL = 400 ng g-1) and the decision limit (CCα) and the detection capability (CCβ) 
were determined as 500 and 600 ng g-1, respectively. Serum and muscle samples from 
flumequine-treated broilers were analyzed and the concentrations found in serum 
were always higher than those found in muscle (average serum/muscle ratio was 3.5). 
This proved the applicability of the BIA in serum as predictor of the flumequine 
concentration in muscle. 
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In conclusion (Chapter 10), blood serum and milk are suitable sample materials for 
the biosensor detection of antibiotics in the food chain. Such assays are fast, robust, 
automated, easy to handle, and require simple sample preparations (dilutions in 
antibody-containing buffer). However, the applied four-channel systems are 
expensive, too limited in multiplexing and the antibodies are too specific for the 
simultaneous detection of more antibiotics from different groups. Therefore, cheaper 
alternatives and more extended multiplex systems need to be explored, in which the 
knowledge obtained in the present research will likely be of great value. Possible 
alternatives - ranging from low-cost, imaging and localized SPR-based systems to 
other multiplex biochip and suspension microarray systems as well as nanoparticle-
based detections and the use of artificial “antibodies” (molecularly imprinted 
polymers (MIPs) and/or aptamers) or whole cell- or their functional ingredients-based 
assays - are described in the future perspectives (Chapter 10). This potential brings 
great promise for future custom-made and cost-effective screening assays in the 
different areas and at different control points in the food chain. 
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De voedselketen wordt bedreigd door verscheidene gevaren en de aanwezigheid van 
restanten van antibiotica, gebruikt in de veeteelt, is één van de serieuze risico’s voor 
consumenten. In voedselanalyse voor antibiotica zijn screeningsmethoden sterke 
instrumenten die het mogelijk maken om snel grote aantallen monsters te analyseren 
als conventionele analytische methoden te bewerkelijk zijn. Door hun eenvoud en 
grote doorvoercapaciteit zijn immunologische testen toepasbaar voor het screenen in 
de voedselketen. Over het algemeen zijn zij echter erg specifiek en daardoor alleen 
geschikt voor het tegelijkertijd detecteren van maar één of twee antibiotica waardoor 
hun toepassing wordt gelimiteerd. Nieuwe antilichamen en testvormen met multiplex 
capaciteiten zouden nieuwe mogelijkheden kunnen bieden voor controle-instanties en 
voedselindustrieën om meer intensieve en efficiëntere controles op voedselconta-
minanten te kunnen gaan toepassen. 
Op Surface Plasmon Resonance (SPR) gebaseerde optische biosensoren met vier 
serieel koppelbare vloeistofstroomkanalen zijn op de markt gebracht met claims als 
het geschikt zijn voor snelle (in minuten) vierplex testen, het verzorgen van een 
makkelijk (labelvrije) detectie en een volledig geautomatiseerde werking en de 
mogelijkheid voor de directe detectie (zonder labels) van kleine moleculen (zoals 
antibiotica). 
Het doel van dit proefschrift was om deze nieuwe optische biosensoren te evalueren 
voor hun mogelijke toepassing als controle-instrument in de voedselketen met 
multiplex immunologische testen voor antibiotica als een model. Om het aantal testen 
te verminderen, werd de ontwikkeling en toepassing van groepspecifieke antilichamen 
(met sulfonamiden als modelverbindingen) onderzocht samen met hun verbeterde 
verrichtingen na modificaties middels `protein engineering`. Hun toepassing in 
immunologische biosensortesten en om hiermee sulfonamideniveaus in weefsel te 
voorspellen aan de hand van niveaus in bloedserum alsmede de combinatie met 
serologische testen voor antipathogenen werden ook onderzocht. De andere 
antibiotica (aminoglycosiden en flumequine) werden als modellen gebruikt om de 
verschillende vormen van immunologische biosensortesten te onderzoeken. 
Onderzoek naar interferenties van dergelijke testen in een multiplex vorm en de 
voorziene matrixinterferenties van eiwitrijke producten zoals melk, vleesextract en 
bloedserum werd ook uitgevoerd. Het eindresultaat zou een antwoord moeten zijn op 
de vraag of het mogelijk is om met biosensoren de behoeften van controle-inspecties 
en voedselindustrieën, aan een meer intensieve en efficiënte controle op de 
aanwezigheid van voedselcontaminanten (zoals antibiotica) in de voedselketen, te 
kunnen verwezenlijken.  
In de inleiding (Hoofdstuk 1) worden de achtergronden van antibiotica, de 
analysemogelijkheden, de toegepaste biosensoren en de verschillende typen aan 
gebruikte antilichamen beschreven. Deel I presenteert het onderzoek naar de 
ontwikkeling van multi-sulfonamide antilichamen waarbij polyklonale (Pabs) en 
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monoklonale antilichamen (Mabs) tegen de ringstructuur van sulfonamiden zijn 
opgewekt (Hoofdstuk 2). Hiervoor werd een sulfathiazolderivaat (afgekort als TS)  
gesynthetiseerd en zodanig aan een dragereiwit gekoppeld dat de aromatische 
aminegroep, aanwezig in alle sulfonamiden, van het eiwit af was gericht. Muizen 
werden geïmmuniseerd met het TS eiwit conjugaat en na de fusie van de miltcellen 
van één van de muizen met myelomacellen, en het screenen van de geproduceerde 
hybidomasupernatanten, werden vier verschillende Mabs verkregen. Met een 
geoptimaliseerd ELISA protocol liet het beste Mab (Mab 27G3) een 50% inhibitie 
zien met acht structureel verschillende sulfonamiden bij concentraties minder dan 100 
ng ml-1 of 5 ng/test.  Hoewel dit een unieke brede specificiteit was met een op dat 
moment niet eerder vertoonde gevoeligheid, was die gevoeligheid voor de 
verschillende sulfonamiden te variabel om het een generieke sulfonamide ELISA te 
noemen. In Hoofdstuk 3 wordt het maken van Pabs tegen acht verschillende 
sulfonamiden beschreven. Hier werd de in alle sulfonamiden aanwezige aromatische 
aminegroep gebruikt voor het koppelen aan dragereiwitten. In ELISA´s lieten deze 
antilichamen een grote gevoeligheid en een hoge specificiteit zien. Hun prestaties 
werden vergeleken met multi-sulfonamiden Pabs opgewekt tegen de generieke 
structuur van sulfonamiden door het immuniseren met twee sulfonamidederivaten 
(afgekort als TS en PS) zodanig gekoppeld aan dragereiwitten dat deze 
gemeenschappelijke structuur van het eiwit af gericht was. Deze Pabs herkenden 
verschillende structureel verschillende sulfonamiden. De ELISA´s met de anti-TS 
Mabs uit hoofdstuk 2 waren gevoeliger voor verschillende sulfonamiden indien 
vergeleken met andere in de literatuur beschreven Mabs. Echter, de gevoeligheid voor 
enkele belangrijke sulfonamiden, zoals sulfadimidine, was laag. 
Deel II beschrijft de ontwikkeling van multi-sulfonamiden biosensor immunoassays 
(BIAs) gebaseerd op multi-sulfonamiden Mabs en recombinant antilichamen (Rabs) 
afgeleid van één van hen. In Hoofdstuk 4 wordt de ontwikkeling van dergelijke 
biosensortesten in kippenserum beschreven waarbij verschillende antilichamen (één 
Mab en twee Pabs), allemaal opgewekt tegen sulfadimidine en gebruik makend van 
gelijke immunogenen, werden gebruikt. Vergeleken met de specifieke Pabs, 
resulteerde de op Mab 21C7 gebaseerde biosensortest in een betere gevoeligheid voor 
de detectie van sulfadimidine. Deze test werd geschikt bevonden voor het detecteren 
van 8 sulfonamiden in tien keer verdunde kippenserum met detectielimieten (LODs) 
tussen 7 en 20 ng ml-1. In Hoofdstuk 5 wordt de werking van dit unieke Mab 
vergeleken met een andere multi-sulfonamiden Mab geleverd in een commerciële kit 
(Qflex Kit Sulfonamiden) en met een gemuteerd antilichaam (M.3.4) die eerder was 
afgeleid van de anti-TS Mab. Ieder van deze antilichamen lieten interacties zien met 
all 17 geteste sulfonamiden en één (Mab 21C7) was ook gevoelig van N4-acetyl 
metabolieten. De op mutant M.3.4 gebaseerde test werd als het meest gevoelig voor 
de meeste sulfonamiden beoordeeld terwijl de Qflex Kit Sulfonamiden de vijf in 
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Nederland voor pluimvee geregistreerde sulfonamiden detecteert binnen het kleinste 
meetbereik. In Hoofdstuk 6 wordt de toepassing van gemuteerde antilichamen (A.3.5 
en M.3.4) in biosensortesten voor de detectie van sulfamethoxazol en sulfadiazine (de 
meest gebruikte sulfonamiden bij slachtkuikens in Nederland) in serum en plasma van 
behandelde slachtkuikens beschreven. De testen waren snel (5 min per monster), de 
monstervoorbewerking was eenvoudig (alleen verdunning in een antilichamen-
bevattende buffer) en voor de twee sulfonamiden werd een gelijke gevoeligheid 
verkregen met LODs in serum en plasma beneden 10 ng ml-1 (voor de A.3.5-
gebaseerde test). De met de biosensortest gevonden concentraties in serum en plasma 
van behandelde slachtkuikens waren vergelijkbaar en hoger dan de met LC-MS/MS 
gevonden concentraties in weefsel. Om te voorspellen dat de concentraties van de 
twee sulfonamiden in het weefsel waarin de hoogste gehalten voorkomen (vel + vet) 
beneden het MRL niveau van 100 ng g-1 zullen liggen, wordt een actieniveau van de 
multi-sulfonamiden test in serum voorgesteld van 130 ng ml-1. 
Het later ontwikkelde gemuteerde antilichaam (M.3.4), met een betere gevoeligheid 
voor meer sulfonamiden, werd toegepast tijdens een survey. Hierin werden sera van 1 
van de 31 verschillende onderzochte koppels positief bevonden met lage concen-
traties aan sulfamethoxazol (25 ± 21 ng ml-1). Deze test werd uitgevoerd onder 
aangepaste condities, zoals toegepast in de serologische test voor het detecteren van 
drie anti-salmonella serotypen, waardoor het toekomstige toepassingsgebied wordt 
uitgebreid. 
In Deel III wordt de ontwikkeling van BIAs voor aminoglycosiden beschreven. 
Hierbij is begonnen met de directe test, gebruik makend van met antilichamen beladen 
biosensorchips, voor gentamicine en (dihydro)streptomycine (Hoofdstuk 7) die zelfs 
werkzaam waren in melk ver beneden de MRL´s. In dat hoofdstuk wordt de directe 
test voor (dihydro)streptomycine vergeleken met de inhibitietest. Daarbij is een 
streptomycine-eiwitconjugaat op het chipoppervlak geïmmobiliseerd en de 
gevoeligheden in buffer waren vergelijkbaar voor beide geneesmiddelen in beide 
testvormen. Met melk werden interferenties waargenomen in beide testvormen die 
vermoedelijk werden veroorzaakt door niet specifieke binding van melkeiwitten aan 
de met eiwit gecoate chips. Deze interferenties konden worden gereduceerd door het 
toepassen van ultrafiltratie als monstervoorbewerking of door het gebruik van een 
referentiekanaal. In Hoofdstuk 8 wordt de ontwikkeling van één test voor het 
gelijktijdig kunnen meten van vijf aminoglycosiden in gereconstrueerde magere melk 
beschreven. Vier aminoglycosiden (gentamicine, neomycine, kanamycine en een 
streptomycinederivaat) werden direct (zonder koppeling aan eiwitten) op het 
sensoroppervlak geïmmobiliseerd in de vier vloeistofkanalen die serieel werden 
gekoppeld en gebruikt werden in combinatie met een mengsel van vier specifieke 
antilichamen. Melkmonsters werden tien maal verdund in een antilichamen 
bevattende buffer en de detectiegrenzen in gereconstrueerde melk lagen tussen 15 en 
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60 ng ml-1. Deze gevoeligheden waren ver beneden de MRL´s (variërend van 100 tot 
1500 ng ml-1). 
In Hoofdstuk 9 wordt de ontwikkeling van een specifieke BIA voor flumequine 
beschreven. Een dergelijke test was nuttig omdat flumequine één van de 
fluorquinolonen is die het meest frequent worden gebruikt voor de behandeling van 
slachtkuikens in Nederland en, op dat moment, niet op het gewenste niveau kon 
worden gedetecteerd met een multi-fluorquinolonen BIA. Deze test werd gevalideerd 
als een kwantitatieve test voor de uitvoering in vlees van slachtkuikens. Na het 
toepassen van een makkelijk uitvoerbare extractieprocedure met buffer was het 
meetbereik van 4 tot 4000 ng g-1 (MRL= 400 ng g-1). De beslissingsgrens (CCα) en 
het detectievermogen (CCβ)  werden bepaald op respectievelijk 500 en 600 ng g-1. 
Serum en vleesmonsters van met flumequine behandelde slachtkuikens werden 
geanalyseerd en de gevonden concentraties in serum waren altijd hoger dan die 
gevonden in spierweefsel (gemiddelde serum/weefsel verhouding was 3,5). Dit 
bewees de toepassing van de BIA in serum als voorspeller voor de concentraties aan 
flumequine in spierweefsel.  
In Hoofdstuk 10 wordt geconcludeerd dat bloedserum en melk geschikte 
monstermaterialen zijn voor het met de biosensor kunnen meten van antibiotica in de 
voedselketen. Dergelijke testen zijn snel, robuust, geautomatiseerd, makkelijk toe te 
passen en vereisen eenvoudige monstervoorbewerkingen (verdunningen in een 
antilichamen bevattende buffer).  Echter, de toegepaste vierkanaals systemen zijn 
duur, te beperkt m.b.t. multiplexen en de antilichamen zijn te specifiek voor het 
gelijktijdig kunnen meten van meer antibiotica. Daarom moeten goedkopere 
alternatieven en meer uitgebreide multiplexsystemen worden onderzocht waarbij de in 
het huidige onderzoek verkregen kennis van grote waarde kan zijn. Mogelijke 
alternatieven, die variëren van goedkope, “imaging” en “localized” SPR systemen tot 
andere multiplex biochip en suspensie microarray systemen, als ook op nanodeeltjes 
gebaseerde detecties en het gebruik van kunstmatige “antilichamen” (MIPs en 
aptameren) of op hele cellen of hun functionele ingrediënten gebaseerde testen 
worden beschreven in de vooruitblik naar de toekomstige ontwikkelingen (Hoofdstuk 
10). Deze vooruitblik laat goede mogelijkheden zien voor de ontwikkeling van 
klantspecifieke en kostenefficiënte screeningmethoden voor de verschillende 
aandachtsgebieden en controlepunten in de voedselketen. 
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Dit proefschrift is mede tot stand gekomen omdat het ontbreken ervan een handicap 
oplevert in een nieuwe werksituatie waarin het begeleiden van AIO’s meer standaard 
is dan een uitzondering. Omdat niet de gangbare route van een masteropleiding en 
AIO-traject is gevolgd, is het fundament voor dit proefschrift terug te voeren op een 
38 jaar durende carrière. En, waar moet je dan beginnen met bedanken? Wel, 
allereerst natuurlijk bij mijn vrouw Annie voor haar grote steun die ik heb mogen 
ontvangen gedurende mijn gehele carrière binnen het Rijks Zuivel Station (RZS) en 
het RIKILT van adjunct-laborant naar senior onderzoeker en clusterleider. Er zijn vele 
uren in avonden en weekeinden geïnvesteerd in opleiding en werk maar er werd altijd 
soepel mee omgegaan. Annie, bedankt en ik hoop nog op vele gezellige jaren samen 
in een goede gezondheid. Mijn zwager Jan Guldemond wil ik bedanken omdat hij 
destijds dacht dat een laboratoriumomgeving voor mij wel eens geschikt zou kunnen 
zijn en voor het contactleggen met het RZS. 
Daarnaast ben ik natuurlijk dank verschuldigd aan vele collega’s waarvan ik er 
ongetwijfeld een aantal zal vergeten, sorry en bij deze alsnog bedankt. De heren Krol 
en Huiskamp (toen was tutoyeren nog niet toegestaan)  bedank ik omdat zij mij in 
1971 hebben durven aannemen, ondanks hun bedenkingen over de omgang van een  
redelijk uit de kluiten gewassen ex-zeeman met dat fragiele glaswerk. Na een half jaar 
proeftijd bij de heer Dijkstra (vet- en eiwitanalysen) durfden zij de gok aan en kon ik 
mij verder bekwamen in het samenstellingsonderzoek waarbij het plezierige inwerken 
door Rob Coors (lab A), de pijprokende en verstrooide meneer Eissens (hoofd lab A), 
het narekenen (met rekenschijf) van meneer de Wilde (lab B) en met de handen op 
zijn rug ijsberende meneer Krol (hoofd lab B) mij het meest zijn bijgebleven. Vanaf 
1978 ben ik bij Louis Tuinstra terecht gekomen en hij gaf mij de kans om met 
mycotoxinen aan de slag te gaan. Van Lou heb ik het enthousiasme voor het 
publiceren overgenomen en van Arie Roos en Wim Traag de praktijk van het 
chromatograferen. Ik denk nog regelmatig met plezier terug aan die tijd, met collega’s 
als Henk Keukens (bedankt voor de gezelligheid tijdens onze HBO-B opleiding), 
Gerard van Bruchem en Jaap Driessen, waarvoor mijn dank. Bij Han Elenbaas kreeg 
ik de kans om mij te ontplooien als laboratorium hoofdassistent met eiwitchemie als 
onderzoeksterrein. Han, bedankt voor deze interessante periode waarin voor mij snelle 
eiwitscheidingen met FPLC centraal stonden. Robert Schilt en Fred Huf wil ik 
bedanken voor hun inspiratie en het verder kunnen ontplooien als hoofdassistent met 
immunochemische screeningsmethoden en affiniteitschromatografie voor groeibe-
vorderaars als specialisatie. Dit, en het werk van Astrid Hamers en Gerard van 
Bruchem samen met René Paulussen, waren het fundament voor het huidige 
onderzoek en een zeer boeiende en uitdagende periode met veel externe contacten. 
Wim de Wit bedank ik voor de kans om als onderzoeker een eigen club 
(Immunochemie) te mogen leiden. Hij had toen een met mij nog steeds gedeelde visie 
dat kleine groepjes het meest rendabel zijn. Hierbij ben ik veel dank verschuldigd aan 
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Geert Cazemier, Piet Stouten en Anniek Kemmers-Voncken. Samen hebben wij de 
fundering een opbouw gegeven. Latere (tijdelijke) medewerkers, AIO’s en collega’s 
als Jolanda du Pré, Monique Bienenmann-Ploum, Ron Verheijen, Monique Bremer, 
Gerardo Marchesini, Anastasia Meimaridou, Sabina Rebe, Dick Hooijerink, Hüsniye 
Gerçek, Jacqueline Bastiaans, Jeroen Peters, Mirjam van Aalderen en Linda 
Noteboom en het grote aantal studenten wil ik bedanken voor het vormen van de 
inspirerende en uitdagende omgeving. Natuurlijk ben ik ook veel dank verschuldigd 
aan alle konijnen, muizen en kippen voor hun niet vrijwillige maar broodnodige 
bijdrage aan dit onderzoek. Mijn dank gaat verder uit naar de medewerkers van 
EuroProxima B.V., voorheen Euro-Diagnostica B.V., (Piet van Wichen, Lucia 
Streppel, Martin Salden, Cor Arts en Ron Verheijen) voor de jarenlange en prettige 
samenwerking en de extra dimensie die het vermarkten van producten aan het 
onderzoek heeft gegeven en nog steeds geeft. Robert van Gorcom wil ik bedanken 
voor zijn stimulerende manier van leidinggeven en het regelmatig aandringen om toch 
nog eens te gaan promoveren en ik bedank Michel Nielen en Han Zuilhof omdat zij de 
moeite hebben willen nemen om het promotietraject in gang te zetten en voor hun 
inzet om er een goed einde aan te maken. Ik hoop op een mooie voortzetting van onze 
samenwerking met veel creatieve ideeën, AIO’s en projecten. Natuurlijk wil ik 
nogmaals mijn paranimfen Geert Cazemier en Monique Bienenmann-Ploum speciaal 
bedanken voor hun inzet gedurende de vele jaren van samenwerking, want zonder hun 
inzet was het ongetwijfeld anders verlopen. Als laatste wil ik nog Dorothée Becu 
bedanken voor haar hulp met de figuren. 
Ik voel mij bevoorrecht met zoveel support en met een werkgever die dergelijke 
kansen biedt. 
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CURRICULUM VITAE 
 
Willem Haasnoot was born on the 14th of August 1953 in Leiden, the Netherlands. In 
1970 he obtained his secondary school diploma (MULO-B in Voorschoten) after 
which he sailed the world’s seas for 6 months as an ordinary seaman employed by the 
Dutch Royal Nedlloyd. Unfortunately, due to his glasses, a planned carrier as a 
steersman proved to be no option. In March 1971, he was employed as an assistant 
laboratory worker at the Government Dairy Station in Leiden and in September 1971 
he started with a 2-year lasting part-time (evenings) preparatory higher professional 
education (VHBO) for laboratory technicians (Delftse Analisten Cursus) which was 
successfully ended in 1973. His compulsory national service (18 months) ended in 
December 1974, with the rank of sergeant in the Royal Netherlands Army Signal 
Corps, after which he returned to the Government Dairy Station to perform 
composition analyses on dairy products. A 3-year part-time (evenings) higher 
professional education for laboratory technicians (HBO-A: van Leeuwenhoek 
Instituut in Delft) was successfully finished in 1977. In 1979 he moved to 
Wageningen to work as a technician specialized in chromatography and mycotoxins 
and to contribute to the formation of the new State Institute for Quality Control of 
Agricultural Products (RIKILT). In 1982 he graduated from the 3-year lasting part-
time (evenings) higher professional education (HBO-B, chemical direction of the 
O.L.A.N. in Arnhem), after which he started as a senior technician within the 
department of Protein Chemistry of RIKILT. In the years 1984 and 1985, he studied 
chemistry as a part-time student at the Utrecht University. This study was not 
completed because the combination of work, a family - extended with two daughters  
in 1978 and 1980 - and a study was not manageable. From 1987 to 1992, he was a 
senior technician in the department of Biopharmaceutical Analyses (BFA) of RIKILT 
where the research was focused on the development of immunochemical methods for 
the detection of residues of growth promoters. Since 1992, he is responsible for the 
immunochemical research within RIKILT; first in the function of scientific researcher, 
and from 2002 also officially in the function as leader of the group Biomolecular 
Detection. The research was initially focused on the development of immunochemical 
methods (ELISA’s, immunoaffinity chromatography (IAC), immunofiltration (IF), 
strip tests, etc.) for the detection of growth promoters and was gradually enlarged to 
assays for animal drugs, contaminants and proteins. Since 2000, optical biosensors 
play an important role in his research and parts of the results have been used to 
compile this thesis. 
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Willem Haasnoot werd op 14 augustus 1953 in Leiden geboren. In 1970 behaalde hij 
het MULO-B diploma te Voorschoten waarna hij als lichtmatroos in dienst van de 
Koninklijke Nedlloyd gedurende 6 maanden de wereldzeeën bevoer. Een geplande 
carrière als stuurman op de grote vaart zat er, als brildragende, helaas niet in. In maart 
1971 begon hij als adjunct-laborant bij het Rijks Zuivel Station (RZS) te Leiden en 
startte hij met de tweejarige avondopleiding VHBO aan de Delftse Analisten Cursus 
welke in 1973 met succes werd afgerond. Zijn achttien maanden durende militaire 
dienstplicht eindigde in december 1974, met als laatste rang sergeant bij het wapen 
der Verbindingsdienst, waarna hij weer terugkeerde bij het RZS voor het uitvoeren 
van samenstellingsonderzoek aan zuivelproducten. Een driejarige avondopleiding 
(HBO-A aan het van Leeuwenhoek Instituut te Delft) werd in 1977 met succes 
afgerond. In 1979 verhuisde hij naar Wageningen om als analist met de specialisaties 
chromatografie en mycotoxinen mee te werken aan de vorming van het 
Rijkskwaliteits Instituut voor Land- en Tuinbouwproducten (RIKILT). In 1982 werd 
de driejarige opleiding HBO-B (chemische afdeling) aan de avondschool voor 
Laboratorium personeel te Arnhem-Nijmegen (O.L.A.N.) met succes afgerond waarna 
hij startte als laboratorium hoofdassistent  binnen de afdeling Eiwitchemie van het 
RIKILT. In de jaren 1984 en 1985 volgde hij de deeltijdopleiding scheikunde aan de 
Rijksuniversiteit Utrecht. Deze opleiding werd niet afgerond omdat de combinatie van 
werken, een gezin - uitgebreid met twee dochters in 1978 en 1980 - en een studie niet 
was vol te houden. Van 1987 tot 1992 was hij laboratorium hoofdassistent binnen de 
afdeling Biofarmaceutische Analyse (BFA) waar onderzoek werd uitgevoerd naar de 
ontwikkeling van (immunochemische) methoden voor het aantonen van residuen van 
groeibevorderende stoffen. Sinds 1992 is hij verantwoordelijk voor het 
immunochemisch onderzoek binnen het RIKILT, eerst in de functie van 
wetenschappelijk onderzoeker, en vanaf 2002 ook officieel als leider van de cluster 
Biomoleculaire Detectie. Dit onderzoek was in eerste instantie gericht op het 
ontwikkelen van immunochemische methoden (ELISA’s, immunoaffiniteits-
chromatografie (IAC), immunofiltratie (IF), striptesten, etc.) voor de detectie van 
groeibevorderaars en werd later uitgebreid met testen voor diergeneesmiddelen, 
contaminanten en eiwitten. Sinds 2000 hebben optische biosensoren een belangrijke 
rol gespeeld bij het onderzoek en delen van de hiermee verkregen resultaten zijn 
gebruikt voor het samenstellen van dit proefschrift.  
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